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ABSTRACT 
Yuanyuan Qin: Dietary exposures contribute to different diseases through the microenvironment 
(Under the direction of Liza Makowski) 
 
Genetic predispositions play an important role in our health, but these are not absolute; 
lifestyle choices help determine how long and how well we live. The global pandemic of obesity 
and related diseases is a good example. Lifestyle can contribute to diseases through altering the 
microenvironment of important tissues including adipose in obesity.  
In this dissertation, the consequences of lifestyle components on local and systemic 
inflammation and hyperinsulinemia were investigated, both of which contribute to risk of 
diseases such as obesity, insulin resistance, and breast cancer. Using preclinical mouse models, 
we aimed to uncover mechanisms by which alcohol and obesogenic diet exposures alter the 
microenvironment in the pathogenesis of adipose and mammary gland dysfunction. We found 
that binge ethanol exposure followed by burn injury exacerbated the adipose inflammatory 
response induced by burn alone, with significant elevations in macrophage infiltration and 
secretion of pro-inflammatory mediators when compared to controls not exposed to binge 
alcohol intake. It is well established that adipose inflammation contributes to insulin resistance, 
especially associated with obesity. We discovered that fatty acid transporter 1 (FATP1) 
predominantly on alternatively activated macrophages contributes to decreased local and 
systemic inflammation. Macrophage FATP1 overexpression suppressed inflammatory 
response,while FATP1 knock out exaggerated inflammatory factor expression in vitro. Mice
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transplanted with Fatp1-/- bone marrow and fed an obesogenic diet gained more weight and 
greater epididymal white adipose accretion, and became hyperglycemic and glucose intolerant. 
Obesity is a strong risk factor for an aggressive subtype of breast cancer called basal-like breast 
cancer (BBC) and reducing adiposity is predicted to lower incidence of BBC in human 
populations. Thus, we made mice obese in early adulthood and induced weight loss by a diet 
intervention. Mice, which lost weight following an initial weight gain, reversed obesity-driven 
tumor aggressiveness and mammary gland hyperplasia and ductal carcinoma in situ through 
alterations in kinase activation. The obese microenvironment of mammary glands in adulthood 
therefore can promote early tumor onset. Importantly the composition of the mammary gland can 
be reprogrammed with weight loss and restored to a lean phenotype associated with significantly 
reduced tumor aggressiveness. 
     
                                                                                             v 
To my parents, Yueqing Qin and Yuqin Wu, for their unconditional love and support throughout 
my graduate studies. 
To my mentor, Liza Makowski, for serving as an incredible role model of women in science, 
guiding me the way to a scientist, trusting my ability and potientials, encouraging and pushing 
me forward all the time. 
To my committee members, for their guidance, support and advice towards my successes as a 
doctoral student. 
To my friends, for their patience, understanding and encouragement.
     
                                                                                             vi 
PREFACE 
Chapter 2 of this work was published in Alcohol Clin Exp Res. in 2014. The following 
authors contributed to the work in the following manner. Y. Qin designed, conducted and 
analyzed majority of the experiments, wrote manuscript, J. L. Hamilton conducted and analyzed 
gene expression data, M. D. Bird conducted the experiments and analyzed protein expression 
data, M. M. Chen and A. Zahs provided input on protein expression, E. J. Kovacs designed and 
conducted the experiments, L. Makowski oversaw studies, provided intellectual input and 
participated in all aspects of analyzing data and preparation of manuscript.  
Chapter 3 of this work is in revision. The following authors contributed to this work: 
Amy R. Johnson, Yuanyuan Qin, Alex J. Freemerman, Megan J. Huang, Alyssa J. Cozzo, 
Liyang Zhao, Brante P. Sampey, J. Justin Milner, Melinda A. Beck, Blossom A. Damania, 
Joseph A. Galanko, Matthew L. Edin, Darryl C. Zeldin, Patrick T. Fueger, Brittney Bivins, 
Andreas Stahl, Liza Makowski. Specific author contributions to this work are as described. A. R. 
Johnson designed, conducted and analyzed majority of experiments and wrote manuscript. Y. 
Qin designed, conducted and analyzed majority of experiments and wrote manuscript. A. J. 
Freemerman and M. J. Huang conducted and analyzed gene expression data, J. A. Galanko 
performed statistical analysis for the data, B. Bivins conducted immunoblot for FATP1 protein 
expression. A. Stahl provided FATP1-/- mice and provided intellectual input. L. Makowski 
oversaw all studies and analyses and contributed to the writing of the manuscript. 
Chapter 4 of this work has been submitted to Breast Cancer Research and Treatment. The 
following authors contributed to this work: Yuanyuan Qin, Sneha Sundaram, Luma Essaid, Xing
     
                                                                                             vii 
 Chen, Samantha M. Miller, David B. Darr, Joseph Galanko, Stephanie A. Montgomery, 
Ben Major, Gary L. Johnson, Melissa A. Troester, Liza Makowski. Specific author contributions 
to this work are as described. Y. Qin designed, conducted and analyzed majority of experiments 
and wrote manuscript, X. Chen conducted Multiplexed Inhibitor Bead Affinity Chromatography.  
J. A. Galanko performed statistical analysis for the data,  S. A. Montgomery conducted the 
pathological analysis.  L. Makowski oversaw all studies and analyses and contributed to the 
writing of the manuscript. 
All work in this dissertation was supported by the following grants: UNC University 
Cancer Research Fund, NIH NIAAA AA017376; NIH NIEHS/NCI ES019 472; NIH NIDDK 
P30DK056350 and P30DK034987, NIH F32HL75970, P30DK056350, Sanofi Global Scholar 
pre-doctoral fellowship, NIH NIEHS/NCI ES019472, The Mary Kay Foundation, NIH NCI 
CA180134, University Cancer Research Fund 
     
                                                                                             viii 
TABLE	OF	CONTENTS	
LIST OF TABLES ........................................................................................................................ xi 
LIST OF FIGURES ......................................................................................................................xii 
LIST OF ABBREVIATIONS.......................................................................................................xiv 
CHAPTER I: INTRODUCTION.................................................................................................1 
Significance .........................................................................................................................1 
Alcohol consumption in the US ..........................................................................................4 
Alcohol Metabolism.............................................................................................................5 
Binge Drinking and Trauma................................................................................................5 
The Obesity Pandemic ........................................................................................................6 
Macrophage Subtypes  ........................................................................................................8 
Fatty Acid Transporter Protein 1 ......................................................................................10 
Breast Cancer.....................................................................................................................13 
Risk Factor.........................................................................................................................14 
Intrinsic Subtypes Based on Gene Expression...................................................................15 
Basal-like Breast Cancer ...................................................................................................16 
C3(1)-Tag Mouse Model...................................................................................................18 
High Fat Diet, Obesity and Breast Cancer.........................................................................19 
Weight Loss and Breast Cancer.........................................................................................21 
The Possible Mechanisms of Obesity-induced Cancer......................................................22 
Summary ...........................................................................................................................26 
     
                                                                                             ix 
CHAPTER П: ADIPOSE INFLAMMATION AND MACROPHAGE  
INFILTRATION AFTER BINGE ETHANOL AND BURN INJURY..................................27 
Overview............................................................................................................................27 
Introduction .......................................................................................................................28 
Results ...............................................................................................................................29 
Discussion .........................................................................................................................34 
Materials and methods ......................................................................................................40 
Tables and Figures ............................................................................................................44 
CHAPTER III: MACROPHAGE FATTY ACID TRANSPORTER 1  
(FATP1) DRIVES ALTERNATIVE MACROPHAGE POLARIZATION  
AND LIMITS OBESITY-INDUCED INFLAMMATION......................................................50 
Overview............................................................................................................................50 
Introduction .......................................................................................................................51 
Results ...............................................................................................................................54 
Discussion .........................................................................................................................64 
Materials and methods ......................................................................................................72 
Tables and Figures ............................................................................................................82 
CHAPTER IV: REMODELING THE MICROENVIRONMENT IN  
EARLY ADULTHOOD BY WEIGHT LOSS RESTRAINED  
DIET-INDUCED BASAL-LIKE BREAST CANCER PROGRESSION.............................100 
Overview..........................................................................................................................100 
Introduction......................................................................................................................102 
Results .............................................................................................................................104 
Discussion .......................................................................................................................110 
Materials and methods ....................................................................................................118 
Tables and Figures...........................................................................................................124 
     
                                                                                             x 
CHAPTER V: SYNTHESIS.....................................................................................................141 
Summary of research findings ........................................................................................141 
Direction for future research ...........................................................................................142 
Public Health Significance...............................................................................................144 
REFERENCES ..........................................................................................................................145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
                                                                                             xi 
LIST OF TABLES 
Table 3.1: Hematologic analysis of Fatp1+/+ and Fatp1-/- blood....................................................96 
Table 3.2: Flow cytometric analysis of circulating Fatp1+/+  
and Fatp1-/- lymphocytes................................................................................................................97 
Table 4.1: Adiposity predicts BBC latency in C3(1)-Tag mice...................................................136 
Table 4.2: Mice with higher body weight have shorter latency...................................................137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
                                                                                             xii 
LIST OF FIGURES 
Figure 1.1: Macrophage phenotypes..............................................................................................10 
Figure 1.2: FATP1 topology model...............................................................................................12 
Figure 1.3: Progression of breast cancer........................................................................................14 
Figure 1.4: C3(1)-Tag Mouse Model.............................................................................................19 
Figure 1.5: Microenvironment regulates tumor induction and progression..................................23 
Figure 2.1: Interleukin-6 (IL-6) levels increase after single and episodic  
binge ethanol exposure and burn injury.........................................................................................44 
Figure 2.2: Adipose expression of neutrophil chemokine KC after single 
and episodic binge ethanol and burn injury...................................................................................46 
Figure 2.3: Episodic binge ethanol and burn injury drives crown like  
structure formation.........................................................................................................................47 
Figure 2.4: Adipose chemokine levels of monocyte chemotactic protein-1 
(MCP-1) and adiponectin were inversely regulated after single and episodic 
binge ethanol and burn injury........................................................................................................48 
Figure 2.5: Single and episodic binge followed by burn injury failed to  
upregulate pro-inflammatory mediators........................................................................................49 
Figure 3.1: FATP1 is predominantly expressed in AAMs and transplant 
of fatp1-/- marrow results in FATP1 deficient macrophages........................................................82 
Figure 3.2: Deletion of MΦ Fatp1 increased susceptibility to weight gain,  
glucose intolerance, and increased white fat mass. Lipids are absorbed by  
small intestinal enterocytes and repackaged into chylomicrons for  
distribution to peripheral tissues..................................... ..............................................................83 
Figure 3.3: Lack of MΦ FATP1 increased adipose inflammation, inflammasome 
priming, and markers of oxidative stress in HFD-fed mice...........................................................85 
Figure 3.4: Fatp1 deletion decreased acyl-CoA synthetase (ACSL) 
activity and resulted in a metabolic shift from lipid oxidation to 
glycolysis that resulted in exacerbated CAM and less AAM activation.......................................87 
Figure 3.5: Lack of FATP1 in CAM-polarized BMDM enhanced  
Pentose Phosphate Pathway activity..............................................................................................89 
 
     
                                                                                             xiii 
Figure 3.6: Over-expression of FATP1 in RAW264.7 MΦs induced  
a substrate switch with enhanced lipid metabolism and reduced glucose  
metabolism resulting in blunted CAM-activation..........................................................................91 
Figure 3.7: Over-expression of FATP1 reduced inflammatory response  
in RAW264.7 macrophages...........................................................................................................93 
Figure 3.8: FATP1 expression level had no effect on lean  
body mass, liver weight or brown adipose (BAT) weight.............................................................98 
Figure 3.9: Deletion or over-expression of FATP1 had no  
effect on cell size or viability.........................................................................................................99 
Figure 4.1: Weight loss protected against HFD-mediated early BBC onset...............................124 
Figure 4.2: Body composition predicts latency...........................................................................125 
Figure 4.3: Diet did not affect tumor initiation............................................................................126 
Figure 4.4: Pathological changes in the unaffected mammary gland induced  
by high fat diet were reversed by weight loss..............................................................................127 
Figure 4.5: Kinome profiling of unaffected mammary glands revealed  
dramatic regulation of PKD1-PKC-α-PKA-MEK3 by diet exposure.........................................128 
Figure 4.6: Protein-Protein interactions of significantly altered kinases  
in unaffected mammary gland of mice on 60-10% diet compared to  
mice on 60% diet............................. ...........................................................................................129 
Figure 4.7: Tumor burden and size are not affected by diets.......................................................131 
Figure 4.8: Measures of glucose intolerance were not altered by diet.........................................132 
Figure 4.9: Kinome profiling reveals significant regulation  
of pathways by HFD that are reversed with weight loss.............................................................133 
 
 
 
 
 
 
     
                                                                                             xiv 
LIST OF ABBREVIATIONS 
2-DG  2-deoxyglucose  
4-HNE  4-hydroxynonenal  
7-AAD 7-aminoactinomycin D 
AAM  Alternatively activated macrophages  
ABCA1 ATP binding cassette transporter ABCA1  
ABCG1 ATP binding cassette transporter ABCG1  
ACSL  Acyl-CoA synthetase  
ADH  Alcohol dehydrogenase  
ADK  Adenosine kinase  
AKT  Protein kinase B 
ALDH  Aldehyde dehydrogenase  
AMPK  5'-AMP-activated protein kinase  
ANOVA Analysis of variance  
ATMs  Adipose tissue macrophages 
AUC  Area under the curve  
BBC  Basal-like breast cancer  
BMDM Bone marrow derived macrophages 
BMI  Body mass index  
Bmp2K Bone morphogenetic protein-2-inducible protein kinase  
BMT  Bone marrow transplant  
CAA  Cancer-associated adipocytes  
CAF  Cancer associated fibroblasts  
CAM  Classically activated macrophages  
     
                                                                                             xv 
CBCS  Carolina Breast Cancer Study  
CCR2  C-C chemokine receptor type 2 
CD36  Cellular differentiation  
CDC  Centers for Disease Control and Prevention 
CETP  Cholesterol ester transfer protein  
CIS  Carcinoma in situ  
CK  Cytokeratin 
CLS  Crown-like structures  
CO2  Carbon dioxide  
CoA  Coenzyme A 
CSFR1 Colony stimulating factor 1 receptor 
CYP2E1 Cytochrome P4502E1  
DAB  Diaminobenzidine 
DCIS  Ductal carcinoma in situ  
Ddr1  Epithelial discoidin domain-containing receptor 1  
DIO  Diet induced obesity 
DMEM Eagle's minimal essential medium 
DTH  Delayed-type hypersensitivity  
ECAR  Extracellular acidification rates  
EGF1R Epidermal growth factor 1 receptor 
EGFR  Epidermal growth factor receptor  
ER  Estrogen receptor 
ER  Endoplasmic reticulum  
     
                                                                                             xvi 
ERK  Extracellular signal-regulated kinases 
EtOH  Ethanol 
eWAT  Epididymal white adipose  
FAEE  Fatty acid ethyl ester 
Fas  Fatty acids  
FAT/CD36      Long-chain fatty acyl coenzyme A  
FATP1 Fatty acid transporter 1  
FATP1-EV FATP1 empty vector  
FATP1-OE FATP1 overexpressing  
FATPs  Fatty acid transport proteins  
FBS  Fetal bovine serum 
FFPE     Formalin Fixed Paraffin Embedded  
Fn3k  Ketosamine-3-kinase  
GEMM Genetically engineered mouse model  
GLUT1 Glucose transporter 1 
GLUT1-EV GLUT1 empty vector 
Glut1MΦ-/-     Macrophage specific Glut1 knock out 
GLUT1-OE GLUT1 over expresser  
GSH  Reduced glutathione  
GSSG  Oxidized glutathione 
GTT  Glucose tolerance test  
H&E   Hematoxylin and eosin 
HBSS  Hank’s buffered saline solution  
     
                                                                                             xvii 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER2  Human epidermal growth factor receptor 2 
HFD  High fat diet  
HGF  Hepatocyte growth factor  
HIF1α  Hypoxia inducible factor 1  
HMG-CoA 3-hydroxy—methylglutaryl coenzyme A  
i.p.  Intraperitoneal 
ICAM   Intercellular adhesion Molecule 
ICAM-1 Intercellular Adhesion Molecule 1 
IDC  Invasive ductal carcinoma  
IFN  Interferon  
IFNɣ  Interferon gamma 
IGF1R  IGF1 receptor  
IGFs  Insulin-like growth factors 
IHC  Immunohistochemistry 
IL-10  Interleukin-10 
IL-1β  Interleukin-1β 
IL-6  Interleukin-6 
iNOS  Inducible nitric oxide synthase  
INSR  Insulin receptor 
Irak1  Interleukin-1 receptor-associated kinase 1  
IRS  Insulin receptor substrate  
ITT  Insulin tolerance test 
     
                                                                                             xviii 
JAK  Janus kinase 
JNK                 C-Jun N-terminal Kinase   
Kit  Mast/stem cell growth factor receptor Kit 
LCCC  Lineberger Comprehensive Cancer Center  
LCFAs Long chain fatty acids  
LFA1    Lymphocyte function-associated anti-gen 1 
LFD  Low fat diet 
Lfng  Luntatic fringe 
LPS  Lipopolysaccharide 
LXR  Liver X receptor  
MAPK  Mitogen-activated protein kinase 
Mark1  Serine/threonine-protein kinase MARK1 
MCP-1 Monocyte chemoattractant protein 1  
M-CSF    Monocytes colony stimulating factor 
MEK3  Specificity mitogen-activated protein kinase kinase 3 
MEOS  Microsomal ethanol oxidizing system  
MIB  Multiplexed Inhibitor Bead  
MMPs  Matrix metalloproteinases 
MMTV Mouse mammary tumor virus 
MP1U  Mouse Phase I Unit  
MRI  Magnetic resonance imaging 
MS  Mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
     
                                                                                             xix 
MΦ  Macrophage 
NAD+  Oxidized nicotinamide adenine dinucleotide 
NADH  Reduced nicotinamide adenine dinucleotide 
NAF  Normal associated fibroblasts 
NF-KB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLRP3 NOD-like receptor family, pyrin domain containing 3 
NO  Nitrix oxide 
OCR  Oxygen consumption rate  
OxLDL Oxidized low density lipoprotein  
PAI-1  Plasminogen activator inhibitor-1 
PBS  Phosphate buffered saline 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
Pik3c3  Phosphatidylinositol 3-kinase catalytic subunit type 3  
PPARs  Peroxisome proliferator-activated receptor 
PPP  Pentose Phosphate Pathway 
PR  Progesterone receptor 
Prkaa2  5'-AMP-activated protein kinase catalytic subunit alpha-2 
Prkca  Protein kinase C alpha type 
Prkd1  Serine/threonine-protein kinase D1  
PTEN  Phosphatase and tensin homolog  
qPCR  Quantitative PCR  
RIPA  Radioimmunoprecipitation assay buffer 
ROS  Reactive oxygen species 
     
                                                                                             xx 
RPMI  Roswell Park Memorial Institute medium 
Salk-1  Soluble serine/threonine-protein kinase receptor R3  
SAM  S-adenosylmethionine  
SDS  Sodium dodecyl sulfate 
SMC  Smooth muscle cells 
SR-A  Scavenger Receptor Class A Type I/II 
SREBP Steroid receptor element binding protein 
SREBP1 Sterol regulatory element binding protein 1  
STAT3 Signal transducer and activator of transcription 3 
STRING Search Tool for the Retrieval of Interacting Genes/Proteins 
SV40  Simian virus 40 
T2D  Type 2 diabetes 
TAG  Triacylglyceride 
Tag  T antigen  
TCGA  Cancer Genome Atlas  
TGFα  Transforming growth factor alpha 
TLR4  Toll-like receptor 4  
TLRs   Toll-like receptors 
TNBC  Triple-negative breast cancer 
TNF-α  Tumor necrosis factor-α 
ULK3  Unc-51 like kinase 3  
VCAM Vascular cells adhesion molecule 
VEGF  Vascular endothelial growth factor 
     
                                                                                             xxi 
VEGFA Vascular endothelial growth factor A  
VLCFAs Very long chain fatty acids  
WD     Western Diet 
WHO  World Health Organization  
WHR  Waist hip ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
                                                                                             1 
CHAPTER I: INTRODUCTION   
Significance 
Lifestyle plays a very important role in both the health of individuals and the public. 
Obesity-related diseases like cardiovascular heart disease, stroke, type 2 diabetes and certain 
types of cancer are the major causes of death in the US that have modifiable risk factors, making 
them potentially preventable diseases1. Our genetic predisposition, which was once considered to 
be a determining factor for many diseases, may not be as important as we thought it was. Take 
cancers as an example. The study of cohorts of twins from Sweden, Denmark and Finland found 
that inherited genetic factors make a minor contribution to susceptibility to most types of 
cancers2. The majority of cancers is considered preventable and could be avoided by adopting 
healthy lifestyle practices and avoiding unhealthy environmental factors3. In addition, diet can 
potentially modify genetic effects on diseases (the gene–environment interaction)4. 
One of the leading causes of preventable death in the US is excessive alcohol 
consumption5. Binge drinking is the most common form of excessive alcohol consumption. In 
the US, approximately half of trauma-related patients were under the influence of alcohol at 
admission, and the majority of these patients engaged in binge drinking6-8. Ethanol exposure is a 
significant problem especially prior to burn injury because it dramatically elevates systemic and 
tissue-specific inflammatory responses9,10, increases susceptibility to infections, and is associated 
with poorer outcomes including longer hospital stays and increased mortality11. However, it was
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unknown if adipose tissue, an important organ in whole body metabolism, contributed to the 
inflammatory status after alcohol consumption and injury. Thus, part of this thesis aimed at 
discovering the underlying causes of systemic inflammation with alcohol exposure and focused 
on alterations to the adipose microenvironment.  
Why is adipose tissue such an important organ to study as a contributing factor in many 
preventable diseases? More than one-third of U.S. adults (35%) are obese, and another one-third 
are overweight12. Obesity is considered to be a low-level chronic inflammatory condition that 
contributes to insulin resistance, type 2 diabetes, cardiovascular disease, cancer, and many other 
diseases13,14. It has been indicated that the infiltration of macrophages into adipose plays an 
important role in the inflammatory status associated with obesity15-17. Different phenotypes of 
macrophages contribute in varied ways to disease. Generally, classically activated macrophages 
(CAM), also called M1 macrophages, are found in adipose tissue of obese individuals, 
contributing to inflammation; while alternatively activated macrophages (AAM), also known as 
M2 macrophages, are found dispersed in lean adipose tissue maintaining tissue function and 
homeostasis18. Importantly, M1 macrophages rely upon glucose as their main fuel, while M2 
macrophages primarily use fatty acids19-21. With the recent knowledge that substrate metabolism 
is different in CAM versus AAM, the concept of metabolic reprogramming has arisen, wherein 
metabolism may drive the inflammatory response. Considering the important role of fatty acids 
and lipid metabolism in AAM, fatty acid transport proteins (FATPs) could be central in 
macrophage-mediated inflammation and obesity22-27. While it was unknown whether 
manipulating FATPs could affect macrophage biology and the inflammatory response of adipose 
tissue and the whole body, it may be important in understanding the contribution of FATPs to 
obesity and related diseases.  
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A disease tightly linked to obesity and often inflammation is breast cancer. Breast cancer 
alone is estimated to account for 29% (226,870) of all new cancer cases among women in the US 
in 2012, and it is the leading cause of cancer death among women ages 20 to 59 years28. An 
important advancement in the field of breast cancer research is recent stratification of breast 
cancer to different intrinsic subtypes based on gene expression profiles29. One of the subtypes 
called basal-like breast cancer (BBC) is highly aggressive with poor survival. Because it is triple 
negative for ER (estrogen receptor), PR (progesterone receptor) and HER2 (human epidermal 
growth factor receptor 2), it currently has no targeted therapy. Importantly, it is also more 
prevalent in premenopausal African-American women30.  
Obesity is a well-known risk factor for BBC, although the mechanism of the relationship 
between obesity and BBC is not well known. Therefore, obesity could be an intervention target 
for breast cancer, especially in BBC prevention. Based on the Carolina Breast Cancer Study 
(CBCS), Milikan et al. estimated that up to 68% of BBC could be prevented by promoting 
breastfeeding and reducing abdominal adiposity31. It has not been proven, though, whether 
reducing weight would decrease the risk of BBC in women. Weight loss may protect against 
BBC onset and/or progress by modulating the microenvironment of the mammary glands32. The 
mechanisms need to be further explored and are investigated in this thesis. 
Thus, burn injury after ethanol, insulin resistance, and basal-like breast cancer are all 
regulated by the alteration of the adipose microenvironment. In recent years, attention has 
increasingly been drawn to the microenvironment. Cancer is a good example.  Zamboni’s group 
reported that the tumor microenvironment of triple-negative breast cancer affected nanoparticle 
drug delivery and therapeutic outcomes33. The data presented in this dissertation demonstrate 
that lifestyle-related factors like alcohol intake, hight fat diet and obesity could contribute to 
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disease onset and progress by regulating growth factors, kinases, cytokines, chemokines and 
possibly through other unknown pathways in the microenvironment. Therefore, our findings 
contribute to a growing body of evidence that the microenvironment (i.e. cellular composition, 
metabolism, and activation of specific kinase signaling cascades) in specific tissues contributes 
greatly to local and systemic pathologies.  
 
Alcohol Consumption in the US  
The Alcohol-Related Disease Impact report from the Centers for Disease Control and 
Prevention of the United States indicated that excessive alcohol use led to approximately 88,000 
deaths and 2.5 million years of potential life lost each year from 2006 – 2010. Furthermore, 
excessive drinking accounted for 1 in 10 deaths among adults aged 20-64 years34. The economic 
costs of excessive alcohol consumption in 2006 were estimated at $223.5 billion, or $1.90 a 
drink35. In the United States, a drink is defined as 0.6 ounces (14.0 grams) of pure alcohol. Based 
on Dietary Guidelines for American 2010, a drink can be 12-ounces of beer (5% alcohol content), 
8-ounces of malt liquor (7% alcohol content), 5-ounces of wine (12% alcohol content), or 1.5-
ounces of 80-proof (40% alcohol content) distilled spirit or liquor (e.g., gin, rum, vodka, 
whiskey). Excessive alcohol consumption is the third leading cause of preventable death in the 
US34. Excessive drinking includes binge drinking, heavy drinking, and any drinking by pregnant 
women or people younger than 21 years old according to the National Institute on Alcohol 
Abuse and Alcoholism. Binge drinking is defined as consuming 4 or more drinks for women or 5 
or more drinks for men on one occasion. Heavy drinking is defined as consuming 8 or more 
drinks per week for women or 15 or more drinks per week for men. Most people who drink 
excessively are not alcoholics or alcohol dependent36. Alcoholismor alcohol dependence 
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syndrome is also known as alcohol use disorder (AUD). Individuals must meet certain number of 
criteria in the Diagnostic and Statisticsal Manual of Mental Disorders (DSM) to be diagnosed 
with an mild, moderate or severe AUD37. 
 
Alcohol Metabolism 
Alcohol metabolism takes places primarily in the liver by three enzymatic pathways. The 
main pathway, which is responsible for most ethanol oxidation, is through alcohol 
dehydrogenase (ADH) – aldehyde dehydrogenase (ALDH). The second pathway is the 
microsomal ethanol oxidizing system (MEOS) catalyzed by cytochrome P4502E1 (CYP2E1). 
CYP2E1 has been reported to be expressed in hepatocytes, Kupffer cells and adipocytes38. The 
third pathway for ethanol elimination is a nonoxidative pathway catalyzed by fatty acid ethyl 
ester (FAEE) synthase, resulting in the formation of fatty acid ethyl esters39. Importantly, besides 
in the liver, alcohol exposure involves changes in other organ systems, including intestinal 
barrier function, the innate immune system, and, as we and one other group has demonstrated, 
adipose tissue40.   
 
Binge Drinking and Trauma 
Binge drinking is the most common form of excessive drinking in the US. Alcohol 
consumption is a major risk factor for all types of injuries, such as falls, fires, drowning, assaults, 
suicides, and motor vehicle collisions41,42. Around half of all alcohol-related deaths are due to 
injuries. Among alcohol-related incidents, injuries resulting from motor vehicle collisions are the 
leading cause of death34,43.  Alcohol has been reported to cause changes in the physiological 
response following trauma, leading to increased complications and mortality44-46. Half of the 
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patients with burn-related injuries in the US have alcohol in their system at the time of admission, 
and the vast majority of those subjects are binge drinkers rather than chronic alcoholics8. 
Burn injuries induce dramatic insulin resistance, hyperlipidemia, hyperglycemia and 
hepatosteatosis in patients, greatly contributing to elevated morbidity and mortality47-49. Insulin 
resistance in liver, skeletal muscle and adipose tissue can persist even 3 weeks after a burn 
injury49,50. Burn injuries also drive systemic inflammation with elevations in pro-inflammatory 
cytokines and suppressed cell-mediated immunity, leading to multi-organ dysfunction51. Ethanol 
exacerbates burn-induced inflammation systemically and in the lung and adipose tissue52,53, and 
impairs the immune response, thus increasing a patient’s susceptibility to infection9. Clinical and 
laboratory studies have demonstrated that ethanol exposure prior to traumatic injury, such as a 
burn, markedly elevates systemic and tissue-specific inflammatory responses9,10 and is associated 
with poorer outcomes11.  It is well established that alcohol increases the dysregulated 
inflammatory and immune response caused by burns in animal models and human patients, but 
most of the previous focus has been on the lung and susceptibility to infection9. To date there 
were no studies examining the role of adipose tissue in contributing to the inflammatory response 
and insulin resistance associated with alcohol and burn trauma. 
 
The Obesity Pandemic 
The World Health Organization (WHO) defines overweight and obesity as excessive fat 
accumulation that is a risk factor to human health. A crude yet convenient population measure of 
obesity is the body mass index (BMI): a person’s weight (in kilograms) divided by the square of 
his or her height (in meters)54. 
BMI= Weight (kg) / Height2 (m2)  
     
                                                                                             7 
        = Weigh (Ib) / Height2 (in2) * 703 
In Western countries, a person with a BMI of 30 or more is considered obese, and a person with 
a BMI greater than or equal to 25 is considered overweight. Overweight and obesity are risk 
factors for many diseases, including diabetes, cardiovascular diseases and many types of cancers. 
The fundamental cause of obesity and overweight is an energy imbalance between calorie intake 
and calorie expenditure. Globally, there has been an increase in intake of energy-dense foods that 
are high in fat and sugar, and a decrease in physical activity due to the increasingly sedentary 
lifestyle of work, changing modes of transportation, and increasing urbanization55. Once 
considered a problem only in developed countries, overweight and obesity are now on the rise in 
developing countries. Recently the WHO estimated that in 2014, more than 1.9 billion adults 
were overweight globally. Of these, over 600 million were obese. Overall, around 39% of adults 
(38% of men and 40% of women) were overweight, and 13% of the world’s adult population (11% 
of men and 15% of women) was obese in 201454. The worldwide prevalence of obesity more 
than doubled between 1980 and 201454. The situation in the United States is even worse. More 
than one-third of U.S. adults (35%) and approximately 17% (or 12.7 million) of children and 
adolescents were obese as reported by Ogden et al. in 201412. Some of obesity-related diseases 
like heart disease, stroke, type 2 diabetes and certain types of cancer are the leading causes of 
preventable death in the US (CDC guildline)56. Obesity also brings an economic burden. The 
estimated annual medical cost of obesity in the U.S. was $147 billion U.S. dollars, and the 
medical costs for people who are obese were $1,429 higher than those of normal weight in 
200857.  
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Macrophage Subtypes   
The currently accepted understanding of obesity as low-level chronic inflammation that 
contributes to insulin resistance, type 2 diabetes, cardiovascular disease, cancer and many other 
diseases emerged in the early 1990s13,14. Although the mechanism is not fully understood, it has 
been indicated that the infiltration of macrophages into adipose tissue plays an important role in 
the inflammatory changes seen in obesity15-17.  
Macrophages are important immune cells which reside in many tissues of the body, like 
microglia, Kupffer cells, osteoclasts, etc. Macrophages clear pathogens and apoptotic cells, and 
produce immune effector molecules58. They have a central role in protecting the host but also 
hinder the resolution of inflammation, which is a hallmark of numerous diseases, including 
atherosclerosis, obesity, tumor, asthma, etc.59. When there is tissue damage or infection, the 
precursors, monocytes, are rapidly recruited from the circulation to the tissue and differentiate 
into tissue macrophages60. Macrophages are remarkably plastic and can change their functional 
phenotypes depending on the environmental cues58.  
There is a spectrum of macrophages in adipose tissue. The phenotype of the macrophage 
can affect the inflammatory status in the microenvironment of adipose tissue, which is integral to 
obesity and diabetes. Generally, CAMs are found in obese adipose tissue, forming crown-like 
structures surrounding dying adipocytes, while AAMs are dispersed in lean adipose tissue 
maintaining tissue function18. Importantly, CAMs utilize glucose, while AAMs primarily use 
fatty acids19-21 (Figure 1.1). Other activated immune cells like T cells have been reported to 
exhibit a similar Warburg-like metabolism20,61-65. Most cancer cells predominantly rely on 
aerobic glycolysis which is an ineffective way to produce ATP, while normal cells rely on 
mitochondrial oxidative phosphorylation with a relatively low rate of glycolysis66,67. 
     
                                                                                             9 
CAMs are a prominent source of pro-inflammatory cytokines such as iNOS, TNFα, 
MCP1 and IL6. In contrast, AAMs are involved in tissue remodeling and repair68,69. Considering 
the important role of fatty acids and lipid metabolism in regulating macrophage biology, fatty 
acid transport proteins could be central in macrophage-mediated inflammation and obesity 
through metabolic reprogramming22-27. 
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Fatty Acid Transporter 1  
The fatty acid transport protein (FATP) family consists of six members in humans and 
mice and is expressed in tissues with high levels of fatty acid uptake and active lipid metabolism, 
like adipose tissue, heart and skeletal muscle70-73. We have found that FATP1 and FATP4 are the 
Adapted from Johnson AR, 2012 
Figure 1.1. Macrophage polarization. Macrophages can be generally categorized as 
classically activated macrophage (CAMs) and althernatively activated macrophages 
(AAMs). CAMs are pro-inflammatory and polarized from precursor M0 macrophages 
via components of bacteria such as lipopolysaccharide (LPS) and type 1 T-helper (Th1) 
inflammatory cytokines interferon γ (IFNγ) and TNFα. AAMs are activated by type 2 
(Th2) cytokines IL-4 and IL-1, involved in remodeling, tissue repair and maintenance 
of insulin sensitivity and considered anti-inflammatory. There is plasticity along the 
macrophage polarization spectrum. 
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main FATPs expressed in macrophages, with macrophage FATP1 expressed at mRNA 
concentrations as high as those in the total adipose tissue. FATPs have been shown to be fatty 
acyl-CoA synthetases with an affinity for long chain fatty acids (LCFAs) and very long chain 
fatty acids (VLCFAs)74,75. Acyl-CoA synthetases are enzymes that add a CoA to the fatty acid 
(Figure 1.2). Purified FATP-1 exhibited substrate specificity for fatty acids 16-24 carbons in 
length, while uptake of fatty acids shorter than 10 carbon atoms is unaffected by FATP 
expression70,74,76. The majority of FATP1 is found on intracellular structures like the 
endoplasmic reticulum (ER) and mitochondria77-79. Insulin can induce translocation of FATP1 
from an intracellular compartment to the plasma membrane, but doesn’t change FATP1 protein 
expression in adipocytes80. Adiponectin can increase FATP1 expression in skeletal muscle but 
not adipose tissue or liver81. TNFα is a negative regulator of FATP1 expression both in the liver 
and adipocytes80,82. Fatty acids and their derivatives are ligands for PPARs, and a PPAR binding 
site has been identified in the murine FATP1 promoter83, so a positive feedback loop might 
regulate expression of FATP1 84,85. A particular member of the nuclear receptor family, the TR4 
orphan nuclear receptor facilitates lipid accumulation in 3T3-L1 adipocytes by activating FATP1 
gene expression86. To date, there have been no reports of FATP1 function in macrophages. 
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Whole body FATP1 deletion protected mice from fat-induced insulin resistance and 
intramuscular accumulation of fatty acyl-coA without alteration in adiposity87. Insulin-stimulated 
fatty acid uptake was completely abolished in adipocytes and greatly reduced in skeletal muscle 
of the FATP1 knockout mouse following a high-fat diet, while basal LCFA uptake by both 
tissues was unaffected88. In the same mouse model, lipids were redistributed from adipose tissue 
and muscle to the liver, leading to a complete protection from diet-induced obesity and insulin 
resistance88. FATP1 overexpression in human muscle cells led to enhanced palmitate and oleate 
uptake and the incorporation into triacylglycerides (TAG)89. A recent study indicated that 
FATP1, together with DGAT1, is part of a TAG synthesis complex that facilitates lipid droplet 
expansion in Caenorhabditis elegans78. However, some in vivo and in vitro studies also suggested 
Jurgen Pohl. 2004 
Figure 1.2. FATP1 is a transmemberane protein. A short segment of the N-terminus 
is located in the extracellular side of the membrane bilayer while the C-terminus faces 
the cytoplasm. Amino acid residues 1–190 of FATP1 are transmemberane domains. 
Amino acid residues 190–257 are in the cytoplasma side and contain the AMP-binding 
motif (rectangle) that has acyl CoA-synthetase activity. Amino acid residues 258–475 
are also associated with the inner leaflet of the plasma membrane. 
     
                                                                                             13 
FATP1 channeled FA to oxidation by activating AMP-activated protein kinase (AMPK)90-92. 
Therefore, it is likely that FATP1 can transport LCFA to both lipid storage and lipid oxidation 
depending upon the cells, growth factors and tissues.  
The role of FATP1 in insulin resistance is likely to be tissue-specific based on where and 
how fatty acids are stored. An increased FATP1-mediated fatty acid uptake into adipose tissue is 
beneficial for protecting muscle from harmful triacylglycerol accumulation, a phenomenon 
called “lipotoxicity”, while an increase in FATP1-mediated fatty acid uptake into muscle will 
contribute to insulin resistance. Macrophages can have extensive fatty acid metabolism, TG and 
cholesterol ester storage, especially AAMs or lipid-laden foam cells. Foam cells are fat-laden 
macrophages involved in fatty streak formation in atherosclerosis93. However, how FATP1 
affects macrophage biology and the inflammatory response is unknown but may be important in 
understanding cell-specific contributions to obesity, inflammation and insulin resistance. Our 
research showed that when fed a high fat diet (HFD), mice with specific FATP1-/- macrophages 
are glucose intolerant, had greater weight gain, larger fat pads, and an increased inflammatory 
response in epidydimal adipose tissue and systemically when compared to control mice on HFD.  
 
Breast Cancer  
Breast cancer is the most common cancer in women in the world and 2nd in cancer 
deaths in the US94. Breast cancer can be divided into two main groups: the sarcomas and the 
carcinomas. Sarcomas are rare cancers that arise from the stromal components of the breast95. 
These stromal cells include myofibroblasts and endothelial cells and cancers arising from these 
cells are phyllodes tumors and angiosarcoma, respectively 96. Sarcomas account for less than 1% 
of primary breast cancers97, while carcinomas comprise the majority of all breast cancers. 
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Carcinomas are cancers that arise from the epithelial component of the breast, which consists of 
the cells that line the lobules (milk glands) and milk ducts (thin tubes that carry milk from the 
lobules of the breast to the nipple). Ductal carcinoma is the most common type of breast cancer. 
Lobular carcinoma begins in the lobules of the breast, and ductal carcinoma originates from the 
milk duct. Generally ductal carcinoma can progress from atypical ductal hyperplasia (ADH) to 
ductal carcinoma in situ (DCIS, meaning within the ducts), and then to invasive ductal carcinoma 
(IDC) where the tumor invades the stroma surrounding the ducts98 (Figure 1.3). Breast cancer 
occurs in both men and women, but male breast cancer is rare99.   
 
Risk factors 
The strongest risk factor for breast cancer is age100. A woman’s risk of developing breast 
cancer increases as she gets older. Other risk factors of developing breast cancer include 
Adapated  from Kopans DB, 1989 
Figure 1.3. Breast cancer progression in C3(1)-Tag mouse model. Ductal carcinoma 
progresses from atypical ductal hyperplasia (ADH) to ductal carcinoma in situ (DCIS) 
and to invasive ductal carcinoma (IDC). For C(3)1-Tag mice, at 8 weeks old, females 
developed ADH; at 12 weeks DCIS appeared; around 16 weeks femal mice developed 
tumors and DCIS became IDC. 
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inherited changes in certain genes, like Brca1 and Brca2, a family history of breast cancer, 
geographical location (developed country), higher breast density, menarche at early age (before 
age 11), menopause at older age (after age 54), a first full-term pregnancy after age 30, never 
having been pregnant, obesity, excessive alcohol consumption and low socioeconomic status101. 
There is high lifetime risk of developing breast cancer for women in the US. Approximately 12.3% 
of women will be diagnosed with breast cancer at some point during their lifetime, according to 
Cancer Statistics (2012) based on incidence data from the National Cancer Institute, the Centers 
for Disease Control and Prevention, and the North American Association of Central Cancer 
Registries102. The number of new cases of breast cancer was 124.6 per 100,000 women per year, 
and the number of deaths was 22.2 per 100,000 women per year in the US, using age-adjusted 
data based on 2007-2011 cases and deaths102. In 2011, there were an estimated 2,899,726 women 
living with breast cancer in the United States102. 
 
Intrinsic subtypes based on gene expression 
Breast cancer is not a single disease. Instead it is composed of a spectrum of tumor 
subtypes with distinct cellular origins, somatic changes, and etiologies103. In 2000, Perou’s group 
used a semi-unsupervised approach to identify breast cancer subtypes in a population of 40 
patients with locally advanced disease treated with neoadjuvant chemotherapy104. They identified 
496 genes, termed the intrinsic gene set, which showed little variance within repeated tumor 
sample, but high variance across different tumors, and then used this gene set for subtype 
discovery. Among these breast cancers, patterns of expression of these genes divided the tumors 
into five subtypes, which are called “intrinsic subtypes”, because the gene list that defines them 
reflects intrinsic properties of breast cancers rather than selected clinical behavior104. These 6 
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intrinsic suptypes include luminal A, luminal B, her2-enriched, basal-like, claudin-low and 
normal-like breast cancers105. These subtypes have been consistently identified in independent 
datasets using multiple different methods106-108. They are conserved across ethnic groups, and are 
present in preneoplasia109,110. Importantly, the intrinsic subtypes of breast cancer can predict 
patient relapse, overall survival, and response to endocrine and chemotherapy regimens111,112. 
 
Basal-like breast cancer 
In clinical studies, there is a group of breast tumors known as “triple-negative” due to 
their typical immunohistochemical (IHC) staining that is negative for ER, PR, and HER2, which 
are commonly scored for predictive markers in breast cancer clinics113. About 80% of triple-
negative breast cancer (TNBC) is basal-like106. Likewise, a majority of basal-like breast cancers 
are triple-negative; about 25% of basal-like tumors are not triple-negative114. The basal-like 
subtype is characterized by low expression of the luminal genes and the HER2 gene cluster, high 
expression of the proliferation cluster, and high expression of genes called the basal cluster106. 
The basal gene cluster includes basal epithelial cytokeratins (CK) such as CK5, 6, 14, and 17; 
epidermal growth factor receptor (EGFR); c-Kit; Vimentin; P-Cadherin; Fascin; Caveolins 1 and 
2; and aB-crystallin106. Importantly, it was the expression of cytokeratins 5, 6, 14, and 17 that 
gave rise to the term “basal-like,” as these are typically cytokeratins that are expressed within 
basal epithelial cells of the skin and airways103.  
Several genetic risk factors for developing basal-like tumors have been identified. One of 
the most interesting links is between the basal-like subtype and BRCA1 mutation carriers115-117. 
Specifically, if a woman is a BRCA1 muatation carrier and develops breast cancer, over 80% of 
the time her cancer is the basal-like subtype103. Although BRCA1 mutation carriers usually 
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develop basal-like breast cancer, most basal-like breast cancers are sporadic, and the BRCA1 
gene and protein appear intact in these tumors118. Other known genetic defects in basal-like 
tumors include a high P53 mutation rate119,120 and loss of RB1 function121,122. P53 and Rb are 
two tumor suppressor genes. Loss or mutation of P53 and/or Rb results in increased cell 
proliferation that is manifested by the high expression of the “proliferation signature”123. 
Another notable association is between the basal-like subtype, race, and age. Several population-
based studies have suggested that the basal-like subtype is prevalent in young women with breast 
cancer, especially in the African-American population120,124,125 126. In the Carolina Breast Cancer 
Study, which is a population-based, case-control study of environmental and molecular 
determinants of breast cancer risk that oversampled African American and premenopausal 
women120,127, basal-like breast cancer was the most common among premenopausal African-
American women (27%) and least common among postmenopausal non African-American 
women (9%)31. Interestingly, this over-representation of basal-like cancers is even more 
prevalent in Africans in Nigeria128. These findings suggest that there may be a genetic 
predisposition of Africans to basal-like tumors. The frequency of MYBL2 alleles has been found 
to be increased in basal-like cases versus controls129. In the Cancer Genome Atlas (TCGA) study, 
when tumors from different organs were analyzed based on their gene expression, basal-like 
breast tumors fell into their own category, indicating that basal-like breast cancer is distinct from 
other breast cancer subtypes130. 
There are life history risk factors for developing basal-like cancers, including multiple 
pregnancies (≥3), no lactation, and having a high waist/hip ratio (a more accurate indicator of 
obesity compared to BMI)31. Notably, pregnancy is a protective factor for luminal breast cancer. 
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This indicates that basal-like and luminal subtypes require different prevention strategies based 
on different risks. 
 
C3(1)-Tag Mouse Model 
The C3(1)-Tag mouse model was created on FVB/N background in Jeffery Green’s lab at 
NCI. It was originally created for the study of prostate cancer. C3(1)-Tag mice express simian 
virus large T antigen (Tag) under the 5’ region of prostate steroid binding protein.  SV 40 Tag 
can inactivate p53 and Rb, which are tumor suppressor genes, by directly or indirectly binding to 
them131. Researchers found that male C3(1)-Tag mice develop prostate cancer, while female ones 
develop breast cancer132. Green’s lab reported that, at 8 weeks old, C(3)1-Tag mice developed 
atypical hyperplasia of ductal epithelium; at 12 weeks ductal carcinoma in situ (DCIS) appeared; 
at 16 weeks female mice developed tumors and DCIS became invasive ductal carcinoma 
(IDC)132,133. The SV40 Tag used in the C3(1)-Tag model inactivates p53 and RB, which also 
occurs in human basal-like tumors because these tumors are known to harbor p53 mutations134 
(Figure 1.3&1.4). Hershkowitz et al. demonstrated that tumors from C3(1)-Tag mice 132 display 
characteristics consistent with human basal-like breast tumors including BRCA1-deficiency, 
TP53 mutant/deficiency, and high expression of Keratin 5, 17, and P-Cadherin135. Thus, for 
basal-like breast cancer, the C3(1)-Tag mouse is representative of human tumors.  
Using genetically engineered modified mouse models (GEMM) such as the C3(1)-Tag 
mouse is advantageous because the timeline of tumor progression is clearly established in this 
mouse model and it allowed us to investigate basal-like breast carcinogenesis, namely to 
understand the role of obesity in promoting tumorigenesis and decreasing tumor latency. In 
contrast to xenograft models (which often have altered tissue composition due to clearing of the 
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fat pad and/or altered immune function), the C3(1)-Tag mouse has an intact stroma and requires 
no chemical treatment to initiate tumors.   
 
 
High Fat Diet, Obesity and Breast Cancer 
Obesity is associated with increased risk of cancers, including breast cancer. Increased 
body weight was associated with increased death rates for all cancers in a prospective cohort 
study of U.S. adults136. Considering the high prevalence of obesity (35.7%) and overweight 
(68.8%) in the US137, targeting obesity could be an effective intervention for cancer prevention. 
Adulthood is an important window of susceptibility for obesity-induced breast cancer138. Early 
epidemiologic studies indicated that obesity did not increase breast cancer risk among 
premenopausal women, but did increase risk in postmenopausal women by around 50%139. 
Indeed, weight gain during adult life increases the risk of breast cancer among postmenopausal 
Adapted from Murphy ED, 1966 
Figure 1.4. C3(1)-Tag mouse model. C3(1)-Tag mice are on FVB/N background and 
express simian virus 40 (SV40) large T antigen (Tag) under the 5’ region of prostate 
steroid binding protein (PSBP).  SV 40 Tag can lead to cancer onset by inactivating p53 
and Rb, which are 2 tumor suppressor genes, by directly or indirectly binding to them. 
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women in the prospective Nurses' Health Study. However, recent advances in technology have 
shed light on breast cancer biology130 and specifically on obesity-induced risk. It has been 
established that breast cancer has multiple subtypes29. Breast cancer can be classified based upon 
different intrinsic subtypes each with distinctive gene expression profiles as discussed above 29. 
This genomic-based classification is now being used to better understand breast cancer and can 
predict prognosis based on each subtype140. Therefore, early epidemiologic studies (that were not 
stratified based on subtype or only examined ER status) which suggested that obesity is only a 
risk factor in post-menopausal women, were actually based on populations heavily represented 
by the most prevalent breast cancer: Luminal A. Luminal A is a subtype that affects mainly older 
Caucasian women. In the case of BBC, several epidemiologic studies have demonstrated that 
obesity as measured by BMI or waist hip ratio (WHR) is associated with risk of BBC in both 
young (pre-menopausal) and older (post-menopausal) women31,141,142 . The prevalence of BBC is 
about 12.3–36.7% of all breast cancer cases143. The mechanism defining the relationship between 
obesity and BBC is not well known and is the subject of my studies. Of all the subtypes of breast 
cancer, BBC is a severe clinical problem because there are no targeted therapies, driving us to 
investigate potential modifiers of risk. 
Studies in preclinical models demonstrate that obesity is associated with shortened 
mammary tumor latency144,145. Soner et al. found a connection between body weight and 
mammary tumor incidence and development in MMTV (mouse mammary tumor virus)-TGFα 
mice146. MMTV-HER2/Neu mice fed on a diet with 45% of calories from fat for a year starting 
at 4 weeks old had increased body weight, fat mass, and increased mammary tumor numbers 
compared to mice fed a LFD (10% calories from fat)147. Dunlap et al. reported that C57BL/6 
mice receiving a xenograft fed a HFD (60% calories from fat) for 14 weeks have increased tumor 
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progression of claudin-low breast cancer compared to mice fed a control diet (10% calories from 
fat)148. Obesity induced by HFD was also found to promote mammary tumor progression in 
C57BL/6 mice with MMTV-Wnt-1 tumor cell xenografts149. Prior to our recent publications, no 
studies examined the effects of obesity on BBC using murine models. We previously reported 
that obesity significantly decreased BBC latency in C3(1)-Tag mice150.  
 
Weight Loss and Breast Cancer 
The WHO suggested that body weight and physical inactivity together account for 
approximately one-fifth to one-third of the most common cancers, including breast cancer151. It 
may be possible to decrease the risk of breast cancer by exercising and maintaining a healthy 
weight152-154. Michels et al. reported that weight loss of 5 kg or more since age 18, maintained for 
at least 4 years, was related to lower incidence of premenopausal breast cancer when compared 
to maintaining a stable weight155. In the Iowa Women's Health Study based on 34,000 women, 
maintaining ≥5% weight loss reduced post-menopausal breast cancer risk by approximately 
25%156. A prospective cohort study within the Nurses' Health Study indicated that weight loss 
after menopause is associated with a decreased risk of breast cancer157. Furthermore, weight loss 
of 10% or more reduces breast cancer risk in postmenopausal overweight and obese women158.  
Based on Carolina Breast Cancer Study, it has been estimated that up to 68% of BBC could be 
prevented by promoting breastfeeding and reducing abdominal adiposity31. However, it hasn’t 
been proved whether reducing weight in adulthood would decrease the risk of BBC in 
experimental models. Weight loss in animal models is commonly induced by calorie restriction. 
Caloric restriction is defined as the consumption of fewer calories without malnutrition159. 
Calorie restriction protects against the development of different types of cancers including breast 
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cancers in various animal models 157. A meta-analysis of experimental mouse models also 
suggested that energy restriction decreased tumorigenesis in the mammary gland160. Cleary et al. 
reported that intermittent calorie restriction-refeeding provided a moderate protective effect 
against mammary tumor development in MMTV-neu transgenic mice, which is an animal model 
of luminal breast cancer161. Caloric restriction using a murine xenograft model of BBC 
demonstrated reduced tumor growth148.  None of these studies examined weight loss in a 
BBCwith a GEMM model. Green et al. demonstrated the protective benefits of exercise on BBC 
tumor progression, potentially through a significant exercise-induced weight loss, but the effects 
of exercise versus weight loss were not investigated162. Our group previously showed that in 
C3(1)-Tag mice made obese from weaning that were then induced to lose weight demonstrated a 
decrease in tumor progression that correlated with weight loss163. In sum, human and murine 
models demonstrate that high fat diet induced obesity is a strong but modifiable risk factor for 
breast cancer, although the protective effects and mechanisms of weight loss specifically on BBC 
must be further investigated. 
 
The Possible Mechanisms of Obesity-induced Cancer 
There are many hypotheses about how obesity is linked to cancer including hormonal 
promotion, alterations to the microenvironment, and release of growth factors13. Since BBC is 
triple negative (estrogen receptor, progesterone receptor, and HER2-negative), it is likely that 
obesity-induced production of estrogen through aromatase is not a strong driver of tumor onset. 
Indeed, our recent work in C3(1)-Tag mice has demonstrated no obesity-induced alterations in 
systemic estrogen levels or mammary gland concentrations of aromatase150. The role of the 
microenvironment or the “seed and soil” theory, where cancer cells (the seeds) are modulated by 
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the stroma (the soil) is a likely hypothesis that may contribute to carcinogenesis. The 
microenvironment surrounding a tumor has been realized to play an important role in tumor 
onset and progression32. When the microenvironment is normal, it can suppress tumorigenesis. 
However, changes in the microenvironment can also promote tumorigenesis and progression32 
(Figure 1.5).  
 
 
 
Modulated from Bissell MJ 2011; Sundaram S 2013. 
Figure 1.5. The role of microenvironment in tumor progression. Normal tissue 
homeostasis and architecture inhibit progression of cancer. Disruption in the 
microenvironment (e.g. obesity) can promote tumorigenesis and progression. 
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The metabolites, growth factors, hormones and modifications of extracellular matrix in 
this microenvironment have critical effects on tumor cells. In fact, multiple reports from the 
Troester lab have demonstrated that BBC is characterized by unique epithelial-stroma 
interactions, which likely play a role in the etiology164. There were numerous alterations in the 
gene expression profiles in the microenvironment of breast tumors compared to normal breast 
tissues165. BBCs are more likely to recur locally than non-BBC cancers166, even after 
mastectomy with clean margins, suggesting a local field defect167 that may arise from epithelial 
or stromal alterations in the microenvironment.  
Stroma-derived growth factors and metabolites are strongly relevant to obesity-induced 
cancer onset by modifying the extracellular matrix or angiogenic factors provided by the stroma.  
Hepatocyte growth factor (HGF) is a good example. High expression of cMet, the receptor of 
HGF, is significantly correlated with BBC in mouse and humans168. Our previous studies have 
shown that obesity upregulates HGF and cMet expression in the normal mammary gland of 
C3(1)-Tag mice, and this upregulation of HGF/cMet is correlated with a shortened latency150. 
Likewise, after life-long obesity, weight loss also decreased HGF/cMet expression in normal 
mammary glands163. cMet signature in 87% of BBC tumors and patients predicted worse 
outcomes169. In a mutant mouse deficient for luntatic fringe (Lfng), a sugar transferase, the Perou 
lab demonstrated induction of BBC with amplification of the cMet locus and elevated cMet 
signaling170.  
Furthermore, we and other research groups have demonstrated that obesity is associated 
with low-grade adipose inflammation in adipose tissue18,23,171. In the mammary gland, ours and 
Dannenberg’s labs have reported that macrophage infiltration occurs in the normal mammary 
gland of human subjects172-174. We have also found increased macrophage infiltration in 
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mammary glands of obese C3(1)-Tag mice (manuscript in prep). In addition to HGF release from 
immune cells like monocytes and macrophages, inflammatory cytokines release from activated 
macrophages contribute to breast cancer onset and development175,176.  
Obesity can also disturb the microenvironment by reprogramming the kinome, or 
activating and interrupting growth factor/receptor signaling, such as leptin andother 
mediators13,18. Leptin is a hormone produced by adipocytes in proportion to adiposity. A meta-
analysis of case-control studies reported that women with breast cancer have elevated plasma 
leptin levels. High leptin receptor mRNA expression in breast cancer tissue was also established 
to predict poor prognosis in patients with high serum leptin levels.  Therefore leptin may play a 
central role at the interface of obesity and breast cancer and may act through several pathways13. 
One way that leptin may drive BBC is that leptin promoted the survial of cancer stem cells 
(CSCs) in vivo 177, and leptin signaling is required to maintain CSC-like properties in triple 
negative breast cancer cells, which was shown to mediate tumor recurrence and metastasis in 
orthotopically transplanted mice. Leptin signaling also induces breast tumor cell growth through 
activation of the JAK-STAK and PI3K signaling pathway in both human and mouse cell lines. 
Leptin receptor deficiency in MMTV-PyMT mice was shown to attenuate tumor growth and 
metastasis through increasing mitochondrial respiration capacity in tumor cells and deactivating 
the downstream ERK and STAT3 pathways. About one fourth of all kinases may be involved in 
oncogenesis. Protein kinases regulate cell proliferation, survival, and metabolism and can 
contribute to tumor progression.  
Taken together, in many ways, the microenvironment of breast tumors may be modified 
by obesity. Therefore, based on published literature and findings from our lab, it is likely that the 
microenvironment plays a strong etiologic role in BBC. 
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Summary  
In modern society, lifestyle related factors might play a more important role in diseases 
compared to the genetic background. There is compelling evidence that the microenvironment 
can regulate disease onset and progress. This dissertation details evidence that the life style alters 
the microenvironment, which  reflects and contributes to systemic inflammation, obesity, glucose 
intolerance, and basal-like breast cancer. This dissertation also addresses the gap in knowledge 
among obesity and cancer studies, which may shed light on mechanisms of how the 
microenvironment is regulated by lifestyle factors and leads to different diseases. Considering 
the high prevalence of obesity in the US and the high rate of alcohol consumption (87.6% of 
adults), our studies will have a significant potential to develop prevention strategies for these 
public health issues, like breast cancer and inflammation-related diseases. 
Hypothesis: Lifestyle-related factors like alcohol consumption and high fat diet 
contribute to varied diseases including obesity and breast cancer through altering the 
microenvironment.  
The hypothesis is tested in 3 different studies, which will be described in details below. 
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CHAPTER П: ADIPOSE INFLAMMATION AND MACROPHAGE INFILTRATION 
AFTER BINGE ETHANOL AND BURN INJURY. 
Qin Y, Hamilton JL, Bird MD, Chen MM, Ramirez L, Zahs A, Kovacs EJ, Makowski L. 
 
Overview 
Ethanol (EtOH) exposure prior to traumatic injury, such as a burn, elevates systemic and local 
inflammatory responses and increases morbidity and mortality. Adipose is a large tissue mass 
that is often inflamed during obesity or other stresses, which disturbs metabolic homeostasis. To 
date, there has been little investigation into the inflammatory response of adipose tissue after 
combined EtOH exposure and burn injury. Two EtOH exposure regimens were utilized to 
examine the role of inflammation in adipose tissue after EtOH and burn injury. Mice were either 
given a single or episodic binge exposure to EtOH or saline followed by scald (burn) or sham 
injury 30 minutes later. Twenty-four hours post injury, serum and adipose tissue were collected 
for assessment of inflammatory mediators. Single binge EtOH alone induced no inflammation in 
adipose when compared with sham vehicle-treated mice. However, single binge EtOH followed 
by burn injury induced significant elevations in mRNA and protein concentrations of pro-
inflammatory mediators interleukin-6 (IL-6), KC, and monocyte chemoattractant protein 1 
(MCP-1) compared with either insult alone or sham vehicle group. Additionally, EtOH exposure 
and burn injury significantly blunted inducible nitric oxide synthase (iNOS), indicating a 
complex inflammatory response. Episodic binge EtOH exposure followed by burn injury 
exacerbated the postburn adipose inflammatory response. The magnitude of the episodic binge
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 induced inflammatory parameters postburn were 2- to 5-fold greater than the response detected 
after a single exposure of EtOH, indicating EtOH-induced potentiation of burn-induced 
inflammatory response. Finally, inflammatory loci and crown-like structures in adipose were 
significantly increased by episodic binge EtOH and burn injury. This is the first report of binge 
and burn-induced crown-like structure formation. Evidence presented herein suggests an 
important role for alcohol and burn as an additional mediator of adipose inflammation in 
postburn injury, a common complication in burn patients. 
Introduction 
Burn-induced hyperglycemia, hepatosteatosis, and insulin resistance are common 
complications observed in the burn patient population and are associated with poor outcomes, 
contributing significantly to morbidity and mortality47,48. Insulin resistance in liver, skeletal 
muscle, and adipose can persist even 3 weeks after burn injury49,50,178. Burn injury also drives 
systemic inflammation with elevations in pro-inflammatory cytokines and suppressed cell-
mediated immunity, leading to multi-organ dysfunction179. One mechanism of systemic insulin 
resistance may be through adipose dysfunction and inflammation180. Macrophages are known to 
infiltrate adipose during states of metabolic stress, such as in obesity, and contribute to 
inflammation, uncontrolled lipolysis, as well as local and systemic insulin resistance180.  
Clinical and laboratory studies have demonstrated that ethanol exposure prior to 
traumatic injury, such as a burn, markedly elevates systemic and tissue-specific inflammatory 
responses9,10 and is associated with poorer outcomes11. In the United States, half of the patients 
with burn-related injuries have alcohol in their system at the time of admission and the vast 
majority of those subjects are binge drinkers rather than chronic alcoholics8. It is well-established 
that alcohol increases the dysregulated inflammatory and immune response caused by burn in 
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animal models and patients (reviewed in9). We and others have shown previously that 
neutrophils infiltrate the gut, lung, and site of injury after the combined insult181-186.  While the 
primary role of neutrophils is to clear pathogens, they often cause damage due to production of 
enzymes such as elastase, reactive oxygen species, and pro-inflammatory cytokines including IL-
6, IL-1β, and tumor necrosis factor alpha (TNF). Serum cytokines IL-6 and TNF and tissue 
levels of KC and IL-6, are elevated in response to the dual insult of ethanol and burn injury 
compared to either injury alone182,186. 
Chronic ethanol has been shown to drive macrophage infiltration into adipose tissue and 
it is associated with reduced fat mass due to upregulated lipolysis187,188. To date, it is not known 
how ethanol exposure combined with burn injury affects the adipose microenvironment. Using 
an established murine model of binge ethanol exposure and burn injury, we demonstrated that 
the combined insults drove systemic and adipose inflammation 24 hours post-injury. 
Furthermore, we found that employing an episodic multi-day binge ethanol exposure paradigm 
followed by burn injury potentiated adipose inflammation and induced macrophage infiltration, 
indicating that binge, and especially episodic binge ethanol exposure, followed by burn drives 
adipose inflammation that could contribute to systemic inflammation.  
Results 
Single and episodic binge and burn injury drive inflammation in adipose tissue 
In our previous work, we demonstrated that serum IL-6 was higher at 24 hours after 
combined ethanol exposure and 15% total body surface area scald compared to either insult 
alone 189. To determine if adipose tissue might contribute to the elevated systemic inflammation 
seen after ethanol and burn injury, we examined the expression of IL-6 and other inflammatory 
mediators in adipose tissue. As shown in Figure 2.1A, IL-6 mRNA levels were not altered by 
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ethanol exposure alone and increased 4-fold with burn injury compared to sham mice. IL-6 
mRNA was significantly upregulated after the combined insult when compared to all other 
groups (P<0.001). Likewise, the adipose tissue level of IL-6 protein was unchanged after ethanol 
exposure alone, and was 6-fold higher in adipose tissue from burn vehicle mice compared to 
sham mice (Figure 2.1B). Ethanol exposure doubled the burn-induced elevation in adipose IL-6 
protein (Figure 2.1B, P<0.05 burn ethanol vs. sham groups).   
Further studies were conducted to determine if a more severe alcohol exposure paradigm, 
such as a multi-day episodic binge prior to burn would drive adipose inflammation when 
compared to a single binge followed by burn. To accomplish this, mice were given ethanol (or 
saline) for 3 days, rested 2-4 days, and exposed again for 3 days prior to burn or sham injury. 
Ethanol alone did not modulate IL-6 mRNA or protein expression (Figure 2.1C&D). After 
episodic binge ethanol exposure and burn, adipose tissue IL-6 mRNA levels were 18-, 42- and 
12-fold higher than sham vehicle, sham alcohol and burn vehicle, respectively, (Figure 2.1C, 
P<0.001 all groups versus burn ethanol). Significant interactions existed between burn and 
ethanol in single binge treatment and in episodic binge for IL-6 mRNA expressions. No 
significant interactions were found in single and episodic binge for IL-6 protein expression. 
Moreover, adipose levels of IL-6 protein reached 110 pg/mg, a value which is approximately 2 
times that of burn alone and 8-fold that of sham groups (Figure 2.1D, P<0.05). Of note, IL-6 
protein levels in adipose tissue were 3 times greater in tissue obtained from episodic binge and 
burn injury mice compared to tissue from mice exposed to a single binge and burn (Figure 2.1B 
compared to Figure 2.1D).  
The presence of neutrophils in adipose tissue after either ethanol exposure or burn injury 
alone, or the combined insult was investigated, as was previously observed in gut and lung 182,189. 
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Like IL-6, levels of the neutrophil chemokine KC were not increased after a single binge ethanol 
exposure, however, burn alone (in the absence of ethanol exposure) elevated KC mRNA and 
protein by approximately 5-fold, although this did not reach significance (Figures 2.2A&B). A 
statistically significant interaction between single binge and burn existed in the mRNA 
expression of KC (p<0.05), but this was lost at the protein level. Combined binge ethanol and 
burn exposure significantly elevated expression of KC 8-fold at the mRNA level compared to all 
other groups (Figure 2.2A, P<0.01), while ethanol plus burn increased KC protein levels 50% 
over burn alone (Figure 2.2B, P<0.05 versus sham groups). Based upon elevations in neutrophil 
chemokine, we next examined if there was neutrophil infiltration into adipose tissue in response 
to ethanol exposure and burn injury by measuring expression of elastase, an enzyme enriched in 
neutrophils and demonstrated to correlate with neutrophil infiltration into adipose 190. There were 
no significant changes in adipose tissue mRNA levels of neutrophil elastase following any 
treatment (Figure 2.2C). Although burn elevated KC mRNA levels compared to sham in 
episodic binge treatment, there were no statistically significant alterations between groups 
(Figure 2.2D). In contrast, while adipose tissue KC protein levels were not altered by ethanol 
alone, KC protein levels were nearly 4 times higher after burn alone compared to sham ethanol 
mice and were elevated 4-fold in ethanol plus burn injured mice compared to both sham groups 
(P<0.05, Figure 2.2E). There were no statistically significant interactions between burn and 
episodic binge in KC mRNA or protein expression. Relative to sham vehicle mice, mRNA levels 
of elastase were not significantly elevated after episodic binge exposure (Figure 2.2F). Burn 
alone was not different than sham vehicle, but was reduced to 40% the level of sham episodic 
binge (Figure 2.2F, P<0.05). However, episodic binge ethanol and burn injury dramatically 
blunted elastase expression 83% compared to sham vehicle (P<0.01) or by 89% versus sham 
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ethanol treated mice (P<0.001, Figure 2.2F). This latter observation in episodic binge exposure 
differs from the adipose response to single ethanol exposure with and without injury where no 
significant differences were detected (Figure 2.2C&2.2F). No interaction was found in elastase 
mRNA expression in single binge, but there was a significant interaction (p<0.05) between burn 
and ethanol in episodic binge.  
Macrophage infiltration is evident in adipose tissue after episodic binge exposure and burn 
injury 
We next sought to examine if macrophages were responsible for the observed elevations 
in adipose IL-6 levels by investigating the degree of macrophage infiltration into adipose tissue 
after episodic binge ethanol exposure and burn injury. We and others have demonstrated that the 
formation of crown-like structures is a well-documented measure of adipose tissue inflammation 
that correlates with insulin resistance23,180,188. Immunohistochemical (IHC) analysis was used to 
quantitate the number of F4/80-positive (F4/80+) crown-like structures. Representative images 
are shown in Figure 2.3A. No crown-like structures were detected in sham vehicle mice (Figure 
2.3B). Mice exposed to ethanol or burn injury alone had detectable crown-like structures, but 
these measures did not reach statistical significance compared to sham vehicle mice (Figures 
3B). However, the combined injury of episodic ethanol exposure and burn yielded a significant 
2.5-and 4-fold increase in the crown-like structures compared to sham episodic binge, and burn 
vehicle, respectively (Figure 2.3B, P<0.01 both vehicle groups vs. burn ethanol, P<0.05 sham 
ethanol vs. burn ethanol). Sham ethanol treated adipose samples displayed an 8-fold elevation in 
F4/80+ inflammatory loci compared to sham vehicle (Figure 2.3C, P<0.05). There was a 
significant 12-fold increase in inflammatory loci in adipose tissue from burn vehicle, and a 16-
fold increase from episodic binge and burn mice, over that of sham vehicle mice (Figure 2.3C, 
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P<0.01 sham vehicle vs. burn vehicle and P<0.001 sham vehicle vs. burn ethanol). No 
interaction between burn and ethanol was found in episodic binge with the numbers of crown-
like structures or inflammatory loci. 
The expression of monocyte chemokine MCP-1 was next examined because it is a pro-
inflammatory mediator demonstrated to be necessary and sufficient to drive macrophage 
infiltration into adipose tissue and induce crown-like structure formation180. In the absence of 
burn injury, mRNA and protein levels of MCP-1 were not altered by single binge ethanol alone 
(Figure 2.4A&B). The ethanol plus burn group displayed significant 5-fold increases in MCP-1 
mRNA expression compared to both vehicle groups (Figure 2.4A, P<0.05). Burn injury alone 
doubled MCP-1 protein content in adipose versus sham vehicle (Figure 2.4B). MCP-1 protein 
was significantly increased in ethanol plus burn injured mice compared to sham treated groups 
(Figure 2.4B, P<0.01 sham vehicle versus burn ethanol, P<0.05 sham ethanol versus burn 
ethanol). Adiponectin is an anti-inflammatory adipokine that promotes insulin sensitivity 180. 
Nagy et al. demonstrated down regulation of adiponectin mRNA associated with chronic 
ethanol-induced adipose inflammation188. Single binge and burn significantly blunted 
adiponectin mRNA expression by 75% (Figure 2.4C, sham vehicle (P<0.001) or burn vehicle 
(P<0.05 vs. burn ethanol). Episodic binge did not change MCP-1 mRNA expression in mice, nor 
were levels significantly upregulated after burn (Figure 2.4D). MCP-1 protein levels were 
elevated more than 2-fold in mice exposed to episodic binge plus burn injury versus sham 
vehicle controls, although this increase was not statistically significant (Figure 2.4E). 
Importantly, MCP-1 protein levels were nearly 3 times as high in adipose tissue obtained from 
mice with episodic binge alcohol exposure prior to burn relative to single ethanol exposure plus 
burn injury (Figure 2.4B compared to Figure 2.4E). Episodic binge did not modulate 
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adiponectin levels (Figure 2.4F). No significant interactions between burn and ethanol were 
found in MCP-1 or adiponectin mRNA or protein expression with single or episodic binge 
treatment. 
Protein levels of other pro-inflammatory (TNFα, IL-1β) or anti-inflammatory (IL-10) 
cytokines were not significantly different between each treatment group in single binge and burn 
studies (Figure 2.5 A-C). Interestingly, inducible nitric oxide synthases (iNOS) mRNA was not 
altered by ethanol exposure alone, but was significantly suppressed by 75% in both burn groups 
when compared to respective sham treated groups with greatest attenuation due to the 
combination of ethanol and burn (Figure 2.5D, P<0.001 burn treated groups vs. sham treated 
groups). Episodic binge followed by burn did not significantly change protein levels of TNFα, 
IL-1β and IL-10 (Figures 2.5 E- G). Similar to acute binge exposure and burn injury, the 
adipose iNOS mRNA level was not significantly altered by episodic ethanol, and was reduced by 
burn injury regardless of ethanol exposure. Compared to sham ethanol, burn ethanol iNOS 
mRNA was blunted 54% (Figure 2.5H, P<0.05). There were no significant interactions between 
burn and ethanol in any of the cytokines with single or episodic binge treatment. 
Discussion 
Half of burn patients admitted to the hospital consumed alcohol prior to sustaining their 
injuries8,191,192 . The vast majority of inebriated burn patients is not chronic alcohol abusers, but 
rather binge drinkers. Recent evidence suggests that binge drinking is on the rise with 1 in 6 
Americans reporting an average of four binge drinking episodes per month. Thus, gaining a 
better understanding about the effects of episodic binge alcohol exposure on post burn morbidity 
and mortality is of immediate public health relevance. Burn injury induces dramatic insulin 
resistance, hyperlipidemia, and hyperglycemia, contributing to elevated morbidity and 
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mortality47,49. Ethanol exacerbates burn-induced inflammation and impairs the immune response, 
thus increasing a patient’s susceptibility to infection9.  
Previous work by our lab has demonstrated that IL-6 is elevated in serum, lungs and gut 
of animals exposed to ethanol and burn182,186. We provide evidence herein that cytokines and 
chemokines are also elevated in adipose tissue suggesting that this tissue may be an additional 
source of circulating inflammatory mediators. Adipose tissue plays a critical role in maintaining 
systemic metabolic homeostasis, and adipose inflammation leads to metabolic dysregulation 
characterized by insulin resistance, hyperlipidemia and hyperglycemia – all of which commonly 
occur in burn patients. We set out to examine the role of adipose inflammation in response to the 
combined insult of ethanol exposure and burn injury. We have demonstrated that mice singly or 
episodically exposed to ethanol alone did not mount a dramatic inflammatory response in 
adipose tissue in the absence of a secondary insult such as burn. However, in mice administered 
a single ethanol binge and burn injury, there was a dramatic elevation in the pro-inflammatory 
response in adipose tissue indicated by elevations of cytokine and chemokines IL-6, KC, and 
MCP-1, along with a blunting of adiponectin, an anti-inflammatory adipokine. IL-6 is primarily 
secreted by macrophages and T cells to stimulate the immune response, e.g. during infection and 
after burn9, and elevated serum IL-6 in injured patients is correlated with negative outcomes193. 
While we detected elevations in KC, we found that there was no change in neutrophil elastase in 
adipose tissue after single binge ethanol exposure, burn injury, or the combined insults. It is 
likely that 24 hours post-injury may not be the correct time point for the neutrophil composition 
of adipose to be dramatically regulated, unlike the neutrophil response in lung, skin, or gut. 
Furthermore, Nagy et al. reported down regulation of the anti-inflammatory adipokine 
adiponectin in chronic ethanol-induced adipose inflammation, while Xu et al. showed that 
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increasing adiponectin improves alcoholic fatty liver disease188,194. We demonstrate dramatic 
blunting of adiponectin after single binge and burn, which may aid in driving the pro-
inflammatory milieu. Finally, iNOS was down-regulated by single binge ethanol and burn injury. 
Interestingly, Syapin et al. have demonstrated that iNOS is inhibited by ethanol in glial cells195. 
In other tissues, burn has been shown to elevate iNOS expression or have no effect196,197. Hence, 
iNOS regulation by ethanol and burn in adipose needs further investigation. Taken together, our 
data support the findings that adipose tissue may be a source of some circulating cytokines after 
single binge ethanol and burn injury.  
Binge drinking is not usually a single acute event; binge drinkers tend to consume alcohol 
in multiple binge episodes. Using an episodic binge model, we demonstrated that burn-induced 
inflammation was markedly elevated in mice given multiple exposures to binge levels of ethanol 
and that this occurred to a greater extent than following a single binge exposure. Similar to single 
binge, after episodic binge and subsequent burn, IL-6 and KC were elevated compared to either 
insult alone or sham vehicle controls. Despite elevations in KC protein in combined injury, 
neutrophil elastase mRNA level was dramatically reduced in burn ethanol groups relative to 
either insult alone. This was a surprising finding because other insults such as a 3 day exposure 
to high fat diet have been shown to induce neutrophil infiltration into adipose tissue190,198, which 
persisted for up to 90 days190. Perhaps a more detailed study of episodic binge and burn injury 
over a time course might capture neutrophil infiltration in response to high levels of KC. Even 
with dramatic increases in IL-6, KC, and MCP-1 associated with episodic binge ethanol 
exposure, iNOS was blunted similar to a single binge. It is evident that while some production of 
pro-inflammatory cytokines or chemokines occurs in response to burn and ethanol, some 
immunosuppression is concurrent. Future studies will include examining the role of IL-6 in 
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adipose inflammation as it has been shown to be both pro-inflammatory and anti-inflammatory 
in binge and burn injured animals, and may mediate some of the divergent effects demonstrated.  
Finally, we report for the first time that F4/80+ macrophages were detected in adipose 
crown-like structures and inflammatory loci resulting from episodic binge ethanol exposure and 
burn injury, likely due to elevations in MCP-1. MCP-1 and its receptor CCR2 have been shown 
to mediate macrophage infiltration into adipose tissue in response to obesity180, and these 
infiltrating macrophages often surround dying adipocytes forming crown-like structures180. Kang 
et al. have demonstrated infiltration of macrophages and production of pro-inflammatory 
cytokines, IL-6, MCP-1and TNF, in adipose tissue after chronic ethanol exposure for 4 
weeks188. Our data demonstrate that macrophage infiltration occurs within days after burn and 
ethanol exposure. 
From our studies it is evident that burn injury primarily drives inflammation in adipose 
tissue, and ethanol exposure prior to burn potentiates this response. The dramatic increase in 
magnitude of response between single and episodic binge exposure suggests that the driving 
factor in the inflammatory response is the frequency of the ethanol exposure, since the burn 
injury and time of sacrifice is identical in each group. Our findings support the relevance of 
adipose inflammatory response to ethanol and burn insult that warrants further investigation. 
Like ethanol, obesity is also associated with a prolonged increase in pro-inflammatory mediators, 
such as IL-6 and MCP-1, an impaired immune response, and an increased susceptibility to 
bacterial infection180,199. Work from our group and others over the past decade has linked adipose 
inflammation to obesity and insulin resistance22,23,180.  
One mechanism linking both obesity-induced inflammation and ethanol exposure that 
could drive insulin resistance is an increase in gut permeability, resulting in bacterial 
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translocation into tissues to induce both organ-specific and systemic inflammation. We have 
previously reported on increased gut permeability and bacterial translocation in ethanol and burn 
models183,186,200,201. In humans and murine models, elevated morbidity and mortality result after 
burn injury due to inflammation secondary to intestinal permeability and septicemia183,186,201-203, 
which is often followed by an exaggerated alcohol-induced suppression of immune function 
through a lower delayed-type hypersensitivity (DTH) response and blunted lymphocyte 
proliferation203-206. At 6 and 24 hours post ethanol plus burn injury, gut permeability is 
compromised, which could account for elevated leukocyte infiltration, and IL-1β and IL-6 in 
mice exposed to ethanol then burn as compared to either insult alone183,186. Gut bacteria also 
regulate obesity susceptibility and systemic inflammation in response to high fat diet207. 
Additionally, we have previously demonstrated the dependence of toll-like receptor 4 (TLR4, but 
not TLR2) in ethanol and burn-induced lung pathology and pro-inflammatory response189. TLR4 
has also been shown to be necessary for obesity-induced inflammation208. Elevated gut 
permeability and bacterial translocation after the combined insult of ethanol and burn may be 
responsible for the rise in lipopolysaccharide (LPS, endotoxin) burden and a TLR4 dependent 
inflammatory response in adipose, similar to obesity.  
A second mechanism regulating ethanol and burn-induced alterations in adipose 
inflammation is lipolysis and adipocyte apoptosis, which would release free fatty acids into the 
local microenvironment and circulation. In humans, chronic alcohol use correlated with reduced 
fat mass209. Burn injury also results in loss of fat mass through apoptotic cell loss210. Duffy et al. 
(2009) demonstrated that insulin and glucose are elevated in patients post-burn compared to 
healthy controls, with burn-induced increases in cytokine release from adipose tissue 
macrophages and circulating monocytes, which could interfere with insulin signaling211. In 
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rodents, single binge and burn drive a transient microvesicular steatosis, while chronic alcohol 
exposure also leads to reduced fat mass and adipocyte size, along with an increase in 
hepatosteatosis and induction of systemic insulin resistance187,212. It has been shown that alcohol-
driven lipolysis is not catecholamine-mediated213. Ethanol has been shown to increase levels of 
phosphatase and tensin homolog (PTEN) and suppressor of cytokine signaling (SOCS3), which 
are important negative regulators of insulin signaling in both liver and adipose and can lead to 
elevated lipolysis and cytotoxicity187,214. It is possible that saturated free fatty acids liberated by 
lipolysis, which are known to signal through TLRs during obesity-induced inflammation and 
insulin resistance215, may mediate a pro-inflammatory response after ethanol and burn exposure. 
Additionally, reduction in fat mass through apoptosis or lipolysis contributes to reduced insulin 
sensitivity because fat is redistributed from adipose to other metabolically sensitive tissues, such 
as the liver where hepatosteatosis ensues180. Liver IL-6 and other pro-inflammatory mediators 
increase with ethanol and/or burn exposure182,216. Emanuele et al. demonstrated single and/or 
combined injury increased hepatic ICAM-1, IL-1β, TNFα, and nuclear NF-KB217 which can lead 
to insulin resistance. Indeed, we have previously reported that insulin administration to rodents 
after ethanol and burn, improves liver inflammation and microvesicular steatosis, demonstrating 
further evidence of links between metabolic homeostasis and inflammatory response217.  
Finally, a third mechanism linking ethanol intake to exacerbated inflammation is 
oxidative stress resulting from alcohol metabolism.  Besides alcohol dehydrogenase (ADH), 
ethanol can also be metabolized through the microsomal ethanol oxidizing system (MEOS) by 
cytochrome P4502E1 (CYP2E1), which has been shown to lead to increased oxidative stress40. 
CYP2E1 is mainly expressed in the liver, but also found in the white adipose tissues218. 
Sebastian et al.  demonstrated that CYP2E1 protein levels in adipose tissue were increased after 
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chronic ethanol feeding219. In our study, we failed to find a significant increase in mRNA or 
protein expression of CYP2E1 in adipose tissue of episodic binge, burned mice, or the combined 
exposure (data not shown). This may due to the type or length of exposure, as our treatment was 
shorter with either a one-dose single binge or episodic binge constituting a total of 6 days of 
ethanol exposure. 
Taken together, we report for the first time that there is an inflammatory response in 
adipose tissue after the combined insult of ethanol and burn injury, and that this response is 
augmented after episodic binge relative to a single ethanol exposure. While binge drinking leads 
to unintentional injuries such as falls, crashes and burns, it may also lead to more insidious tissue 
inflammation as comorbidity with obesity leading to insulin resistance. Future studies in lean 
versus obese rodents could yield further mechanistic insight into burn and ethanol-induced 
effects on local and systemic inflammation. 
Methods 
Mice. Male C57BL/6 mice, 8 to 10 weeks old, were obtained from Jackson Laboratories (Bar 
Harbor, ME). They were housed in cages with food and water available ad libitum at the Loyola 
University Medical Center Animal Facility in rooms that were temperature and humidity 
controlled on a 12-h light-dark cycle. All animal studies described here were performed 
according to the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals, 
National Institutes of Health and were approved by the Loyola University IACUC. Before each 
experiment, mice were weighed and those weighing 22 to 27 grams were used in the studies. 
Murine model of ethanol exposure and burn injury. The murine model of a single binge ethanol 
exposure and burn injury was employed as described previously205,220 with minor 
modifications189. Briefly, mice were given 1) either a single binge dose of 150 μl of 20% (v/v) 
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ethanol solution (1.12 g/kg) intraperitoneally (i.p.) that resulted in a blood ethanol level of 150 
mg/dl at 30 minutes or saline vehicle221 or 2) for episodic binge exposure, mice were given the 
same dose of ethanol (or saline) daily for 3 days consecutively, rested for 2-4 days (rest time did 
not alter outcome, data not shown), and then given 3 additional daily exposures. Thirty minutes 
after ethanol exposure (or the last ethanol exposure in the case of the episodic binge paradigm), 
mice were anesthetized with 100 mg/kg of Ketamine and 10 mg/kg of Xylazine (Webster 
Veterinary, Sterling, MA), their dorsum shaved, and placed in a plastic template exposing 15% 
of the total body surface area of their back220 and subjected to a scald injury in a 90 to 92°C 
water bath for 8 seconds. As a control, sham animals were anesthetized, shaved, and immersed in 
room temperature water. The scald injury resulted in an insensate, full-thickness burn injury of 
approximately 15% total body surface area181. To compensate for fluid loss and prevent 
circulatory shock, all animals received 1 mL of body temperature saline i.p. immediately after 
burn injury and were allowed to recover on warming pads. No other therapeutic intervention was 
provided as administration of anti-inflammatory or analgesic medication may introduce 
confounding factors into the assessment of inflammatory responses. Twenty-four hours after 
burn injury, mice were sacrificed using carbon dioxide (CO2) inhalation and cervical dislocation. 
Blood was collected for serum isolation and measurement of cytokines. Epididymal white 
adipose tissue was removed. Tissue was either snap frozen in liquid nitrogen and stored at -80ºC 
for mRNA isolation or immunologic analysis or fixed in paraformaldehyde, paraffin-embedded, 
and sectioned for immunohistochemistry. 
RNA isolation and analysis. QIAzol Lysis Reagent was used to isolate mRNA from adipose 
tissue with DNAse treatment (RNeasy Lipid Tissue Mini Kit mRNA; Qiagen, Valencia, CA). 
For quantitative PCR (qPCR) analysis, cDNA was synthesized using an iScript cDNA synthesis 
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kit (Bio-Rad, Hercules, CA). Real-time qPCR was completed using TaqMan Assay on Demand 
primers/probe sets (Applied Biosystems, Carlsbad, CA) as previously described23. qPCR 
reactions were run using an Applied Biosystems thermocycler and SDS 2.4 software (Applied 
Biosystems, Carlsbad, CA).  
Quantification of IL-6 in serum. Blood was obtained by cardiac puncture after sacrifice.  Serum 
IL-6 levels were determined by multiplex according to manufacture instructions (Invitrogen, 
Carlsbad, CA), as previously described189.  
Analysis of cytokine and chemokine protein levels. Adipose tissue was homogenized in 1 mL of 
BioPlex Cell Lysis Buffer according to manufacturer’s protocol (BioRad, Hercules, CA). 
Homogenates were then filtered and analyzed for IL-6, MCP-1, KC, TNFα, IL-10 and IL-1β 
protein levels by multiplex (BioRad, Hercules, CA) and normalized to the total amount of 
protein in adipose tissue homogenate as described189.  
Immunohistochemistry (IHC) examination of episodic binge exposed and burn-injured adipose. 
Paraffin-embedded tissues were sectioned at 5 microns and mounted for histological staining. 
Briefly, immunohistochemistry was carried out using anti-F4/80 primary antibody (Abcam 
ab562), similar to Sampey et al.23. All histological sections were digitally scanned on the Aperio 
ScanScope CS Ultra-Resolution Digital Scanner and analyzed by ScanScope Image Analysis 
Toolbox software (Aperio Inc., Vista, CA). Representative images for adipose tissue from each 
treatment group were selected. To determine the inflammatory state of the adipose tissue, ten 
randomly selected 10× fields per study animal were quantified for number of crown-like 
structures and inflammatory loci including F4/80+ macrophage staining. N= 4-7 mice per group.  
Statistical Analysis. Data are shown as means ± SEM. Analysis was performed using two-way 
analysis of variance (ANOVA). Post hoc comparisons were made with the Tukey post hoc test 
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using JMP (SAS Institute, Cary, NC) and significant interactions are described. P < 0.05 was 
considered significant. 
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Figure 2.1. Interleukin-6 (IL-6) levels increase after single and episodic binge ethanol 
exposure and burn injury. Mice received single binge (A-B), episodic binge (C-D), or 
vehicle control. Thirty minutes after ethanol, mice were either subjected to burn or sham 
injury, sacrificed 24 hours later, and adipose tissue was isolated, as described in methods. A. 
IL-6 mRNA was measured by quantitative (q)PCR and normalized to 18S. N=16, 16, 18 and 
19 for sham vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. There was a 
significant interaction between burn and ethanol (p<0.05). *** P<0.001 versus (vs.) all 
groups. B. Whole adipose tissue was homogenized and IL-6 protein levels were determined 
and normalized to the total amount of protein in the homogenate. N=4, 3, 5 and 5 for sham 
vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. No significant interaction 
was found between burn and ethanol. *P<0.05 vs. sham groups. C. After episodic binge and 
burn, IL-6 mRNA was measured by qPCR and normalized to 18S. N=7, 4, 7 and 10 for sham 
vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. There was a significant 
interaction between burn and ethanol (p<0.05). ***P<0.001 vs. all groups. D. IL-6 protein 
levels were detected after episodic binge in adipose tissue and were normalized to total 
protein as above. N=7, 5, 12 and 10 for sham vehicle, sham ethanol, burn vehicle and burn 
ethanol, respectively. There was no significant interaction between burn and ethanol in 
episodic binge treatment.*P<0.05 vs. sham groups. 
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Figure 2.2. Adipose expression of neutrophil chemokine KC after single and 
episodic binge ethanol and burn injury. Mice received single (A-C) or episodic 
binge (D-F), or vehicle control and burn, as described above. A. Adipose tissue KC 
mRNA levels were measured by qPCR and normalized to 18S. N=20, 20, 27 and 21 
for sham vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. There was 
a significant interaction between burn and ethanol (p<0.05). ** P<0.01 vs. all other 
groups. B. Whole adipose tissue homogenate levels of KC protein were determined 
and normalized to the total protein. N=4, 3, 5 and 4 for sham vehicle, sham ethanol, 
burn vehicle and burn ethanol, respectively. No significant interaction was found 
between burn and ethanol. * P<0.05 vs. sham groups. C. Neutrophil elastase mRNA 
level was quantified by qPCR in adipose tissue and normalized to 18S. N=12, 11, 16 
and 15 for sham vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. 
There was no significant interaction between burn and ethanol. D. After episodic binge 
and burn, adipose tissue KC mRNA levels were measured by qPCR and normalized to 
18S. N=6, 4, 7 and 8 for sham vehicle, sham ethanol, burn vehicle and burn ethanol, 
respectively. E. Whole adipose tissue KC protein levels were determined and 
normalized to total protein. N=7, 5, 12 and 10 for sham vehicle, sham ethanol, burn 
vehicle and burn ethanol, respectively. There was no interaction between burn and 
ethanol (p<0.05) in episodic binge treatment. *P<0.05 vs. sham vehicle. ^P<0.05 vs. 
sham ethanol group. F. Neutrophil marker elastase mRNA level was quantified after 
episodic binge or burn by qPCR in adipose tissue. N=7, 4, 7 and 13 for sham vehicle, 
sham ethanol, burn vehicle and burn ethanol, respectively. There was a significant 
interaction between burn and ethanol (p<0.05). *P<0.05 vs. sham ethanol. **P<0.001 
vs. sham vehicle. ***P<0.001 vs. sham ethanol. 
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Figure 2.3. Episodic binge ethanol and burn injury drives crown like structure 
formation. A. Representative immunohistochemical images of macrophage marker 
F4/80-positive staining in adipose tissue from vehicle, episodic binge, sham or burn 
injured mice (10X, N= 4,5, 5 and 7 for sham vehicle, sham ethanol, burn vehicle and 
burn ethanol, respectively). Inflammatory loci (arrow) and crown like structure (*, and 
inset) are indicated. Ten randomly selected 10× fields were assessed for F4/80+ crown 
like structures (B, P<0.01 vs. both vehicle groups, P<0.05 vs. sham ethanol) and 
inflammatory loci (C, *P<0.05, ** P<0.01, ***P<0.001 vs. sham vehicle mice and ^ 
P<0.05 vs. sham ethanol).  No significant interaction was found between burn and 
ethanol. 
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Figure 2.4. Adipose chemokine levels of monocyte chemotactic protein-1 (MCP-1) 
and adiponectin were inversely regulated after single and episodic binge ethanol and 
burn injury. Mice received single (A-C) or episodic binge (D-F), or vehicle control and 
burn. A. Adipose tissue MCP-1 and 18S mRNA levels were measured. N=16, 16, 20 and 
19 for sham vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. * P<0.05 
vs. vehicle. B. MCP-1 protein levels were examined and normalized to total protein. N=4, 
3, 3 and 4 for sham vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. 
*P<0.05 vs. sham ethanol, **P<0.01 vs. sham vehicle. C. Adipose tissue adiponectin and 
18S mRNA levels were measured. N=8, 8, 9 and 8 for sham vehicle, sham ethanol, burn 
vehicle and burn ethanol, respectively. *P<0.05 vs. burn vehicle, ***P<0.001 vs. sham 
vehicle. D. In adipose tissue from mice exposed to episodic binge or burn, MCP-1 and 18S 
mRNA levels were measured. N=6, 4, 6 and 13 for sham vehicle, sham ethanol, burn 
vehicle and burn ethanol, respectively. E. MCP-1 protein was normalized to the total 
amount of protein lysate. N=7, 4, 12 and 11 for sham vehicle, sham ethanol, burn vehicle 
and burn ethanol, respectively. F. After episodic binge, adipose tissue adiponectin and 18S 
mRNA levels were measured. N=7, 4, 7 and 14 for sham vehicle, sham ethanol, burn 
vehicle and burn ethanol, respectively. No significant interactions between burn and 
ethanol were found with single or episodic binge treatment for MCP-1 and adiponectin 
levels. 
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Figure 2.5. Single and episodic binge followed by burn injury failed to upregulate 
pro-inflammatory mediators.  Mice received single (A-D) or episodic binge (E-H), or 
vehicle control and burn. A-C. Adipose tissue TNFα, IL-1β, or IL-10 was measured and 
normalized to total protein. N=4, 3, 5 and 5 for sham vehicle, sham ethanol, burn vehicle 
and burn ethanol, respectively. D. Adipose tissue iNOS mRNA level was measured by 
qPCR . N=12, 12, 15 and 15 for sham vehicle, sham ethanol, burn vehicle and burn 
ethanol, respectively. ***P<0.001 vs. sham groups. ^^^P<0.001 vs. sham groups. E-G. 
After episodic binge and burn, adipose tissue levels of TNFα, IL-1β, or IL-10 were 
measured and normalized to total protein. N=6, 5, 12 and 11 for sham vehicle, sham 
ethanol, burn vehicle and burn ethanol, respectively. H. Adipose tissue iNOS mRNA 
level was measured after episodic binge by qPCR as above. N=7, 4, 7 and 13 for sham 
vehicle, sham ethanol, burn vehicle and burn ethanol, respectively. *P<0.05 vs. sham 
ethanol.  There were no significant interactions between burn and ethanol detected. 
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Overview 
Obese adipose recruits monocytes that become classically-activated macrophages (MΦs) 
associated with insulin resistance. In contrast, alternatively-activated MΦs safeguard insulin 
sensitivity. How the adipose microenvironment directs MΦ polarization remains unclear. MΦ 
subtypes display specific metabolic signatures; the process of alternative activation requires lipid 
metabolism. We discovered an unprecedented role for fatty acid transport and acyl-CoA 
synthetase function through activity of fatty acid transporter 1 (FATP1) which was necessary to 
establish the alternatively-activated MΦ phenotype and maintain glucose tolerance in diet-
induced obesity. C57BL/6J mice transplanted with Fatp1-/- bone marrow and fed a high fat diet 
gained more weight, were hyperglycemic, and glucose intolerant. Lack of MΦ FATP1 increased 
white adipose mass, inflammation, lipid peroxidation, and NLRP3 inflammasome activation. 
Using Fatp1-/- bone marrow derived MΦs (BMDM) and a FATP1 over-expressing (FATP1-OE) 
MΦ cell line, we demonstrated that FATP1 profoundly regulated alternative MΦ polarization 
through controlling substrate metabolism. Fatp1-/- BMDMs exhibited an exaggerated classically-
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activated phenotype while FATP1-OE cells failed to mount a classic LPS response. Importantly, 
specific genetic variations were identified that significantly associated with FATP1 expression 
levels in humans. FATP1 expression level was inversely proportional to waist circumference, a 
strong risk factor for metabolic disease, suggesting FATP1 activity as a novel therapeutic target.  
Introduction   
Chronically inflamed white adipose tissue is a hallmark of obesity and this perpetual, 
low-grade inflammation contributes to systemic metabolic dysregulation such as insulin 
resistance, type 2 diabetes, cardiovascular disease, and cancer 13,18. The adipose 
microenvironment is shaped by local and systemic conditions. Within the adipose milieu, 
alternatively activated MΦs (AAM) safeguard insulin sensitivity and maintain tissue homeostasis 
via remodeling, wound healing, and secretion of anti-inflammatory cytokines like IL-10 18. With 
the onset and progression of obesity, dramatic changes within the adipose microenvironment 
occur, including an influx of monocytes that are directed by the conditions within the 
microenvironment to differentiate into classically activated, pro-inflammatory MΦs (CAM). 
Persistent CAM activation sustains adipose inflammation, eventually leading to impaired 
function of this tissue.   
An array of MΦ subtypes exists which lie along a polarization continuum with CAM and 
AAM at either extreme. Upon activation, CAM and AAM populations can be distinguished by 
characteristic differences in metabolic reprogramming events. CAM exhibit a significant up-
regulation of glucose metabolism, particularly flux through the pentose phosphate pathway to 
generate reactive oxygen species (ROS) that are used to destroy invading pathogens. As second 
messengers, ROS enhance production of inflammatory enzymes, cytokines, and chemokines 
such as iNOS, TNF-, MCP-1 and IL-618,21. Indeed, in a demonstration of the tight link between 
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MФ metabolic reprogramming and polarization state, we reported that CAM polarization is 
achievable by enhancing glucose metabolism via glucose transporter 1 (GLUT1) over-expression 
in an in vitro model222. We showed that the GLUT1-mediated enhancement of glucose 
metabolism through the glycolytic and pentose phosphate pathways was necessary and sufficient 
to polarize MΦs to the CAM phenotype in the absence of other activating stimuli222. Other 
activated immune cells, including T effector cells, exhibit a similar Warburg-like metabolic shift 
similar to that of CAM64. In contrast to CAM, fatty acid metabolism, particularly fatty acid 
oxidative metabolism in the mitochondria, is required to achieve the AAM polarization 
phenotype20.  
Exactly how MΦ phenotypes are regulated within tissue microenvironments remains 
unclear; however, investigation into these processes will reveal unique therapeutic targets aimed 
at controlling obesity-associated inflammation -- an early event in Metabolic Syndrome. It’s 
likely that MΦ inflammatory tone can be modulated by the relative availability of fuel substrates 
to adipose tissue infiltrating monocytes and MΦs18,222. Herein, we aimed to identify novel 
mediators of MΦ metabolism that would control CAM/AMM activation. We hypothesized that 
maintaining persistent AAM activation could be achieved by modulating transport and 
metabolism of specific fatty acids which would ultimately suppress MΦ-mediated inflammation 
and, thus, preserve metabolic health. Fatty acid transport protein 1 (FATP1, SLC27A1) is an 
ideal candidate for controlling AAM polarization: FATP1 is an acyl-CoA synthetase with 
affinity for long and very long chain fatty acids (LCFA and VLCFA, respectively), which lends 
specificity to its function. To date, there are no reports detailing the role of FATP1 in MΦ 
function and inflammatory diseases. We demonstrate for the first time that FATP1 provides a 
unique mechanism by which AAM/CAM ratio may be regulated. FATP1 expression is highest in 
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AAM compared to CAM and plays a critical role in suppressing adipose tissue inflammation and 
maintaining systemic glucose tolerance. C57BL/6J mice lacking MΦ FATP1 after bone (“B”) 
marrow transplant (Fatp1B-/-) gained more weight when fed a high fat diet (HFD), which resulted 
in exacerbated glucose intolerance compared to mice that were transplanted with wild-type 
littermate marrow (Fatp1B+/+) fed the same diet. Systemic glucose dysregulation resulted from 
larger adipose mass in obese Fatp1B-/- mice as well as enhanced inflammation characterized by 
increased MΦ infiltration, crown-like structure formation, greater pro-inflammatory cytokine 
expression, and elevated lipid oxidative damage compared to HFD-fed Fatp1B+/+. The absence of 
MΦ FATP1 increased inflammation was due, in part, to elevated priming and activation of the 
NLRP3 inflammasome in HFD-fed Fatp1B-/- adipose compared to controls.  
To determine the internal MФ metabolic and inflammatory consequences of loss or gain 
of FATP1 function, we turned to in vitro models. Fatp1-/- bone marrow derived MΦs (BMDM) 
underwent a primary substrate switch from fatty acid to glucose as determined by reduced acyl-
CoA synthetase (ACSL) activity, fatty acid uptake and oxidation, with concomitant enhanced 
Glut1 expression, glycolytic rate and shunting of glucose to the pentose phosphate pathway. 
Deletion of Fatp1 primed BMDM for an enhanced pro-inflammatory phenotype and an inability 
to polarize to AAM. In contrast, FATP1-over-expressing RAW246.7 MΦs (FATP1-OE) induced 
the reverse metabolic substrate switch away from glucose and toward fatty acid metabolism: 
FATP1-OE displayed elevated ACSL enzymatic activity and fatty acid uptake, along with 
decreased Glut1 expression, diminished glycolytic rate and glucose oxidation. LPS-stimulated 
expression and secretion of inflammatory cytokines were dramatically blunted in FATP1-OE 
MΦs. Together these data indicate that FATP1 directs MФ metabolic reprogramming and 
promotes AAM polarization. 
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 Finally, we identified variants located in and near FATP1 associated with FATP1 
expression in human adipose tissue. FATP1 transcript levels were inversely correlated with waist 
circumference in population studies. Because central adiposity is a risk factor for metabolic 
disease, our observations suggest that FATP1 expression may influence metabolic health in 
humans. In summary, MΦ FATP1 protects against obesity-induced inflammation and safeguards 
systemic glucose metabolism through maintenance of AAMs and adipose tissue homeostasis.  
RESULTS  
Fatp1 is expressed at greater levels in AAM compared to CAM-polarized BMDM. To 
compare the levels of Fatp1 expression in the CAM and AAM polarization states, BMDMs were 
isolated from C57BL/6J mice and polarized to either the CAM phenotype (5ng/mL LPS, 
10ng/mL IFNɣ) or to the AAM phenotype (10ng/mL IL-4) for 24 hours20,222. Fatp1 mRNA was 
expressed at a level 60% higher in AAM-polarized BMDM compared to CAM-polarized BMDM 
(Figure 3.1A). In silico interrogation of existing mouse expression data suggested that Fatp1 
was down-regulated when BMDM or thioglycollate-elicited peritoneal MΦs isolated from mice 
were stimulated with LPS for 24 or 7 hours, respectively, whereas Fatp1 expression was not 
detected in other immune cells223. 
A lack of FATP1 in MΦs exacerbates HFD-induced weight gain, hyperglycemia, and 
glucose intolerance. Based on the observed differential expression pattern of Fatp1 in CAM and 
AAM, we investigated the extent to which MФ FATP1 contributed to inflammation and HFD-
induced obesity. Male C57BL/6J recipient mice were randomized onto either LFD or HFD at 3 
weeks of age. After 3 weeks on the diets (i.e., at 6 weeks of age), fasting glucose and MRI-
determined body composition were identical for all mice regardless of diet group (data not 
shown). At this time point, recipient mice were lethally irradiated and transplanted with bone 
     
                                                                                             55 
marrow from Fatp1+/+ and Fatp1-/- donor mice to generate chimeric mice harboring either 
Fatp1bonemarrow+/+ (FATP1B+/+) or Fatp1bonemarrow-/- (Fatp1B-/-) (Figure 3.1B). Control mice that 
were irradiated but did not receive marrow died within 10 days of irradiation. Hematologic and 
flow cytometric analysis of Fatp1+/+ and Fatp1-/- donor mice demonstrated no significant 
differences in any measure including white blood cells, lymphocytes, granulocytes, monocytes, 
by either total numbers of cells or percentage of cells within the total blood cell population 
(Tables 3.1 and 3.2). 
To confirm successful ablation and reconstitution of Fatp1-deficient marrow, BMDM 
were isolated from a cohort of LFD-fed and HFD-fed Fatp1B+/+ and Fatp1B-/- mice; there were 
no significant differences in number or appearance of BMDM isolated from the transplanted and 
diet-exposed mice (Figure 3.1C). Figure 3.1D illustrates that the irradiation and reconstitution 
with Fatp1+/+ or Fatp1-/- marrow was successful as only the mutated Fatp1 allele was detectable 
in the BMDM isolated from mice transplanted with Fatp1-/- bone marrow. Gene expression (not 
shown) and immunoblot analysis of these BMDM demonstrated that FATP1 was successfully 
ablated from MΦs in this model (Figure 3.1E).  
As expected, C57BL/6J recipient mice fed HFD gained more weight compared to LFD-
fed mice, regardless of Fatp1 bone marrow genotype until the time of BMT (Figure 3.2A). After 
irradiation and reconstitution, Fatp1B-/- mice gained significantly more weight compared to 
Fatp1B+/+ on HFD (P<0.0001 from 15 weeks through to sacrifice at 23 weeks on diet). After 23 
weeks on diet, random-fed blood glucose concentrations were significantly elevated in Fatp1B-/- 
mice compared to Fatp1B+/+ on HFD (P< 0.05, Figure 3.2B). At termination, however, 6-hour-
fasted blood glucose concentrations did not differ significantly by genotype (data not shown). 
LFD-fed Fatp1B+/+ and Fatp1B-/- fasted blood glucose concentrations were an average of 133 
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mg/dL for both genotypes, whereas HFD-fed concentrations were 131.5 and 147 mg/dL, 
respectively. Six-hour-fasted plasma insulin concentrations at termination revealed no significant 
differences among the groups (Figure 3.2C). Likewise, there were no differences in homeostasis 
model assessment of insulin resistance (HOMAIR) or homeostasis model % β cell function 
(HOMA%) (data not shown). 
Glucose tolerance test (GTT) and insulin tolerance tests (ITT) were performed to evaluate 
systemic metabolic responses in Fatp1B+/+ and Fatp1B-/- LFD- and HFD-fed mice. Overall, HFD 
in this BMT model did not induce dramatic defects in glucose disposal, similar to other BMT 
models (Figure 3.2D). However, circulating glucose concentration at 15 minutes post glucose 
injection was significantly higher in Fatp1B-/- mice on HFD (P<0.001), which correlated to 
delayed and inefficient disposal of glucose compared to Fatp1B+/+ for the remainder of the time 
course (30 minutes: P=0.004; 60 minutes: P=0.03, 120 minutes: P=0.04). Area under the curve 
(AUC) calculations of the GTT results corroborated the HFD-fed Fatp1B-/- glucose intolerance 
(Figure 3.2E). Interestingly, ITT and AUC calculations indicated that neither diet nor genotype 
affected the glucose response to an injection of insulin (Figures 3.2F and G). Furthermore, 
histologic and immunohistologic analysis of insulin staining and morphology of islets in 
pancreata did not demonstrate significant alterations in number or size of islets between diet and 
genotypes (data not shown).  
Fatp1B-/- mice have greater fat mass and larger eWAT fat pads when fed HFD. Body 
composition was next investigated to determine if MΦ FATP1 contributed to alterations in 
adipose tissue. Mice fed a HFD displayed significantly increased percent body fat as measured 
by MRI as well as elevated plasma leptin concentrations, yet no genotype differences were 
evident in either measure (P<0.001, Figures 3.2H and I, respectively). However, eWAT depots 
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in HFD-fed Fatp1B-/- mice were 40% heavier compared to HFD-fed Fatp1B+/+ mice (P<0.01, 
Figure 3.2J). Lean mass, liver and brown adipose weights were not altered by genotype 
(Figures 3.8A-C).  
Deletion of MΦ Fatp1 led to augmented eWAT MΦ influx, CAM-associated inflammation, 
activation of the NLRP3 inflammasome, and oxidative damage. Infiltration of MΦs from 
transplanted marrow into eWAT was confirmed by PCR-based genotyping of eWAT genomic 
DNA to detect the mutated Fatp1 allele (Figure 3.3A). Histological examination of eWAT 
sections (Figure 3.3B-E) revealed slightly increased adipocyte size with HFD feeding in 
Fatp1B+/+ and Fatp1B-/- mice, but no genotype-mediated differences were evident (data not 
shown). However, there was a 60% increase in the number of F4/80+ crown-like structures 
(CLS) observed in eWAT from HFD-fed Fatp1B-/- mice compared to HFD-fed wild type controls 
(Figures 3.3F-I and quantified in 3.3J, P<0.01). Furthermore, qPCR gene expression analysis 
for monocyte/MΦ markers emr1 (F4/80), Cd11b, and Cd11c indicated dramatic increases in 
obesity-associated MΦ influx in HFD-fed Fatp1B-/- eWAT compared to Fatp1B+/+ (P<0.01, 
P<0.05, and P<0.001, respectively, Figure 3.3K). Expression of the pro-inflammatory cytokine 
Il-6 was 5-fold higher in eWAT from Fatp1B-/- mice compared to Fatp1B+/+ on HFD (P<0.01, 
Figure 3.3L). Likewise, expression of the pro-inflammatory cytokine Il-1, was doubled in 
eWAT from Fatp1B-/- mice compared to Fatp1B+/+ on HFD (P<0.05, Figure 3.3M). IL-1 
production results from activation of the inflammasome224. We observed significantly elevated 
expression of NLRP3 inflammasome subunits including Nlrp3 and Pycard  in eWAT from 
Fatp1B-/- mice compared to Fatp1B+/+ on HFD (P<0.01, Figure 3.3N). Furthermore, significantly 
increased concentrations of 8-iso-PGF2, an indicator of non-enyzmatic oxidative damage, in 
conjunction with elevated positive staining for 4-hydroxynonenal (4-HNE), a marker of lipid 
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peroxidation, indicated increased oxidative damage in eWAT from HFD-fed Fatp1B-/- mice 
compared to HFD-fed Fatp1B+/+ mice (Figures 3.3O (P<0.05) and 3.3P).  
Lack of FATP1 induces a metabolic substrate switch from fatty acid toward glucose 
metabolism. We hypothesized that MΦ FATP1 plays a role in supporting the AAM phenotype 
by directing lipid metabolism in MΦs. To test this hypothesis, BMDM were isolated and 
differentiated from age-matched, chow-fed male Fatp1+/+ and Fatp1-/- total body knockout mice. 
There were no differences in the number or gross morphology of BMDM generated from Fatp1-/- 
mice compared to Fatp1+/+ mice (data not shown and Figure 3.4A), similar to the results from 
the BMT study (Figure 3.1C). The lack of FATP1 protein (Figure 3.4B) and a 40% reduction in 
total ACSL enzymatic activity (P<0.01, Figure 3.4C) had no effect on the size or viability of the 
generated BMDM (Figure 3.9A-B).  
To determine if deletion of Fatp1 led to compensatory up-regulation of other Fatp family 
members, Fatp gene expression was profiled in unpolarized (Un), CAM and AAM-polarized 
Fatp1+/+ and Fatp1-/- BMDM by qPCR. Only expression of Fatp1 and Fatp4 were detected at 
meaningful concentrations, with Fatp6 being minimally detectable (Figure 3.4D). In Fatp1+/+ 
BMDM, Fatp1 expression was 2-fold higher in AAM compared to CAM BMDM, replicating 
our previous observation (Figure 3.1A). Fatp1 expression was reduced in Fatp1-/- BMDM, as 
expected. Relative to Fatp1, BMDMs express Fatp4 at higher concentrations in all polarization 
states. In contrast to Fatp1, Fatp4 expression is increased 3-fold in CAM-polarized MΦs 
compared to unstimulated and AAM. We did not detect compensation for Fatp1 deficiency by 
Fatp4 or Fatp6; in fact, in CAM-polarized BMDM, Fatp4 was detected at lower levels in Fatp1-
/- compared to Fatp1+/+ BMDM (P<0.0001, Figure 3.4D).  
     
                                                                                             59 
To examine effects of lack of FATP1 on MΦ metabolism, we next examined cellular 
bioenergetics, fatty acid uptake, and substrate metabolism. Mitochondrial metabolism, as 
measured by oxygen consumption rate (OCR), was elevated in AAM compared to unstimulated 
or CAM. OCR was significantly elevated in Fatp1-/- compared to Fatp1+/+ in both unstimulated 
(P<0.01) and AAM-polarized (P<0.05) BMDM (Figure 3.4E). In Fatp1+/+ BMDM, AAM-
polarization induced a 57% and 97% increase in palmitate internalization, respectively, when 
compared to unstimulated (P<0.0001) or CAM (P<0.001; Figure 3.4F). Fatty acid uptake was 
reduced by 21% and 24% in unstimulated (P<0.05) and AAM-polarized Fatp1-/- BMDM 
(P<0.0001), respectively. The diminished fatty acid uptake in AAM-polarized Fatp1-/- BMDM 
correlated to a 17% reduction in complete oleate oxidation (P<0.0001, Figure 3.4G). There were 
no significant differences in incomplete fatty acid oxidation as measured by14C incorporation 
into acid soluble metabolites (Figure 3.4H).  
Because MФs markedly enhance glucose metabolism when CAM polarized20,21,222, we 
determined if inhibition of lipid metabolism via deletion of FATP1 would reprogram BMDM 
metabolism toward increased glucose usage, similar to the CAM phenotype. We found that 
expression of glucose transporter 1 (Glut1) was significantly increased in CAM-polarized Fatp1-
/- compared to Fatp1+/+ BMDM (P<0.0001, Figure 3.4I), yet there was no significant increase in 
acute glucose uptake (Figure 3.4J). Thus, extracellular acidification rate (ECAR) was used to 
measure glycolytic rate. Fatp1-/- BMDM displayed significantly increased glycolytic rates, as 
measured by ECAR in unpolarized (P<0.05), CAM- (P<0.001) and AAM-polarized (P<0.05) 
states compared to Fatp1+/+ BMDM (Figure 3.4K). Glycolytic capacity was similarly elevated 
in the absence of FATP1 (Figure 3.4L). Neither glucose oxidation or glycogen synthesis were 
affected by Fatp1 genotype (Figures 3.4M-N). 
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Lack of FATP1 primes MФs for exaggerated pro-inflammatory activation upon CAM 
polarization and hinders polarization to the AAM phenotype. Expanding on our observations 
that Fatp1-/- BMDM internalized and oxidized less fatty acid compared to Fatp1+/+, together 
with existing evidence linking MΦ substrate metabolism and inflammatory phenotype, we next 
measured the basal expression and inflammatory response of CAM or AAM-polarized Fatp1+/+ 
and Fatp1-/- BMDM. Expression of the classic CAM marker inducible nitric oxide synthase 
(Nos2) was 2-fold higher in Fatp1-/- compared to Fatp1+/+ CAM-polarized BMDM (P<0.0001, 
Figure 3.4O). In addition, CAM-polarization resulted in increased Tnf gene transcription in 
Fatp1-/- BMDM compared to Fatp1+/+ control (P<0.05, Figure 3.4P). A commonly used AAM 
MФ marker is expression of Arginase-120. We observed that Arginase-1 transcription was up-
regulated in AAM BMDM, but this up-regulation was significantly blunted in Fatp1-/- compared 
to Fatp1+/+ BMDM (P<0.05, Figure 3.4Q).  
Metabolomic analysis of Fatp1-/- BMDM indicates enhanced glucose metabolism, 
particularly through the pentose phosphate pathway. The intracellular metabolic signature of 
Fatp1-/- BMDM was significantly different than that of the Fatp1+/+ BMDM when comparing 
CAM-polarized cells relative to unstimulated (Figure 3.5). Intermediates of the first half of the 
glycolytic pathway were significantly increased in Fatp1-/- BMDM, while glycolytic end 
products phosphoenolpyruvate and lactate were reduced, corroborating our bioenergetics results. 
CAM-polarized Fatp1-/- BMDM exhibited enhanced pentose phosphate pathway activity as 
evidenced by increased 6-phosphogluconate, ribose, and arabitol. Purine metabolism, drawing on 
intermediates from the pentose phosphate pathway and increased biopterin, was significantly up-
regulated, while thymidine concentration was decreased. Deletion of Fatp1 also resulted in 
increased concentrations of glycerolipid metabolites glycerol 3-phosphate, 
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glycerophosphorylcholine, and ethanolamine. Cytidine 5’-diphosphocholine concentrations were 
significantly decreases possibly indicating a block in the CDP-choline pathway. A significant 
down-regulation in Fatp1B-/- BMDM of amino acid metabolism was evident, particularly in 
branch-chain amino acids. B-vitamin metabolism was altered with significant decreases observed 
in concentrations of pyridoxal (vitamin B6), niacin-containing electron carriers including NAD+ 
and NADH, and riboflavin (vitamin B2). Interestingly, there were significant increases in both 
phosphopantetheine (vitamin B5) which is required for the formation of coenzyme A (CoA), and 
CoA itself a necessary cofactor for FATP1’s ACSL activity. Lastly, increased concentrations of 
the polyamines spermidine and spermine indicate enhanced polyamine synthesis in BMDM 
lacking Fatp1. 
FATP1 over-expression increased ACSL activity and fatty acid uptake into RAW264.7 
MΦs. We next determined if the CAM-like RAW mouse MΦ cell line could be metabolically 
reprogrammed toward an AAM phenotype via FATP1 over-expression (FATP1-OE). First, we 
profiled expression levels of the 6 members of the Fatp family. RAW MΦs expressed only 
Fatp1 and Fatp4, both of which were induced 2-fold by 24 hour LPS activation (Figure 3.6A). 
We successfully achieved over-expression of both Fatp1 mRNA (P<0.001, Figure 3.6A) and 
FATP1 protein in FATP1-OE compared to empty vector controls (FATP1-EV, Figure 3.6B). 
FATP1 protein is essentially undetected in unstimulated RAW MΦs, thus FATP1 over-
expression created a gain of function model. A significant decrease in Fatp4 expression in 
FATP1-OE MΦs upon LPS activation was evident compared to FATP1-EV (P<0.05). FATP1 
over expression had no effect on cell size, viability, or growth (Figure 3.9C-D). 
ACSL activity assays were performed on FATP1-EV and FATP1-OE MΦs to ensure that 
the over-expressed FATP1 was functional. Total ACSL activity was increased by 20% in 
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FATP1-OE compared to FATP1-EV (P<0.05, Figure 3.6C). We also observed a 17% increase in 
fatty acid uptake in FATP1-OE compared to FATP1-EV in the unstimulated state (P<0.01, 
Figure 3.6D). LPS activation increased fatty acid uptake by 2.3-fold in FATP1-EV, while 
FATP1-OE showed a 2.7-fold increase. Thus, after LPS stimulation, fatty acid uptake into 
FATP1-OE was 36% greater than FATP1-EV controls with (P<0.0001). 
FATP1 over-expression reprograms RAW MΦs toward an AAM metabolic phenotype. 
LPS-activation of RAW MΦ led to dramatically reduced complete fatty acid oxidation regardless 
of FATP1 genotype, demonstrating a disconnect between fatty acid uptake and oxidation. There 
were no FATP1-mediated differences in either complete or incomplete oleate oxidation (Figures 
3.6E-F). At baseline, there were no differences in Glut1 expression, however with LPS 
stimulation Glut1 expression was 39% lower in FATP1-OE compared to FATP1-EV (P<0.01, 
Figure 3.6G). Acute glucose uptake was reduced in FATP1-OE MФs, though this result did not 
reach statistical significance (Figure 3.6H). However, bioenergetics measurements taken over 2 
hours demonstrated a 60% reduction in glycolytic rate in FATP1-OE MΦs compared to FATP1-
EV controls in both unstimulated and LPS-stimulated conditions (P<0.01, Figure 3.6I). 
Glycolytic capacity was also significantly reduced with FATP1 over-expression to levels 60% of 
those in FATP1-EV (P<0.05, Figure 3.6J). In addition, FATP1-OE MΦs demonstrated a 23% 
reduction in glucose oxidation upon LPS-activation (P<0.05, Figure 3.6K). Finally, glycogen 
synthesis was unaffected by FATP1 expression in either unstimulated or LPS-activated MΦs 
(Figure 3.6L). 
FATP1 gain of function inhibits MΦ pro-inflammatory response. To examine the 
consequence of FATP1-mediated alterations in metabolism on the inflammatory response in 
RAW MΦ, we performed mRNA and cytokine production analyses of pro- and anti-
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inflammatory markers in unstimulated and LPS-stimulated cells. FATP1 over-expresion 
significantly suppressed the expression of LPS-induced pro-inflammatory enzyme Nos2 (P<0.01, 
Figure 3.6M) and pro-inflammatory cytokine Tnf (P<0.01, Figure 3.6N). Secretion of IL-6 and 
MCP-1 protein was inhibited in response to LPS stimulation in FATP1-OE compared to FATP1-
EV (P<0.01 and P<0.05, Figures 3.6O and P, respectively). IL-1β protein secretion was also 
reduced in FATP1-OE compared to FATP1-EV (P<0.01, Figures 3.6Q). AAM-markers Mrc-1 
and Arginase-1 were not detectable in FATP1-EV and FATP1-OE cells in either the 
unstimulated or LPS-stimulated state (data not shown). 
FATP1 over-expression down-regulated glucose metabolic pathways. Concentrations of 
glycolytic, pentose phosphate pathway, and TCA cycle intermediates, including succinate, 
malate, and fumarate, were all decreased in CAM-polarized FATP1-OE compared to CAM-
polarized FATP1-EV (Figure 3.7A). FATP1 over-expression led to decreased intracellular 
concentrations of specific amino acids including alanine, aspartate and branched-chain amino 
acids in CAM-polarized FATP1-OE versus FATP1-EV RAW MΦs. N-acetyl-beta-alanine, a 
metabolite significantly reduced in Fatp1-/- BMDM, was increased, as were glutamate and 
glutamine in FATP1-OE. Purine and pyrimidine metabolism was diminished in the FATP1 over-
expressing cells. FATP1 over-expression modulated one-carbon metabolism as demonstrated by 
reduced 5-methyltetrahydrofolate and biopterin, along with associated metabolites cysteine, 
glycine, serine, and methionine compared to controls. Elevated concentrations of S-
adenosylmethionine (SAM) were measured in CAM-polarized FATP1-OE cells which correlated 
with significantly higher concentrations of putrescine, spermine, and spermidine whose synthetic 
enzymes require SAM. LCFA and eicosanoid metabolism was reduced with the exception of 9-
HODE, which was significantly increased by FATP1 over-expression compared to empty vector 
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controls. Finally, FATP1 over-expression blunted induction of iNOS in response to CAM 
polarization as evidenced by a significant decrease in citrulline concentration and a concomitant 
increase in polyamine-associated metabolites, all indications of redirection of arginine from 
being a substrate for iNOS toward use by ARGINASE-1 (Figure 3.7B).  
FATP1 SNPs are associated with FATP1 expression levels in human adipose. We searched 
public databases for genetic variants located within 1 Mb of FATP1 that were associated with 
FATP1 expression (eQTLs) in human adipose tissue. The Multiple Tissue Human Expression 
Resource (MuTHER) study of 856 female twins showed the strongest eQTL for FATP1 with 
rs9137 (P=1.3x10-13), which is located in the 3'UTR of FATP1. In the METabolic Syndromes In 
Men (METSIM) study of 1,381 men, the strongest association with adipose FATP1 expression 
was observed for rs3212793 (P=1.8x10-4), located ~300 kb downstream of the FATP1 gene. 
These results demonstrate that FATP1 levels vary between individuals and that these and/or 
other nearby variants may be involved in the regulation of FATP1 expression.  
We next examined the relationship between FATP1 expression and eight metabolic traits 
in the METSIM study. Increased FATP1 expression showed a trend toward an association with 
decreased waist circumference (beta = -0.33; P = 0.056).  
DISCUSSION   
  Understanding the link between metabolism and inflammation is of particular interest, 
especially within the context of understanding diabetes risk. In lean white adipose tissue, AAM 
maintain tissue homeostasis by mediating tissue remodeling and secreting cytokines that promote 
insulin sensitivity. With obesity, the heightened demand for lipid storage promotes rapid 
expansion of adipose tissue and increased adipocyte stress and death. Recruited in response to 
stress signals and to phagocytize the dead and dying adipocytes, monocytes entering the obese 
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adipose microenvironment are differentiated and polarized to the CAM phenotype. Thus, the 
dominant MФ phenotype shifts toward CAM and the adipose becomes inflamed. Due to the 
distinct metabolic characteristics of CAM versus AAM, the availability of fuel substrates within 
the adipose microenvironment can be an important modifier of MΦ polarization. Obese adipose 
exposes local MΦs to high levels of free fatty acids and triacylglycerides resulting from 
enhanced lipolysis and engulfment of dying adipocytes; subsequently, MΦs become engorged 
with lipid18. In uncontrolled diabetes, MΦs are also exposed to high blood glucose 
concentrations, thus, setting the stage for the sustained expansion of the CAM population within 
adipose. MΦs are especially sensitive to toxicity induced by high concentrations of glucose, 
cholesterol, as well as fatty acids225-227. Yet, generation of the AAM phenotype is a fatty acid 
oxidation-dependent process20. Due to this seemingly contradictory response to fatty acids, we 
hypothesized that metabolism of specific fatty acids plays a critical role in suppressing 
inflammation and maintaining insulin sensitivity. Integrating the use of loss- and gain-of-
function models, we report for the first time that FATP1 is necessary to maintain the AAM 
phenotype, plays an important role in systemic glucose metabolism, and that SNPs exist in 
human FATP1 that regulate expression relevant to body composition.  
Herein, we demonstrate the reliance of AAM on FATP1 function. FATP1 expression 
levels are highest in tissues characterized by active fatty acid uptake and lipid metabolism, such 
as adipose, heart, and skeletal muscle71,73. Functional characterization of FATP1 and activation 
of fatty acids through its ACSL activity have been conducted in these tissue and cell 
types80,88,92,228. FATP1 has an affinity for L/VLCFA74, which is unique compared to other MΦ 
fatty acid transporters such as CD36, which is highly promiscuous as a fatty acid transporter and 
scavenger receptor. Studies of total-body Fatp1 knockout mice demonstrated that loss of FATP1 
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protected mice from HFD-induced obesity, insulin resistance and intramuscular accumulation of 
fatty acyl-CoAs. Lipids were redistributed from adipose and muscle to the liver, accounting for 
the observed protection from diet-induced obesity and insulin resistance88. Because of its 
complex pattern of expression among different tissue types, the contribution of FATP1 to the 
development of insulin resistance is likely to be tissue- and cell-type specific. Our focus on 
preferential metabolic substrate usage by MΦ has demonstrated that FATP1 is a novel metabolic 
reprogramming regulator and, as such, directly controls MФ polarization and adipose 
inflammation. 
MΦs have a high capacity for lipid metabolism26. We demonstrated that FATP1 is 
expressed at highest levels in AAM, the MΦ subtype especially reliant upon lipid metabolism20. 
In striking contrast to the total-body Fatp1-/- mice, we now present data indicating that chimeric 
mice harboring MΦ that are deficient in FATP1 were more susceptible to diet-induced obesity in 
terms of weight gain and adiposity, hyperglycemia, and glucose intolerance compared to diet-
matched Fatp1B+/+ mice, indicating that MΦ FATP1 plays a specific role in limiting obesity.  
How can MФ FATP1, specifically, have such an effect on systemic metabolism?  Fatp1B-
/- mice fed a HFD had a dramatic shift in body composition with massive fat pads that were 
characterized by excessive crown-like structures (CLS), MΦ infiltration and inflammatory 
cytokine production. CLS are classic histologic markers of inflammation in adipose, the presence 
of which are hallmarks of obesity associated with Metabolic Syndrome18. Oxidative stress is 
another hallmark of obesity; ROS are signaling cascade second messengers associated with 
enhanced expression of pro-inflammatory mediators. We and others have shown that persistent 
activation the ROS–generating pathways results in increased oxidative stress222,229. Evidence of 
oxidative stress was detected through targeted analysis of 8-iso-PGF2, as well as histological 
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detection of 4-HNE, suggesting that FATP1 normally suppresses MΦ ROS production, further 
demonstrating the regulatory role of FATP1 in AAM. Finally, priming and activation of the 
NLRP3 inflammasome, an intracellular stress sensor for nutrients and other stimuli, as well as its 
potent pro-inflammatory product, Il-1, was highest in HFD-fed Fatp1B-/- adipose tissue. It is 
well-established that the NLRP3 inflammasome contributes to insulin resistance230 and can be 
regulated by metabolism of glucose and fatty acids224,230,231. Therefore, our data support that 
FATP1 functions as a MΦ regulatory protein maintaining the AAM phenotype since deletion of 
MΦ FATP1 primes and activates the inflammasome, potentially through a metabolic shift in 
metabolism and ROS production. 
By using etomoxir to block CPT1-mediated fatty acid -oxidation, Vats et al. 
demonstrated that oxidative metabolism was essential for generate of the AAM phenotype. This 
seminal article was among the first publications to document a role for metabolism in regulating 
MΦ function. To characterize the metabolic alterations resulting from modulation of Fatp1 
expression, our approach entailed using an ex vivo BMDM loss-of-function model as well as a 
gain-of-function in vitro RAW MΦ cell line. BMDM and RAW MΦs express only Fatp1 and 
Fatp4. We did not detect compensatory Fatp expression in response to loss of FATP1. 
Additionally, total ACSL activity was significantly reduced in Fatp1-/- BMDM, demonstrating 
that while other acyl-CoA synthetases were present to activate fatty acids, such as ACSL1227, 
there was a lack of enzymatic compensation overall. ACSL-mediated addition of CoA targets 
fatty acids to certain metabolic fates, which participate in the regulation of inflammation. For 
example, ACSL1 is active in MΦs227. However, in direct contrast to our findings, deletion of 
ACSL1 protects MΦs from the inflammatory effects of diabetes and atherogenesis227, thus 
highlighting the existence of non-redundant roles for ACSLs within MΦs. Metabolic analysis of 
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Fatp1-/- BMDM demonstrated that, along with reduced ACSL activity, deletion of FATP1 
resulted in blunted fatty acid uptake and reduced oxidation of fatty acids, particularly in AAM-
polarized BMDMs, even in the context of elevated mitochondrial respiration. These data suggest 
that deletion of FATP1 fundamentally altered an aspect of mitochondrial function or the electron 
transport chain – perhaps uncoupling-- which is under further investigation. As deletion of 
FATP1 served to blunt lipid metabolism, it reprogrammed MΦ metabolism toward activated 
carbohydrate pathways. Specifically, we observed transcriptional up-regulation of the MΦ 
glucose transporter Glut1 and glycolytic rates in Fatp1-/- BMDM. While deletion of FATP1 
enhanced glucose metabolism, we observed the opposite shift in substrate metabolism in RAW 
MΦs over-expressing FATP1: FATP1 over-expression suppressed Glut1 expression, which 
subsequently reduced glucose oxidation, glucose uptake, glycolytic rate and capacity. Along with 
reduced glycolysis, CAM-like RAW MΦs expressing more FATP1 failed to be activated by LPS 
as illustrated by reduced Nos2, Tnf, IL-6, MCP-1, and IL-1. RAW MΦs are originally derived 
from viral-induced mouse leukemia and display a Warburg-like metabolism reminiscent of the 
CAM phenotype, thus the inhibition of activation by the metabolic switch due to FATP1 is 
striking.  
In accordance with the higher expression of pro-inflammatory cytokines in eWAT from 
HFD-fed Fatp1B-/- mice, BMDM from Fatp1-/- mice displayed an exaggerated inflammatory 
response, as well as more CAM-like and less AAM-like polarization upon activation to the 
different MΦ subtypes. CAM and AAM polarization results in distinct shifts in arginine 
metabolism (Figure 3.7B). CAM-polarized MΦs shunt arginine to iNOS, which catalyzes the 
conversion of arginine to the ROS species nitric oxide. In contrast, AAM-polarized MΦs divert 
arginine instead to ARGINASE-1, which converts arginine to ornithine. Ornithine, a precursor to 
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collagen synthesis, is necessary for AAM’s regulator function in tissue remodeling and wound 
repair. Importantly, with greater ARGINASE-1 expression, less arginine is directed towards 
iNOS and, therefore, production of ROS and collateral tissue oxidative damage is reduced. 
Expression and metabolomic analysis of BMDM from Fatp1-/- revealed increased iNos (Nos2) 
and metabolites supportive of a shift in arginine metabolism. Oxidative damage due to lack of 
MΦ Fatp1 was evident in obese adipose in Fatp1B-/- mice, further supporting metabolic shifts 
linked to increased ROS production. 
In complementary gain-of-function studies, over-expression of FATP1 in RAW MΦs 
enhanced total ACSL activity and fatty acid uptake. Despite the increased fatty acid uptake, 
FATP1 over-expression did not enhance fatty acid oxidation, indicating that fatty acids were 
being directed to compartments other than the mitochondrial matrix for β-oxidation. 
Metabolomics data indicated that FATP1 modulated glycerolipid metabolism with significant 
changes observed in ethanolamine, glycerophosphocholine and CDP-choline. Phospholipids 
serve as a pool of bioactive lipids including arachidonic acid and palmitate, both substrates of 
FATP1, which could modulate MΦ-mediated inflammation. Therefore, future studies will 
determine if FATP1 regulates polarization via regulation of ratios of phospholipid classes, fatty 
acid composition within those classes, as well as eicosanoid production.  
One regulatory complex of the innate immune system that is at the nexus between 
metabolism and inflammation is the NLRP3 inflammasome. The NLRP3 inflammasome is 
activated in obesity, leading to insulin resistance and diabetes231. Transcription of NLRP3 
inflammasome components and its product Il-1 was significantly increased in adipose from 
HFD-fed Fatp1B-/- compared to controls. The NLRP3 inflammasome is a nutrient sensitive 
sensor that is activated by a “two-hit” process typically initiated by signal 1 (e.g. excessive 
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glucose, palmitate, uric acid, or LPS, among other TLR4 ligands), which serves to prime the 
inflammasome by driving increased expression of inflammasome components. Subsequent 
activation by the second signal, which could be palmitate, ceramide, ROS, glucose, uric acid, or 
amyloid, fully activates the inflammasome, inducing CASPASE 1-mediated cleavage of pro-IL-
1 to active IL-1 (reviewed in231). Once secreted, IL-1β induces production of cytokines and 
chemokines including IL-6, IL-8, TNF and monocyte chemoattractant protein 1 (MCP-1, or 
CCL2), which collectively promote further MΦ activation and migration. Our data indicated that 
FATP1 plays a central role in both priming and activation of the NLRP3 inflammasome both in 
vivo and in vitro. 
Finally, we identified variants located in and near FATP1 associated with FATP1 
expression in human adipose tissue. Furthermore, FATP1 transcript levels were inversely 
correlated with waist circumference, a strong risk factor for Metabolic Syndrome. As these 
findings were detected in total subcutaneous adipose tissue, we were unable to take into account 
the complexity of the cellular composition of the adipose microenvironment and its effect 
specifically on adipose MΦs. Indeed, few large population genetic studies focus solely on 
monocyte/ MΦs. However, the existence of FATP1 variants that regulate expression suggests 
that animal MΦ FATP1 findings presented here may translate to human metabolic disease. 
Future studies are aimed at investigating the relationship between FATP1 variants and MΦ 
function in vitro.  
 In summary, we present mechanistic insight into the relationship between a novel 
regulator of MΦ substrate metabolism and the inflammatory response. MΦs are an extremely 
heterogeneous population of cells whose capacity for metabolic flexibility has important 
implications for local and systemic responses. We have demonstrated the ability to manipulate or 
     
                                                                                             71 
“metabolically reprogram” the inflammatory potential of MΦs via novel FATP1-mediated 
pathways. Over the past 30 years, the prevalence of obesity has increased in both Western 
nations and developing countries12. Current treatment approaches for Type 2 diabetes are 
focused on increasing pancreatic insulin release while also reversing hyperglycemia by inhibiting 
gluconeogenesis or increasing insulin sensitivity and glucose excretion. Additionally, immune-
based therapies offer promising interventions232,233 including several approaches aimed at 
increasing insulin sensitivity by blocking the action of inflammatory mediators, specifically  
previous reports implicate IL-1, IL-1, TNF, MCP-1 (CCL2) and IL-6 as important 
mediators232-235. Studies suggest that targeting the inflammatory response is beneficial; patients 
with chronic auto-immune diseases who are taking anti-inflammatory medicines as part of their 
treatment regimen have reduced risk of diabetes236,237. Our previous work demonstrated that 
modulating lipid mediator generation and trafficking in MΦs is an effective tool against obesity, 
insulin resistance, and diabetes25,26,238. We now propose that controlling MΦ metabolic 
phenotype through FATP1 activity could be a significant advance in the treatment of altered 
body composition and glucose intolerance. Identifying novel regulators of FATP1 ACSL activity 
could open the door to macrophage-specific therapeutics such as nanoparticles targeted to the 
mononuclear/ MФ phagocytic system (MPS). Controlling the “immune-metabolic” milieu could 
break the pro-inflammatory cycle by restoring tissue homeostasis and a healthy AAM/CAM ratio 
within adipose tissue. 
Methods  
Reagents 
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise noted. IFN 
and IL-4 were obtained from R&D Systems (Minneapolis, MN). Lipopolysaccharide (LPS, 
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Sigma E. coli L4391) was diluted in sterile PBS at a final concentration of 1mg/mL. Novolin® 
human insulin was purchased from Novo Nordisk (Plainsboro, NJ). Antibodies were purchased 
from the following sources: F4/80 (AbD Serotec/BioRad, Hercules, CA); 4-hydroxynonenal (4-
HNE) (Abcam, Cambridge, MA); CD16/32 (Fc Block, BioLegend, San Diego, CA), CD45-
FITC, F4/80-PE, Ly6G/C-PE-Cy7, CD11b-APC, CD11c-APC-eFluor 780 (Ebioscience, San 
Diego, CA), and insulin (H-86; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). 
Animals and diets  
Mice were housed in a climate controlled Department of Laboratory Animal Medicine facility 
with a 12 hour light:dark cycle and ad libitium access to food and water. Fatp1-/- mice 228 were 
backcrossed >12 generations to the C57BL/6J genetic background. Fatp1 total body knockout 
(Fatp1-/-) and Fatp1 wild type (Fatp1+/+) bone marrow donor mice were generated using Fatp1-/+ 
breeding pairs to generate littermate controls. MΦ Fatp1+/+ (Fatp1bonemarrow+/+, Fatp1B+/+) and 
deficient (Fatp1B-/-) chimeric mice were generated using bone marrow transplant (BMT) strategy 
as outlined in Figure 3.1B. Briefly, 3-week-old male C57BL/6J recipient mice were purchased 
from Jackson Laboratories (Bar Harbor, ME). Upon arrival, C57BL/6J mice were randomized to 
either a purified low fat diet (10% kcal from fat, LFD; D07010502, Research Diets, New 
Brunswick, NJ) or an obesogenic high fat diet (HFD, 45% kcal from fat, HFD; D06011802, 
Research Diets, New Brunswick, NJ). At 6 weeks of age, recipient mice were administered 2 
doses of X-ray radiation (500cGy x 2, spaced 4 hours apart; X-RAD, North Branford, CT). 
Simultaneously, bone marrow was harvested from 6 week old male Fatp1-/- and Fatp1+/+ donor 
mice maintained on standard chow and transplanted as in Makowski et al. 24. Control irradiated 
animals that were not reconstituted with bone marrow died within 10 days of irradiation. 
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Fatp1B+/+and Fatp1B-/- chimeric animals were maintained on LFD or HFD for a total of 23 
weeks. N=16-17 mice per diet group and genotype.  
Metabolic phenotyping  
Body composition was measured immediately prior to BMT and prior to sacrifice (at 23 weeks 
on diet) using magnetic resonance imaging (MRI, EchoMRI, Houston, TX). Blood glucose was 
measured at 3 weeks on the diets and again at termination, both following a 6 hour fatty acidst. 
Randomly fed blood glucose was measured at 9:00 AM after 23 weeks on diet. Intraperitoneal 
glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed at weeks 19 and 
20 on diet, following 6 or 4 hour fatty acidsts, respectively 239. Briefly, 2.0gm/kg body weight of 
glucose or 0.75U of insulin was injected intraperitoneally, and blood glucose was measured over 
120 minutes. All blood glucose measurements were performed using a FreeStyle Freedom Lite 
glucometer (Abbot Diabetes Care, Inc., Alameda, CA). Plasma insulin was measured by ELISA 
(EMD Millipore, Billerica, MA). Fatty acidsting glucose (mg/dL) and insulin (pmol/L) 
concentrations measured just prior to euthanasia were used to calculate HOMAIR and HOMA%B. 
Tissue and blood collection 
Animals were euthanized with tribromoethanol/amylene hydrate (1.25%, Sigma Aldrich, St. 
Louis, MO). Blood was collected via cardiac puncture and plasma was separated from other 
blood components by centrifugation at 200xg for 5 minutes at 4°C. Epididymal white adipose 
(eWAT) and pancreata were collected and fixed in 10% formalin for histological analyses. A 
portion of eWAT tissue was flash frozen and pulverized in liquid nitrogen.  
Hematologic analysis 
Hematologic analysis was conducted on fed 10-week-old Fatp1+/+ and Fatp1-/- age-matched 
male and female mice maintained on ad libitum chow. Blood was collected by submandibular 
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bleed into EDTA-coated tubes. Hematologic analysis occurred in the UNC Mouse Clinical 
Chemistry Core using an automated hematology analyzer. In addition, flow cytometry was used 
to enumerate circulating leukocyte populations. Blood was collected from samples for 
hematologic analysis, and red blood cells were lysed in ACK lysis buffer. Cells were washed 
twice in HBSS, resuspended in PBS, counted, and then 1x105 cells were stained with CD45-
FITC, F4/80-PE, Ly6G/C-PE-Cy7, CD11b-APC, CD11c-APC-eFluor 780 in the presence of 
anti-CD16/32 (Fc block) in FACS buffer (1% FBS in PBS) as described in Murphy et al. 240. 
Samples were analyzed on the Dako CyAN ADP flow cytometer (Beckman Coulter, Inc., 
Fullerton, CA) and FlowJo Software (TreeStar, Ashland, OR).  
Quantitation of secreted cytokines and chemokines 
Concentrations of plasma leptin, IL-6, TNF, and MCP-1 or conditioned media IL-1, IL-6, Il-
10, and MCP-1 were measured using a MAGPIX Luminex kit (EMD Millipore, Billerica, MA). 
Fatp1 genotyping 
Genomic DNA was isolated from tail biopsies, eWAT, and BMDM using a DNeasy Blood and 
Tissue kit (Qiagen, Valencia, CA). Genotyping was performed using the following primers: 
Fatp1 forward: GGCGGTCAATGTTAAGTAAACTGG, Fatp1+/+ reverse: 
CTCACACCACCCTGCAAGACTCT, Fatp1-/- neomycin cassette reverse: 
GTAATGGGATAGGTCACGTTGGTG228. iProof High-Fidelity PCR super mix (Bio-Rad, 
Hercules, CA)-based genotyping was performed on a C1000 thermocycler (Bio-Rad, Hercules, 
CA).  
Gene expression analysis 
Total mRNA was isolated from eWAT and cultured cells using a RNeasy kit (Qiagen, Valencia, 
CA). RNA quantity and quality was determined using Nanodrop (ThermoScientfic, Wilmington, 
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DE) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Gene 
expression was quantitated by qPCR using Assay-On-Demand chemistries on an ABI 7900HT 
machine (Life Technologies, Grand Island, NY) 52. Expression levels of genes of interest were 
normalized to expression of 18S. Animals whose body weight was at or above the mean body 
weight for the experimental group were selected for analysis; therefore, unless indicated, N= 8-
9/group for mouse data and N=3-6 experiments for cell culture studies. 
Morphological and immunohistochemical analyses of eWAT and pancreata 
Adipocyte size was determined by measuring the longest diameter of 100 adipocytes from each 
sample on H&E-stained 5µM sections. Anti-F4/80 and 4-HNE immunohistochemistry staining 
was conducted as previously described23. Pancreatic islets of Langerhans were visualized by 
positive insulin staining as previously described23,241. All histological sections were scanned on 
an Aperio ScanScope CS Ultra-Resolution Digital Scanner and analyzed using ScanScope Image 
Analysis Toolbox software (Buffalo Grove, IL)242. 
Bone marrow derived MΦ (BMDM) isolation, differentiation, and activation 
Bone marrow was collected from gender- and age-matched male Fatp1+/+ and Fatp1-/- mice. 
Marrow was cultured in RPMI-1640 containing 30% L929 conditioned media supplemented 
with 10% FBS, 2mM glutamine, 100 IU/mL penicillin and 100µg/mL streptomycin (Sigma-
Aldrich, St. Louis, MO) . For bioenergetics assays, BMDM were differentiated using M-CSF 
(20ng/ml). BMDM were left as naïve unstimulated MΦs (Un), or polarized using 5ng/mL LPS 
and 10ng/mL IFNγ (CAM) or 10ng/mL IL-4 (AAM) for 24 hours20. Cell densities and viability 
were determined by hematocytometer and trypan blue exclusion, respectively. Cell size, volume, 
and viability were determined using a Sceptor™ handheld automated cell counter (Millipore, 
Billerica, MA). 
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FATP1-OE stable MΦ cell line generation and characterization 
The DNA sequence for Fatp1 was obtained from the National Institutes of Health Mammalian 
Gene Collection. Fatp1 cDNA containing a 5’ EcoRI site followed by a Kozak sequence and 
Flag tag and a 3’ NotI site was cloned into the pCI-neo Mammalian Expression vector (Promega, 
Madison, WI). The upstream primer: 5’-
GATCGAATTCGCCACCATGGATTACAAGGATGACGACGATAAGCGGGCTCC 
TGGAGCAGGAACAGCC-3’. The downstream primer: 5’-
GATCGCGGCCGCTCAGAGTGAGAAGTCGCCTGC-3’. Sequencing confirmed the fidelity 
of the sequence. Mouse RAW264.7 MФ cells (ATCC, Manassas, VA; ATCC# TIB-71) were 
transfected with either the empty vector (FATP1-EV) or FATP1 expression construct (FATP1-
OE) using the AMAXA Nucleofector V kit (Lonza, Cologne, Germany). Stable cell lines were 
established and diluted serially to obtain clonal isolates under selection using 400 μg/ml G418 
Sulfate (Cellgro, Manassas, VA) for 2 weeks. All transfected MΦs were subsequently 
maintained in 200 µg/mL G418 Sulfate. RAW264.7 FATP1-EV and FATP1-OE cells were 
grown in Dulbecco’s minimal essential media (DMEM) 4.5g/L glucose supplemented with 10% 
FBS, 100 IU/mL penicillin and 100µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO). Studies 
reported herein were repeated in a second set of clones and the parent heterologous population of 
FATP-EV and FATP1-OE from which the clones were isolated (data not shown). Cell viability, 
size and volume were determined as above. Cell proliferation was determined by 3-(4, 5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay (ATCC) over 24-96 hours of 
culture222. 
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Immunoblot 
FATP1 protein expression was measured by immunoblotting as described76. Polyclonal anti-sera 
raised against the C-terminus of FATP1 or antibody against -tubulin diluted 1:1000 in PBS with 
0.1% Tween-20, overnight was used. Primary antibodies were detected with LI-COR secondary 
antibodies and imaged on the LI-COR Odyssey Imaging System (Lincoln, NE). 
ACSL activity assay   
Total long chain acyl-CoA synthetase (ACSL) activity was measured as described243. 14C-Oleate 
acid (PerkinElmer Life Sciences, Akron, OH) was incubated with cell homogenate and reactions 
were terminated after 10 minutes. Heptane-washed aqueous phase (0.6mL) was counted on a 
Wallac 1409 Liquid scintillation counter (PerkinElmer Life Science, Waltham, MA). Total 
ACSL activity was expressed as nanomoles of oleate-CoA ester formed/minute//mg protein. 
Substrate uptake and metabolism 
FATP1-EV and FATP1-OE RAW264.7, or Fatp1+/+ and Fatp1-/- BMDM were plated at 1.5x105 
or 7.5x105 cells/well, respectively, into 24 well plates, allowed to attach overnight and stimulated 
as above. Cells were washed with PBS and then incubated untreated or with 2μM BODIPY® C16 
fluorescent palmitic acid (Molecular Probe, Grand Island, NY) in DMEM for 30 minutes at 37°C 
244.  Fluorescence was measured using a CyAn ADP Analyzer flow cytometer (Beckman 
Coulter, Fullerton, CA) and FlowJo software (TreeStar, Ashland, OR)245. To measure fatty acid 
oxidation, 1.0 μCi/mL BSA-conjugated 1-[14C]-oleic acid (PerkinElmer Life Sciences, Waltham, 
MA) was added to DMEM containing 12.5mM HEPES, 1mM L-carnitine to a final 
concentration of 0.5%, 100μM sodium oleate. 14C-CO2 was captured and counted using EcoScint 
H. Glucose uptake, oxidation and glycogen synthesis were measured as previously described222. 
Results were normalized to protein concentration.  
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Cellular bioenergetics 
FATP1-EV or FATP1-OE RAW MФs (6x104/well) were seeded into a Seahorse Bioscience 
(Billerica, MA) tissue culture plate, allowed to attach for 3 hours and activated with 100ng/mL 
LPS (RAW264.7) or PBS vehicle control. Fatp1+/+ or Fatp1-/- BMDMs (2x105/well) were 
seeded and allowed to attach for 3 hours and then either left as naïve unstimulated MΦs (Un), 
CAM, or AAM polarized for 24 hrs as above. Prior to analysis, cells were washed twice with 
DMEM (RAW) or RPMI (BMDM) assay media (sodium bicarbonate- and glucose-free DMEM 
or RPMI supplemented with 2mM glutamine, 100 IU/mL penicillin and 100µg/mL streptomycin 
(Sigma-Aldrich, St. Louis, MO) and equilibrated for 1 hour at 37C without CO2. Measures of 
glycolytic rate and glycolytic capacity were determined by recording extracellular acidification 
rates (ECAR, mpH/min) and oxygen consumption rates (OCR, pmol/min) on a Seahorse 
Bioscience XF24 Extracellular Flux Analyzer (Billerica, MA) . The injection of glucose was 
used to measure glycolytic rate (final concentration 25 mM (RAW) or 11mM (BMDM); Sigma, 
St. Louis, MO). Oligomycin was injected to measure glycolytic capacity (final concentration 2.5 
µM; Sigma, St. Louis, MO). 2-deoxyglucose was used to blunt glycolysis (final concentration 20 
mM). N=6 replicates per genotype/treatment. Equal plating density was confirmed by protein 
assay. Experiments were repeated three times. 
Metabolomics 
FATP1-EV and FATP1-OE RAW264.7, or Fatp1+/+ and Fatp1-/- BMDM were plated on low 
binding, non-tissue culture treated plates. 24 hours after plating, both RAW MΦs and BMDM 
were left untreated (Un) or polarized to CAM as above. PBS-washed cells were detached by 
scraping, flash frozen in liquid nitrogen, and metabolomics analysis was completed by 
Metabolon, Inc. (Research Triangle Park, NC)246. N = 4 replicates per group. Missing values 
     
                                                                                             79 
were imputed with the minimum. Data are presented as relative measures of “scaled intensity” 
after normalization to protein and median scaling to 1. For measurement of eWAT 8-iso-PGF2, 
lipids were extracted from 25mg of pulverized tissue and 8-iso-PGF2 was quantified by liquid 
chromatography with an Agilent 1200 Series capillary HPLC (Agilent Technologies, Santa 
Clara, CA, USA) as described247. Negative ion electrospray ionization tandem mass spectrometry 
was used for detection. N = 8 per group. 
Human gene expression, variants, and trait association 
To determine whether human genetic variants may act as cis-regulators of FATP1 expression, we 
searched for expression quantitative trait loci (eQTLs) for FATP1 (SLC27A1) located within 1 
Mb of the coding sequence. We searched the Multiple Tissue Human Expression Resource 
(MuTHER) study of HapMap-imputed variants associated with gene expression in subcutaneous 
adipose tissue from 856 female twins  available in the Genvar database. We used the same 
criteria to look up cis-eQTLs in subcutaneous adipose expression data from the METabolic 
Syndrome In Men (METSIM) study of 1000 Genomes-imputed variants in 1,381 men. 
Expression levels were analyzed after adjustment for 40 inferred determinants from factor 
analysis . We further tested for association between adipose FATP1 expression residuals and 
eight obesity, lipid and adiponectin traits (body mass index, waist circumference, waist-hip ratio, 
triglycerides, HDL-C, LDL-C, total cholesterol and adiponectin) in 1,184-1,380 METSIM 
individuals using models adjusted for age and body mass index, except association with body 
mass index was only adjusted for age.  
Statistics 
For body weight data analyses, a regression model was run with genotype/diet group and week 
(0 thru 23) as predictors. To account for the repeated measures over time within animals an 
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autoregressive within-subject correlation matrix was fit. F-tests using the resulting parameter and 
standard error estimates were constructed to make comparisons of interest. All analyses were 
performed using SAS Version 9.3 (SAS Institute, Cary NC). For all other in vivo, ex vivo or in 
vitro data, statistical differences between experimental groups were determined by two-way 
ANOVA followed by multiple comparisons tests using statistical software within GraphPad 
Prism (GraphPad Software, Inc., La Jolla, CA). For ex vivo and in vitro experiments, 
representative results are reported; at least N=3 experiments were conducted with N=3-6 
replicates per assay. All data are shown as mean ± standard error of the mean (SEM). P values 
less than 0.05 were considered statistically significant.   
Approval for animal studies 
All animal procedures were approved by the University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee. 
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Figures and Tables 
 
 
 
 
 
 
 
 
Figure 3.1: FATP1 is predominantly expressed in AAMs and transplant of fatp1
-/- 
marrow results in FATP1 deficient macrophages A. Fatp1 mRNA expression by qPCR 
in CAM or AAM polarized BMDM. B. Male C57BL/6J weanling mice were randomized 
to a 10% fat diet (LFD) or 45% fat diet (HFD). Mice were lethally irradiated and 
transplanted with bone marrow from either Fatp1
+/+
 or Fatp1
-/- 
mice as described in 
Methods. Diet exposure was continued for a total of 23 weeks, during which time body 
weight and body composition data were collected along with analyses of systemic 
metabolism. C. Representative transplant-derived BMDM from a subset of diet-exposed 
mice (20X). D. Fatp1 genotype of BMDM derived from chimeric mice. E. FATP1 protein 
expression is detected by immunoblot in Fatp1
+/+
 and Fatp1
-/-
 BMDM from chimeric 
mice. Tubulin is used for loading control. 
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Figure 3.2: Deletion of MΦ Fatp1 increased susceptibility to weight gain, glucose 
intolerance, and increased white fat mass. A. Body weights were measured weekly 
(P<0.0001 Fatp1
B-/-
 vs. Fatp1B
+/+
 mice on HFD; *** P<0.001 by mixed regression 
modeling; N=16-17 mice per group). B. Randomly fed blood glucose was measured at 23 
weeks on diet (*P<0.05). C. Insulin was measured by ELISA. D. Intraperitoneal glucose 
tolerance tests (GTT) were conducted at 19 weeks on diet after a 6hr fast. HFD-fed Fatp1
B+/+
 
versus
 
Fatp1
B-/-
 (**P<0.01 and *P<0.05 N=16-17). E. Area under the curve (AUC) was 
calculated for GTT. F. Insulin tolerance tests (ITT) were conducted at 20 weeks on diet after 
a 4hr fast. G. AUC was calculated for ITT. H. Body composition was measured by MRI 
(***P<0.001 LFD vs. HFD). I. Plasma leptin concentration was measured by Luminex 
(***P<0.001 LFD vs. HFD). J. Wet weight of eWAT was measured at sacrifice (P<0.01, LFD 
vs. HFD). In HFD-fed mice, **P < 0.01 in Fatp1
B+/+
 vs. Fatp1
-/-
 mice. Data are means ± 
SEM; all differences detected by Two-way ANOVA, except for panel “A”; N=16-17 mice 
per group. 
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Figure 3.3: Lack of MΦ FATP1 increased adipose inflammation, inflammasome 
priming, and markers of oxidative stress in HFD-fed mice. A. Migration of transplanted 
Fatp1
-/- 
bone marrow cells into epididymal white adipose tissue (eWAT) was confirmed by 
genotyping adipose tissue for the null allele. B-E. Adipose tissue morphology was assessed 
by H&E staining. Representative 10X images presented. F-I. F4/80+ macrophage staining 
was conducted. Representative 10X images presented. J. Quantification of crown like 
structures (CLS, arrows) in eWAT in 5 random 20X fields  (P<0.01 in Fatp1
B+/+
 vs. Fatp1
B-
/-
). K. mRNA expression of MΦ markers emr1 (F4/80), Cd11b and Cd11c was measured by 
qPCR in eWAT (**P < 0.01 and *P < 0.05 Fatp1
B+/+
 vs. Fatp1
B-/-
 within diet. Cd11c  
expression interacts with diet, P < 0.01). Il-6 (L) and Il-1 (M) mRNA expression was 
measured by qPCR (**P<0.01,*P<0.05). N. Inflammasome mRNA expression in eWAT was 
measured by qPCR (**P<0.01). Oxidative damage assessed by 8-iso-PGF2 concentration 
(O; *P < 0.05) and 4HNE immunostaining (P). Data are means ± SEM; differences detected 
by two-way ANOVA; N = 7-9 mice per group.  
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Figure 3.4: Fatp1 deletion decreased acyl-CoA synthetase (ACSL) activity and resulted 
in a metabolic shift from lipid oxidation to glycolysis that resulted in exacerbated CAM 
and less AAM activation. A. Morphology was evaluated in representative (20X) 
photomicrographs in unstimulated (Un), classically activated by 5ng/ml LPS and 10ng/ml 
IFN (CAM), or alternatively activated using 10ng/ml IL-4 (AAM) BMDM. B. FATP1 
protein expression was measured by immunoblot in unstimulated BMDM. Tubulin is used as 
a loading control. C. ACSL activity was measured using 
14
C–oleate in unstimulated Fatp1
+/+
 
and Fatp1
-/-
 BMDMs (*P<0.05). D. Fatp1-Fatp6 mRNA was measured in BMDM generated 
from Fatp1
+/+
 and Fatp1
-/- 
mice on chow diet (**P<0.01; ****P<0.0001 Fatp1
+/+
 vs. Fatp1
-/-
). E. Oxygen consumption rate (OCR) was measured using the Seahorse Bioanalyzer in Un, 
CAM, and AAM-polarized BMDM from Fatp1
+/+
 and Fatp1
-/-
 mice. (**P<0.01 and 
*P<0.05). F. Fatty acid uptake was measured using BODIPY®-palmitate (*P<0.05 and 
****P<0.0001, Fatp1
+/+
 vs. Fatp1
-/-
). Complete (G) and incomplete oxidation (H), as 
measured by acid-soluble metabolites (ASMs), was measured using 
14
C-oleate (*P<0.05). I. 
Glucose transporter 1 (Glut1) mRNA was quantified by qPCR (****P<0.0001). J. Glucose 
uptake was measured by 
3
H-2-deoxyglucose uptake. K. Glycolytic rate, as measured by 
extracellular acidification rate (ECAR), was measured using the Seahorse Bioanalyzer 
(*P<0.05, ***P<0.001, N=3). L. Glycolytic capacity was determined using the Seahorse. 
14
C-glucose oxidation (M) and incorporation into glycogen (N) was measured. O. Inducible 
nitric oxide synthase (Nos2), (P) Tnfα and (Q) Arginase-1 mRNA expression concentrations 
were measured by qPCR (*P<0.05, ***P<0.001); polarization has an effect in all figures 
(P<0.0001). * denote differences between Fatp1
+/+
 vs. Fatp1
-/-
 within a polarization group. 
Data are mean ± SEM; differences were detected by two-way ANOVA. Representative of at 
least N=3 experiments with n=4 replicates per experiment. 
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Figure 3.5: Lack of FATP1 in CAM-polarized BMDM enhanced Pentose Phosphate 
Pathway activity. Key indicates -2 to +2 fold relative concentration of CAM-polarized 
Fatp1
-/- 
BMDM normalized to unstimulated Fatp1
-/- 
BMDM macrophages over CAM-
polarized Fatp1
+/+
 BMDM normalized to unstimulated Fatp1
+/+
 BMDM macrophages. 
Metabolomic profiling demonstrated that deletion of Fatp1 primed BMDM for an enhanced 
shunting of glucose to the pentose phosphate pathway rather than glycolysis (red boxes). N = 
4 per group.  
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Figure  3.6. Over-expression of FATP1 in RAW264.7 MΦs induced a substrate switch 
with enhanced lipid metabolism and reduced glucose metabolism resulting in blunted 
CAM-activation. Fatp1 was stably over-expressed in RAW264.7 MΦs (FATP1-OE).  
FATP1-OE were left untreated or stimulated for 24 hrs with 100ng/ml LPS and were 
compared to empty vector controls (FATP1-EV). A. Fatp1-6 were measured by qPCR. 
(n.d., not determined; ***P<0.001, *P<0.05). B. FATP1 immunoblot in unstimulated 
RAW264.7 (RAW) MΦs, FATP1-EV, and FATP1-OE. Tubulin was used as a loading 
control. C. FATP1-mediated long chain ACSL activity was measured using 
14
C–oleate 
(P<0.05). D. Fatty acid uptake was measured using BODIPY®-palmitate (**P<0.01, 
***P<0.001). Complete (E) and incomplete oxidation (F) of 
14
C-oleate were measured. G. 
Glut1 expression was measured by qPCR (**P<0.01). H. 
3
H-2-deoxyglucose uptake was 
measured. Glycolytic rate (I) and glycolytic capacity (J) were measured using a Seahorse 
Bioanalyzer (**P<0.01, *P<0.05). 
14
C-glucose oxidation (K) and glycogen synthesis (L) 
was measured (*P<0.05). Data are mean ± SEM. Representative of at least N=3 
experiments with n=4 replicates per experiment. Nos2 (M) and Tnf (N) expression was 
measured by qPCR (**P<0.01, ***P<0.001). Secreted IL-6 (O) and MCP-1 (P) were 
measured by Luminex (**P<0.01, *P<0.05). The inflammasome product IL-1 was 
measured by Luminex (Q, ***P<0.001, **P<0.01). Data are mean ± SEM; differences 
were detected by two-way ANOVA. Representative of at least N=3 experiments with n=4 
replicates per experiment. 
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Figure 3.7. Over-expression of FATP1 reduced inflammatory response in RAW264.7 
macrophages. A. FATP1 over-expression resulted in significant changes in concentrations 
of metabolites involved in amino acid, nucleotide, one-carbon, polyamine, carbohydrate 
and lipid metabolic pathways upon CAM polarization. Key indicates -5 to +5 fold relative 
expression of CAM- polarized normalized to unstimulated FATP1-OE macrophages over 
CAM-polarized normalized to unstimulated FATP1-EV macrophages. FATP1 over-
expression blunted activation of iNOS in response to CAM (B, modified from (51). C. 
Model: FATP1 is necessary to maintain the AAM phenotype and to reduce HFD-induced 
adipose tissue inflammation and systemic glucose intolerance.  
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Figure 3.8. FATP1 expression level had no effect on lean body mass, liver weight or 
brown adipose (BAT) weight. A. Body composition is measured by MRI. Liver (B) and 
BAT (C) weights were measured at euthanasia. Data are mean ± SEM; differences were 
detected by two-way ANOVA. ***P<0.001, LFD vs HFD. N=17-19 animals per group. 
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Figure 3.9. Deletion or over-expression of FATP1 had no effect on cell size or viability. 
Fatp1
+/+ 
and Fatp1
-/- 
BMDM (A) and FATP1-EV and FATP1-OE RAW (C) cell diameter and 
volume were measured by Millipore Sceptor. B. BMDM viability was measured by MTT 
assay. Only one MTT measurement was taken for BMDM since these are non-proliferating 
cells. D. RAW cell viability was also measured by MTT assay over three days. For BMDM, 
data were collected from an average of 35,000 cells per genotype. For RAW, data was 
collected from 373000 (FATP1-EV) and 348000 (FATP1-OE) cells.  
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CHAPTER IV: REMODELING THE MICROENVIRONMENT IN EARLY 
ADULTHOOD BY WEIGHT LOSS RESTRAINED DIET-INDUCED BASAL-LIKE 
BREAST CANCER PROGRESSION 
Yuanyuan Qin, Sneha Sundaram, Luma Essaid, Xin Chen, Samantha M. Miller, David B. Darr, 
Joseph Galanko, Stephanie A. Montgomery, Ben Major, Gary L. Johnson, Melissa A. Troester,  
Liza Makowski 
Submitted to Breast Cancer Research and Treatment 
Overview 
Obesity is associated with an aggressive subtype of breast cancer called basal-like breast cancer 
(BBC). BBC is fast proliferating and aggressive, with no targeted therapies, making the need for 
mechanistic insight urgent. Using the C3(1)-Tag murine model of BBC, we previously reported 
that obesity decreased tumor latency. Weight gain in adulthood is a common period of risk and is 
an important period to understand contributors to BBC oncogenesis. Reducing adiposity is 
predicted to lower incidence of BBC in human populations. Thus, the objective of this study was 
to test the hypothesis that a dietary intervention to reduce adiposity prior to tumor onset would 
reverse HFD-induced BBC latency and early progression. Adult C3(1)-Tag mice were fed a low 
fat diet (LFD, 10% calories from fat) or high-fat diet (HFD, 60% calories from fat) to induce 
changes in body composition akin to obesity, and a group initially exposed to HFD was then 
switched to LFD to induce weight loss. Two weeks after weight loss, mice in the diet-switch 
group displayed body weight and adiposity similar to the lean mice on LFD. Importantly, mice 
that lost weight after diet switch displayed significantly delayed median tumor latency (17.1 
weeks) compared to mice fed HFD (15.9 weeks). No difference was found in latency between 
mice in the LFD group (17.6 weeks) and in the diet-switch group. Spearman correlation analysis
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demonstrated that adiposity and bodyweight predicted tumor latency. There was no change in 
tumor burden amongst any of the diet groups. While there were no changes in plasma insulin or 
blood glucose concentrations associated with body composition, plasma leptin concentrations 
significantly increased with weight gain and were reduced to control levels with weight loss. 
Plasma leptin concentration negatively correlated with tumor latency. A second group of mice 
were fed the same diets and were sacrificed prior to average tumor latency to examine changes in 
the unaffected mammary gland microenvironment at 15 weeks of age. Diet switch-induced 
weight loss decreased atypical ductal hyperplasia and ductal carcinoma in situ in mammary 
glands of mice at 15 weeks of age. Therefore the HFD-exposed microenvironment that promoted 
early tumor onset was reprogrammed by weight loss and the restoration of a lean phenotype. To 
determine mechanisms underlying the protection associated with weight loss, we performed 
comprehensive activated kinase analysis in unaffected mammary glands isolated from mice at 15 
weeks of age. Importantly, weight loss reversed HFD-induced activation of PKC-α, PKD1, PKA, 
and MEK3 in unaffected mammary glands, which all likely led to inactivation of the mitogen-
activated protein kinase MAPK pathway and proliferation, resulting in delayed tumor latency in 
mice on the 60-10% diet switch compared to mice fed the 60% HFD.. In sum, HFD-induced 
tumor aggressiveness could be reversed by a diet switch that reduced adiposity and leptin levels 
to those of lean controls. In addition, several kinases were demonstrated to be inversely regulated 
by HFD and weight loss indicating novel regulators of BBC progression which can be translated 
to human studies using conserved biological approaches.  
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Introduction 
Breast cancer is the most common cancer for women worldwide, and the second most 
important contributor to cancer mortality in the US. Of all the breast cancers, basal-like breast 
cancer (BBC) remains the greatest challenge because it is highly aggressive and lacks the 
molecular targets for current targeted drug treatments13. Epidemiologic studies indicate that 
obesity is strongly associated with BBC in both pre- and post-menopausal women30,31. 
Understanding the reversibility and molecular underpinnings of obesity-induced risk is necessary 
to design prevention and treatment strategies.  
Our previous studies have recapitulated epidemiologic findings by showing that HFD-
induced obesity led to an early onset of BBC tumors in a genetically engineered mouse model 
(GEMM)242. Despite correlative findings in humans and mice, the mechanism of how obesity 
increases BBC risk remains unknown13. Obesity alters whole-organism physiology, resulting in 
dysfunctional inflammatory and insulin signaling, among others18. In addition to these complex 
changes, it is also possible that alterations to the microenvironment surrounding a pre-cancerous 
lesion or tumor account for additional obesity-driven contributors to cancer risk. Indeed, it has 
been recognized that the microenvironment plays an important role in tumor formation and 
progression32. The cellular composition, metabolites, growth factors including adipokines such 
as leptin, and modifications to the extracellular matrix in the microenvironment have critical 
effects on tumor biology13,32. Reports from our lab have demonstrated that BBC is characterized 
by unique epithelia-stroma interactions, which likely play a role in the tumor etiology164. Thus, a 
convergence of hyperinsulinemia and hyperleptinemia with alterations to the microenvironment 
may contribute to the conversion of normal epithelial cells to hyperplastic cells and/or drive the 
progression from atypical hyperplasia to carcinoma.  
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The WHO suggested that body weight and physical inactivity account for approximately 
1/5 to 1/3 of several of the most common cancers including breast cancer, and posit that more 
than 1/3 of cancers could be avoided by maintaining a healthy life style. Millikan et al. indicated 
that up to 68% of BBC could be prevented by promoting breastfeeding and reducing abdominal 
adiposity31. Therefore, weight loss may have a protective effect on tumorigenesis or tumor 
progression-possibly through alterations to the microenvironment. The window of dietary 
exposures, including weight gain and weight loss, is another important variable to consider in 
breast cancer risk. Epidemiological studies have shown that weight gain in adult life specifically 
is associated with increased breast cancer risk.   
Based on these findings, we hypothesized that early adulthood HFD-induced 
carcinogenic effects on BBC can be reversed through weight loss and are dependent upon the 
changes in the microenvironment of mammary glands before tumor onset. To test our 
hypotheses, we used C3(1)-Tag GEMMs, which have been previously shown to be a faithful 
preclinical model of human BBC135. Herein, we demonstrate that HFD-accelerated BBC can be 
delayed by weight loss induced by switching from HFD to LFD. HFD-induced changes to the 
mammary gland microenvironment included significantly increased atypical ductal hyperplasia 
and ductal carcinoma in situ in mammary glands before tumor onset. Most importantly, in HFD 
exposed mice, subsequent weight loss and reduction of adiposity successfully reversed atypical 
ductal hyperplasia and ductal carcinoma in situ to the levels detected in lean mice, i.e. the earliest 
markers of disease are affected by body composition. To determine if specific pathways 
regulated by weight loss could explain the reductions in atypical ductal hyperplasia and ductal 
carcinoma in situ, unaffected mammary glands isolated prior to average latency were subjected 
to activated kinome profiling. HFD exposure increased 6 and reduced activity of 4 kinases 
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relative to lean mice. Weight loss induced by diet switch increased activity of 14 and reduced 
activity of 5 kinases relative to lean controls. Importantly, compared to HFD-induced kinase 
changes, weight loss induced regulation included significantly reduced activity of PKC-α, PKD1, 
PKA, and MAPK kinase MEK3 in unaffected mammary glands, which together may result in 
inactivation of the mitogen-activated protein kinase MAPK/ERK pathway associated with 
proliferation. Weight loss after weight gain also decreased the activity of authophagy kinase unc-
51 like kinase 3 (ULK3), and increased the activity of metabolically sensitive kinases such as 5'-
AMP-activated protein kinase AMPK which may alter the metabolic milieu in the 
microenvironment. Our findings suggest that HFD alters the mammary gland prior to frank 
tumor onset, which contributes to atypical ductal hyperplasia, ductal carcinoma in situ and tumor 
latency, and these changes can be controlled by weight loss and reduction in adiposity. 
Results 
Tumor latency reduced by HFD exposure could be delayed by weight loss prior to tumor 
onset. To determine if weight loss in mice fed HFD prior to tumor onset would alter the course 
of tumorigenesis and/or progression, mice were subjected to various diet exposures (Figure 
4.1A). At 8 weeks of age, C3(1)-Tag mice were fed control 10% (n =28) or 60% diets (n=59). 
There were no significant differences in body weight before starting the diet study (8 weeks of 
age, Figure 4.1B). Mice on 60% diet gained more weight than those on control 10% diet, and 
were significantly different after 1 week on diet (P <0.01) and remained significantly different 
until the end of the study (Figure 4.1B). At 11 weeks of age, n=28 mice on the 60% diet were 
switched to 10% diet to induce weight loss (60-10% group, Figure 4.1A). At week 13 (1week 
post diet switch), mice on 60%-10% diet lost weight to the level of 10%-fed mice, and remained 
lean like 10%-fed mice for the remainder of the study. Mice from 60-10% diet group weighed 
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significantly less compared to mice on 60% diet from week 13 to the end of study (P <0.0001, 
Figure 4.1B).  
Time to first tumor was detected as tumor latency in the three C3(1)-Tag diet exposure 
groups. A log-rank Test was performed and chi square was equal to 6.73, with 2 degrees of 
freedom. The hazard ratios comparing either 60% or 60-10% to 10 % were 0.51 and 1.96, 
respectively. Hazard ratios comparing 60% to 10% was 0.51, P<0.01, 60% to 60-10% was 1.961, 
10% to 60-10% was 0.87, p=not significant.  (Figure 4.1C). Mice exposed to 60% HFD diet 
exhibited a significant decrease in median tumor latency compared with lean controls (10%), 
from a median of 17.6 weeks in 60%-fed mice to 15.9 in 10%-fed mice (P<0.01, Figure 4.1C). 
Mean latencies were 16.1 and 17.2 weeks for mice in 60% and 10% diet groups, respectively (P 
<0.05, data not shown). Mice that first gained weight and then lost weight after diet switch had 
significantly delayed tumor latency of 17.1 weeks compared to 60%-fed mice (15.9 weeks, 
P<0.01, Figure 4.1C). No difference in median or mean tumor latency was found between mice 
on 10% diet and on 60-10% diet. There was no change in total tumor burden with a mean of 4.9, 
4.9, 5.0 tumors per mouse in groups fed 10, 60% and 60-10% diet, respectively (Figure 4.7A). 
Interestingly, tumors from mice on 60% diet grew at a significantly slower rate compared to 
tumors from mice on 10% (P<0.05, Figure 4.1D). No significant difference in tumor growth was 
found between 60% and 60-10% groups. Furthermore, no difference was found in the tumor 
volumes among 3 groups at different time points (Figure 4.7B). 
Early adulthood high fat diet-induced changes in body composition are rapidly reversed by 
weight loss. Although the mice only gained a few grams on the 60% HFD, which is typical for 
FVB/N and C3(1)-Tag mice242, there was a significant effect of diet exposure and diet switch on 
body composition. Mice fed the 60% diet gained body fat in the first three weeks (from 8 to 11 
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weeks of age) as determined by MRI (Figure 4.2A). Mice fed 60% diet had significantly greater 
body fat mass compared to the mice on 10% diet at 11 weeks of age (P<0.0001, Figure 4.2A). 
At 13 weeks of age (2 weeks after diet switch), body fat content of mice on the 60-10% diet 
decreased significantly, and remained similar to 10%-fed mice until sacrifice. Mice on 60% diet 
exhibited greater body fat content compared to 10% and 60-10% fed mice from 13 weeks of age 
until sacrifice (P <0.0001 at weeks 13 and 15, and at sacrifice; Figure 4.2A). There were no 
significant differences in absolute lean mass in grams in any of the diet groups tested (data not 
shown). In line with changes in adiposity, plasma concentrations of the adipokine leptin 
increased significantly in mice fed the 60% diet compared to mice fed 10% diet after 3 weeks on 
diet (P <0.0001, Figure 4.2B). After diet switch from 60% to 10% diet, leptin concentrations of 
mice in the 60-10% group were significantly reduced to the concentrations of leptin in lean mice, 
consistent with the adiposity and body weights (P<0.0001, 60-10% vs. 60%; Figure 4.2B). No 
significant difference in leptin was found between 10% and 60-10% groups. The 60%-fed group 
had significantly greater leptin concentrations than the other 2 groups as soon as 2 weeks after 
the diet switch and at sacrifice (P<0.0001, 60-10% vs. 60%; 10% vs. 60%, Figure 4.2B). No 
correlation of plasma leptin concentration and tumor latency was found before diet start at 8 
weeks of age (data not shown). However, at 11 and 13 weeks of age, and at sacrifice, plasma 
leptin concentration negatively and significantly correlated with tumor latency (P=0.017, 0.0043, 
and 0.0029, respectively) (Figure 4.2C-E). There were no diet-induced changes in 6-hour fasting 
plasma insulin (Figure 4.8A) or blood glucose levels (Figure 4.8B) over the course of the study. 
Likewise, HOMAIR, a proxy measure of insulin resistance, did not reveal significant diet effects 
(Figure 4.8C).  
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Adiposity or body weight predicted BBC latency in C3(1)-Tag mice. To further explore the 
association between adiposity, body weight, and tumor latency, we stratified adiposity and body 
weight of all the mice from the 3 diet groups by quartiles. Quartile 1, defined as the bottom 25%, 
includes the mice with the lowest adiposity or bodyweight, while quartile 4 (top 25%) has the 
mice with the highest adiposity or body weight. Adiposity at diet start did not predict latency 
(Table 4.1). However, at 11, 13 and 15 weeks of age (i.e. 3, 5, and 7 weeks on diet) and at 
sacrifice, quartile 4 had significantly shorter latency compared to quartile 1 (P=0.028, 0.046, 
0.035, 0.012 respectively, Table 4.1). Similar results were observed for body weight (Table 4.2).  
Before diet started (8 weeks of age) no difference was found in latency between quartiles 1 and 4 
for body weight. At 13 and 15 weeks of age (i.e. 5, and 7 weeks on diet), quartile 4 had 
significantly shorter latency compared to quartile 1 (P=0.033, 0.0074, respectively, Table 4.2).  
Tumor progression is regulated by the microenvironment of mammary glands. Since HFD 
exposure and weight loss significantly altered tumor latency in this GEMM that is already 
induced, we next sought to examine alterations to the microenvironment that influence growth 
prior to palpation of tumor or latency. Mice were placed on diets as above at 8 weeks of age, and 
diet switch occurred at 11 weeks of age, however all mice were sacrificed at 15 weeks of age to 
examine “unaffected” mammary glands (Figure 4.3A). First, we examined if initiation of diet at 
8 weeks of age altered the number of cells expressing the SV40 Tag transgene. Tag 
immunohistochemistry analysis exhibited no significant changes in unaffected mammary glands 
of mice (quantification in Figure 4.3B and representative images in 4.3C). Second, we 
determined if HFD exposure and diet-induced weight loss altered pre-cancerous lesion 
formation. Histopathologic analysis of unaffected mammary glands was examined for regions of 
normal gland architecture including atypical ductal hyperplasia, ductal carcinoma in situ, and 
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invasive ductal carcinoma (Figures 4.4A-D). C3(1)-Tag mice fed the 60% diet had significantly 
increased atypical ductal hyperplasia in unaffected mammary glands at 15 weeks of age (P<0.05, 
Figure  4.4E). Dietary intervention-induced weight loss significantly decreased atypical ductal 
hyperplasia to the levels detected in mammary glands from lean mice on 10% diet (P<0.05, 60% 
vs. 60-10%, Figure 4.4E). HFD exposure increased ductal carcinoma in situ by about 3-fold; 
interestingly, weight loss significantly decreased ductal carcinoma in situ (P<0.05, 60% vs. 60- 
10%, Figure 4.4F). Although mammary glands from mice fed 60% diet had increased numbers 
of invasive ductal carcinoma in unaffected mammary glands, no statistical differences were 
found between diet exposures (Figure 4.4G). 
Kinome analysis revealed dramatic regulation of kinases by HFD, and diet-induced weight 
loss with important implications for BBC. Global analysis of kinase activity in unaffected 
mammary glands was carried out using MIBs, which consist of mixtures of sepharose beads with 
covalently immobilized, linker adapted, broad pan-kinase inhibitors for different kinases, which 
captures kinases in the active state in a reproducible and reliable assay (Figure 4.5A). Using 
MIB and subsequent mass spectrometry (MIB/MS) analysis, we identified a total of 155 kinases 
from unaffected mammary glands of C3(1)-Tag mice at 15 weeks of age (Figure 4.9). Individual 
runs of 2-4 pooled samples are displayed by kinase family normalized to 10%-fed controls for 
60%-fed mice (Figure 4.9A) and 60-10%-fed mice (Figure 4.9B). Means of the runs for the 
60% and 60-10%-fed mice are displayed (Figure 4.9C). Figure 4.5B shows a kinase signature 
defining a reprogrammed kinome in response to HFD-induced changes to the mammary gland 
microenvironment prior to average tumor latency. Six kinases displayed increased activity by 
>1.5 fold when normalized to control mice on 10% diet, while the activity of 4 kinases were 
decreased to <0.5 fold of mammary glands from mice fed 10% diet. The six kinases elevated by 
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HFD included protein kinase C alpha type (KPCA, Prkca), bone morphogenetic protein-2-
inducible protein kinase (BMP2K, Bmp2K), phosphatidylinositol 3-kinase catalytic subunit type 
3 (PK3C3, Pik3c3), serine/threonine-protein kinase D1 (KPCD1, Prkd1), serine/threonine-
protein kinase MARK1(MARK1, mark1), and mast/stem cell growth factor receptor Kit (KIT, 
Kit). The 4 kinases decreased by HFD included 5'-AMP-activated protein kinase catalytic 
subunit alpha-2 (AAPK2, Prkaa2), interleukin-1 receptor-associated kinase 1 (IRAK1, Irak1), 
ketosamine-3-kinase (FN3K, Fn3k), and epithelial discoidin domain-containing receptor 1 
(DDR1, Ddr1) in unaffected mammary glands (Figure 4.5B). 
Weight loss resulted in decreased expression of all kinases that were elevated in HFD-fed 
mice, since no kinases in the diet switch group increased more than 1.5 fold when normalized to 
mice on 10% diet (Figure 4.9B). Fourteen kinases from the diet switch group showed more than 
a 1.25-fold increase in activity when normalized to mice on 10% diet. In the diet-switch group, 
five kinases decreased to more than 0.5 fold of the 10% diet mice(Figure 4.5C). 
When directly comparing activity of kinases from unaffected mammary glands isolated 
from mice on HFD versus diet switch groups, several important kinases were discovered to be 
regulated by HFD and inversely regulated by weight loss (Figure 4.5D). Five kinases that were 
elevated by HFD feeding and decreased by weight loss included KPCA (Prkca), 
serine/threonine-protein kinase D1 KPCD1 (Prkd1), dual specificity mitogen-activated protein 
kinase kinase 3 (MP2K3) MEK3 (Map2k3, P=0.0044), PKA (Prkacb, P=0.0035), and unc-51 
like kinase 3 ULK3 (Ulk3, P=0.034). In contrast, two kinases were unchanged or reduced by 
obesity and significantly increased by weight loss, respectively, includeding adenosine kinase 
ADK (Adk, P=0.045) and 5'-AMP-activated protein kinase catalytic subunit alpha-2 
(AAPK2/AMPK (Prkaa2, P=0.037). 
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Discussion 
One third of US population is obese and another 1/3 is overweight. Considering the high 
prevalence, obesity could be a target for breast cancer prevention with effective intervention 
strategy including weight loss or dietary modification. Inded, weight loss after bariatric surgery 
is associated with a reduced incidence of cancer and a decreased incidence of metastasis. Weight 
loss induced by decreased dietary fat intake in early-stage breast cancer patients has been shown 
to improve the rate of relapse-free survival. However, the mechanisms mediating protection 
remain unknown. In murine studies, weight loss induced through caloric restriction protected 
against the development of breast cancer148,157,160,161. For example, intermittent caloric restriction 
provided a moderate protective effect against mammary tumor development in MMTV-neu 
mice161. A meta-analysis of experimental murine models also suggested that weight loss induced 
by energy restriction decreased tumorigenesis in mammary glands160. Our lab was the first to use 
a GEMM to study the effect of weight loss induced by dietary intervention on BBC risk. We 
previously reported that in mice fed HFD from weaning and then switched to a LFD in 
adulthood, HFD-induced tumor progression was reversed. Likewise, caloric restriction using a 
murine xenograft model of BBC demonstrated reduced tumor growth148. Furthermore, exercise 
has been reported to reduce body weight and tumor progression in C3(1)-Tag mice162. Thus, 
BBC in humans and varied murine models is responsive to energetics and body composition 
status, but the exact timing and mechanisms remain unclear. 
Herein, we aimed to focus solely on the adult window of susceptibility. Epidemiologic 
observations have demonstrated increase BBC risk in premenopausal women with high BMI30,31. 
Thus, we aimed to induce changes in adiposity akin to weight gain in early adulthood.  This is 
important because BBC is detected at a high prevalence in African Americans, a group more 
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susceptible to both obesity and weight retention after pregnancy, a period most likely in early 
adulthood31. In this study, C3(1)-Tag mice were fed HFD to induce obesity-like changes or left 
lean on LFD control diets starting at 8 weeks of age. Eight weeks of age is after pubertal 
development and is considered early adulthood in the murine life cycle. C3(1)-Tag mice develop 
tumors due to transgenic the simian virus (SV) 40 large T antigen (Tag) under the control of the 
rat prostatic steroid binding protein C3(1) gene132. Tag can bind to and inactivate p53 and Rb, 
two tumor suppressors critical for maintaining homeostasis of cell growth133. It is well-
established that at 8 weeks old, C(3)1-Tag mice develop atypical hyperplasia of ductal 
epithelium as reported previously133. At 12 weeks of age, ductal carcinoma in situ appears, and at 
16-18 weeks of age on average, 100% of female mice develop tumors when ductal carcinoma in 
situ becomes invasive ductal carcinoma132,133. Using this unique BBC GEMM, we demonstrated 
that HFD-feeding in adulthood drove aggressive tumor formation, which resulted in a significant 
reduction in tumor latency, similar to our previous report242. Importantly, weight loss prior to 
average tumor onset significantly delayed tumor latency, reversing the effects of HFD.  There 
were no early effects on tumor initiation in C(3)1-Tag mice as there were no diet-induced 
differences in initiating cells expressing Tag. Therefore, it is likely that HFD doesn’t play a 
dramatic role in the very early regulation of tumor initiation in C3(1)-Tag mice, but rather the 
progression through hyperplasia to ductal carcinoma in situ to detectable malignancy.  
Bissell et al. stated that a normal microenvironment can suppress tumor progression, but 
when the homeostasis is interrupted (e.g. by obesity, certain exposures such as high fat diet, etc.), 
the microenvironment would promote tumor growth. BBC has been reported to have unique and 
significant epithelial-stroma interactions that contribute to oncogenesis164,165. In addition, BBCs 
are more likely to recur locally than non-BBC cancers166, even after mastectomy with clean 
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margins, suggesting a field defect167 that may arise from epithelial or stromal alterations in the 
microenvironment. As defined by morphological features, breast cancer lesions progress through 
atypical ductal hyperplasia, ductal carcinoma in situ, and invasive ductal carcinoma. Importantly, 
the C(3)1-Tag mouse model has intact stroma of mammary glands which allows us to study how 
the microenvironment affects the development of breast cancer. Therefore, histopathologic 
analysis was undertaken on mammary glands isolated from C(3)1-Tag mice at 15 weeks of age 
to detect changes to the microenvironment at a time before frank tumors could be detected by 
palpation. Analysis revealed significantly increased atypical ductal hyperplasia and ductal 
carcinoma in situ after just 7 weeks of HFD exposure. Mice that lost weight and adiposity 
secondary to diet switch were significantly protected from HFD-induced atypical ductal 
hyperplasia and ductal carcinoma in situ development. The number of invasive carcinomas was 
also decreased by diet switch-induced weight loss compared to HFD-fed, but this reduction was 
not statistically significant. The fact that atypical ductal hyperplasia and ductal carcinoma in situ 
were increased by HFD and reversed to the level of lean mice by weight loss indicated that 
adiposity - or other changes to the mammary gland - could affect already initiated proliferating 
cell through modulating tumor progression during a unique window of susceptibility (e.g. from 
initiated cancer stem cells to atypical ductal hyperplasia, or from atypical ductal hyperplasia to 
ductal carcinoma in situ, and from ductal carcinoma in situ to invasive ductal carcinoma) 133. 
Thus, the pathological changes in the mammary gland at this critical period of tumorigenesis 
indicated that the early progression of basal-like tumors can be delayed or reversed by HFD and 
weight loss. 
Adipokines associated with adiposity include growth factors and metabolic regulators 
such as leptin. Leptin is a hormone produced by adipocytes in proportion to adiposity as reflected 
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by concentrations detected in HFD- and diet switch-fed C3(1)-Tag mice. Weight gain in early 
adulthood increased circulating leptin concentrations and weight loss reversed the leptin levels to 
those detected in LFD-fed controls. Spearman correlation analysis revealed significant 
correlations between leptin and latency as early as 3 weeks on diet, with greatest significance at 
sacrifice which suggests a potential role for leptin signaling in BBC. A meta-analysis reported 
that women with breast cancer have elevated plasma leptin levels. High leptin receptor mRNA 
expression in breast cancer tissue was also established to predict poor prognosis in patients with 
high serum leptin levels.  Therefore leptin plays a central role at the interface of obesity and 
breast cancer and may act through several pathways13. One way in that leptin may drive BBC is 
that leptin signaling maintains cancer stem-like properties in triple negative breast cancer cells, 
which was shown to mediate tumor recurrence and metastasis in orthotopically transplanted 
mice. Leptin signaling also induces breast tumor cell growth through activation of the JAK-
STAK and PI3K signaling pathway in both human and mouse cell lines. Leptin receptor 
deficiency in MMTV-PyMT mice was shown to attenuate tumor growth and metastasis through 
increasing mitochondrial respiration capacity in tumor cells and deactivating the downstream 
ERK and STAT3 pathways. Considering the crucial role of leptin signaling in breast cancer 
development, weight loss-associated changes in leptin concentrations could have an important 
contribution to BBC prevention. Other contributors often associated with obesity-induced 
carcinogenesis including glucose and insulin were not altered by diet exposures. The role of 
leptin receptor and stem cells in diet-induced effects on BBC are currently under investigation.  
Obesity can also disturb the microenvironment by reprogramming the kinome, or 
activating and interrupting growth factor/receptor signaling, such as leptin andother 
mediators13,18. Weight loss may help restore these changes in the mammary gland and rebuild 
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homeostasis of the microenvironment. Thus we hypothesized that kinases in the 
microenvironment of mammary glands prior to latency could be regulated by diet-induced body 
composition changes. About one fourth of all kinases may be involved in oncogenesis. Protein 
kinases regulate cell proliferation, survival, and metabolism and can contribute to tumor 
progression. Using novel kinome profiling of activated kinases, our results from unaffected 
mammary glands of mice at 15 weeks of age captured 155 activated kinases from all major 
kinome subfamilies. HFD feeding and weight loss by diet switch up- and down-regulated several 
kinases (Figure 4.6A). Our analysis focused on 7 kinases specifically reciprocally regulated by 
HFD and diet-switch. The kinase that was most elevated by HFD feeding and displayed the 
greatest decrease in activity after weight loss was a serine/threonine protein kinase (KPCA, 
Prkca) known as PKC-α. PKC-α is activated by calcium, phospholipids, phorbol esters, and 
diacylglycerol. PKC-α activates diverse functions in a cell including cell proliferation through 
phosphorylating and activating RAF1, which activates the MAPK/ERK signaling cascade. PKC-
α is a marker for breast cancer aggressiveness  and BBC have high levels of MAPK activation. 
Recent studies have identified PKC-α as over-expressed in triple negative breast cancer cells 
expressing stem-like properties. PKC-α can also activate Y-box binding protein-1, an RNA and 
DNA- binding protein and a marker of aggressive tumors which has been reported in 73% of 
BBC.  Inhibitors targeting PKC-α and cMet, another kinase that we have discovered to be 
regulated by HFD-induced exposure and weight loss242, decreased triple-negative breast tumor 
growth in murine models. Therefore, the fact that PKC-α was positively and negatively regulated 
by HFD and weight loss, respectively, provides a novel mechanism of obesity-associated BBC 
progression with exciting potential for intervention by lifestyle changes or pharmacologic 
intervention in uniquely susceptible overweight or obese populations.  
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An important upstream regulator of PKC-α was demonstrated to be the second most 
potently upregulated kinase by HFD-induced weight gain and dramatically reduced by weight 
loss; the serine/threonine-protein kinase D1 (KPCD1, Prkd1). KPCD1 is also known as PKD1, 
not to be confused with 3-phosphoinositide-dependent protein kinase 1 (PDK1 or PDPK1), 
which is downstream of PI3K which phosphorylates Akt/PkB. KPCD1 or PKD1, activated by 
DAG and phorbol ester, is downstream of novel PKC signals and is involved in the regulation of 
MAPK1/3 (ERK1/2), MAPK8/JNK1 and RAS signaling, and regulates proliferation, similar to 
PKC-α above.  PKD1 has been shown to increase cell proliferation in breast, prostate, salivary 
tumors and pancreatic cancers. In MCF-7 human breast cancer cells, PKD1 stimulated 
proliferation and enhanced tumorigenesis through MEK/ERK signaling. PKD1 also reduced 
serum- and anchorage-dependence for proliferation and survival in vitro and drove tumorigenesis 
in xenograft models of breast cancer. However, some studies on PKD1 and breast cancer are 
contradictory, and suggest that PKD1’s actions may depend on control of tumor initiation and 
progression versus metastasis.  Borges et al. demonstrated that PKD1 is expressed in cells of the 
unaffected mammary gland, and is necessary for preventing epithelial-to-mesenchymal transition 
and invasive carcinoma. Of great relevance to studies presented herein, PKD1 is one of the few 
genes identified as regulator of obesity. Through genome-wide association studies (GWAS), 
PKD1 was identified as a loci associated with human obesity, especially in obesity prevalent 
young adults, which is similar to the window of diet exposure and latency in C3(1)-Tag mice 
studied. Clearly, PKD1 must be further investigated, especially it’s role in obesity-associated 
breast tumorigenesis. Downstream of PKD1 and PKC-α is cAMP-dependent protein kinase 
catalytic subunit beta (KAPCB, Prkacb), also known as PKA. PKA mediates the activation of the 
MAPK/ERK signaling cascade through cAMP-dependent signaling triggered by receptor binding 
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to G-protein coupled receptors, which is involved in tumor progression. Elevated PKA activity in 
the mammary epithelium generated tumors in a murine model and was associated with BBC and 
poorer outcomes in patients.  
The above kinases all act through the MAPK kinase family. Kinome analysis of C3(1)-
Tag mammary glands revealed significant regulation of the MAP kinase kinase family member 
the dual specificity mitogen-activated protein kinase kinase 3 (MP2K3, Map2k3), also known as 
MEK3 or MKK3. MEK3 is a kinase activated by mitogenic and environmental signals and led to 
proliferation and cell survival through increased oncogene RAS expression, as well as activation 
of p38α (MAPK14). RAS expression also led to increased MEK3, creating a feed forward loop 
driving oncogenic transformation of primary cells in breast epithelial cells. Inhibition of MEK3 
led to reduction in cell proliferation and apoptosis. MEK3 was also increased by mutant p53 
leading to increased proliferation and survival, and knockdown of MEK3 led to reduced cell 
viability as well as increased susceptibility to chemotherapeutic agents in vitro and in vivo. 
Interestingly, MEK3 is also linked to obesity and lipotoxicity in human populations, as well as 
diabetes in a murine model. In sum, Figure 4.6B demonstrates how weight loss reversed HFD-
induced activation of PKC-α, PKD1, PKA, and MEK3 in unaffected mammary glands, which all 
likely led to inactivation of the mitogen-activated protein kinase MAPK/ERK pathway and 
proliferation, resulting in delayed tumor latency in mice on the 60-10% diet switch compared to 
mice fed the 60% HFD. 
A final kinase moderately but significantly up-regulated by HFD and down-regulated by 
weight loss is the serine/threonine protein kinase unc-51 like kinase 3, ULK3 (Ulk3). ULK3 
regulates the developmental and oncogenic pathway of sonic hedgehog (SHH) signaling and 
autophagy. Cancer cells often turn to autophagy at times of substrate need or hypoxia. ULK3 is 
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over-expressed in certain cancer cell lines but it’s role in senescence versus tumorigenesis 
unclear. Since it is regulated by diet, and significantly reduced with weight loss after weight 
gain, ULK3 may be a promising target. 
Two kinases were regulated in the inverse direction: reduced by HFD and increased with 
weight loss after diet switch. A kinase whose activity was reduced with HFD to more than 40% 
that of lean mice on LFD, and then reversed to control levels with weight loss is the alpha 2 
catalytic subunit of AMP-activated protein kinase (AAPK2, Prkaa2). AMPK is an energy-
sensing enzyme that controls nutrient metabolism . Under low energy or cellular stress, AMPK is 
activated to increase production of ATP through activation of catabolic pathways including fatty 
acid oxidation and glucose uptake along with inhibition of anabolic processes including fatty 
acid, protein, and cholesterol synthesis27. Consistent with increased activated AMPK by weight 
loss in our results, activation of AMPK has been suggested to be a target for cancer prevention 
and treatment. For instance, a low incidence of cancer in diabetic patients on metformin is likely 
due to the drug's anti-proliferative effect through activation of AMPK. AMPK is also important 
in obesogenesis, diabetes, and exercise physiology. Significant associations were observed 
between AMPK and with weight change in patients on anti-depressants. Other groups have 
demonstrated that HFD-feeding decreased AMPK activity.  However, the role of AMPK in 
cancer prevention may be complex since the EPIC population study did not detect any 
associations between SNPs in PRKA, breast cancer risk or body mass index.  AMPK in BBC 
merits further study. 
Overall, it is important to note that of all cancers, only about 5%-15% have a major 
genetic component. Most cancers are considered to be predominantly caused by environmental 
factors. Lifestyle components, like obesity, lack of exercise, smoking, etc., play an important role 
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in cancer initiation and progression through activating oncogenes and inactivating tumor 
suppressors. Thus, further understanding the tumor and microenvironment changes that occur on 
HFD and after weight loss will help identify novel strategies to prevent the progression of BBC 
to malignancy.  
Methods 
Reagents. Rat/Mouse Insulin ELISA kit was obtained from Millipore (EZRMI-13K; EMD 
Millipore, Billerica, MA, USA). Anti-SV40-Tag (sc-20800) was obtained from Santa Cruz 
(Santa Cruz, Santa Cruz, CA). Rat anti-F4-80 antibody is from a Bio-rad company (#MCA-497, 
AbD serotec, Raleigh, NC, USA). Biotin-SP (longer spacer) AffiniPure Goat anti-Rat IgG was 
from Jackson ImmunoResearch (#112-065-167, Jackson ImmunoResearch Inc. West Grove, PA, 
USA).  
Animals and Diet. Animal studies were performed with approval and in accordance with the 
guidelines of the Institutional Animal Care and Use Committee at the University of North 
Carolina at Chapel Hill. Female C3(1)-Tag mice were obtained in collaboration with the UNC 
Lineberger Comprehensive Cancer Center (LCCC) Mouse Phase I Unit (MP1U). In female mice, 
the simian virus (SV40) large tumor antigen (Tag) is expressed in the distal mammary ductal 
epithelium and terminal ductal lobular unit in a hormone-independent manner leading to the 
development of mammary tumors133. C3(1)-Tag mice were generated by crossing heterozygous 
male mice with FVB/N non-transgenic female mice. During breeding and after weaning at 3 
weeks old, female C3(1)-Tag mice were put on Prolab Isopro RMH 3000 from LabDiet (St. 
Louis, MO, USA) until they were 8 weeks old when they were started on defined diets. Diets 
obtained from Research Diets Inc. (New Brunswick, NJ, USA) were matched for protein, 
vitamins, and minerals, and provided 10% kcal (“10%”); and 60% kcal (“60%”) derived from 
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fat. Details of the diet components are provided in Sundaram et al.242 At 8 weeks of age, mice 
were randomly assigned to low fat diet (LFD) 10% (N=28) and high fat diet (HFD) 60% (N=59) 
diet groups. After 3 weeks on diet, at 11 weeks of age, N=28 mice on 60% were switched to 10% 
diet (See model of study design, Figure 4.1A). A second set of mice were initiated on 10% 
(N=8) and 60% (N=20) at 8 weeks of age. At 11 weeks of age, N=11 of 60%-fed were switched 
to 10% as above. This cohort was sacrificed at 15 weeks of age prior to average tumor latency 
and unaffected mammary glands were isolated. (See model of study design, Figure 4.3A). 
Tumor latency, number, and progression. Mice were monitored for tumor development by 
palpating three times weekly. Tumor latency was defined as age at detection of first tumor in 
weeks. After detection of the first tumor, tumor volumes were measured weekly over 3 weeks 
using calipers to measure the width (short diameter) and length (long diameter) in millimeter for 
each tumor. The tumor volumes were calculated using the formula: length × width2×0.5. The 
percent change in volume over time (tumor progression) was calculated as: (End volume – Start 
volume)/Start volume × 100. Mean tumor progression (percent change in volume) of the first 
palpated tumor is presented. The total number of tumors per mouse was counted at sacrifice for 
total tumor burden.  
Body weight and composition. Body weight was measured prior to starting mice on diet and 
weekly until sacrifice. Body composition including lean mass, fat mass, free water content, and 
total water content of non-anesthetized mice was also measured at 8 (diet start), 11 (diet switch), 
13, and 15 weeks of age, as well as at sacrifice using the EchoMRI-100 quantitative magnetic 
resonance whole body composition analyzer (Echo Medical Systems, Houston, TX, USA). Fat 
mass is presented as percent fat mass over total body weight242.  
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Tissue harvest. Three weeks after detection of the first tumor, mice were fasted for six hours and 
then anesthetized by an intraperitoneal (i.p.) injection of avertin (Fisher Scientific, Pittsburgh, 
PA, USA) prior to sacrifice. Blood was collected by cardiac puncture into a tube with EDTA to 
reach a final concentration of 0.05 mM. Plasma was separated by centrifuging blood at 500 × g 
for 5 min and stored at −80°C. Tumors and/or unaffected 4th mammary glands were collected. 
Portions of the tissues were placed into a cassette and formalin-fixed for immunohistochemistry 
(IHC) and H&E analysis. A portion of the unaffected mammary gland from study 2 was snap 
frozen in liquid nitrogen for proteomic analysis.  
Metabolic parameters and plasma. Blood glucose was measured on mice fasted for 6 hours prior 
to start of diet, at diet switch (3 weeks on diet), 2 weeks after diet switch, and at sacrifice using a 
Bayer Contour Blood Glucose Monitor (Bayer HealthCare LLC, Tarrytown, NY, USA). The 
metabolically relevant biomarker leptin was measured in the plasma collected at different time 
points using the MILLIPLEX MAP Mouse Angiogenesis/Growth Factor Magnetic Bead Panel - 
Cancer Multiplex Assay (EMD Millipore, Billerica, MA, USA). No significant differences were 
detected in other components of this panel. Plasma insulin concentrations were measured using 
Rat/Mouse Insulin ELISA kit (EZRMI-13K; EMD Millipore, Billerica, MA, USA) following the 
manufacturer’s protocol. The homeostasis model assessment was used to calculate the 
approximate insulin resistance (HOMAIR) using the formula (blood glucose (mg/dl at sacrifice) × 
plasma insulin concentration (ng/ml) /405) as previously described242.  
Immunohistochemistry. Briefly, formalin-fixed and paraffin-embedded tissues were sectioned at 
5 microns and mounted for histological staining242. Tissues were blocked in a commercial 
protein blocking solution (Dako, X0909) and exposed to primary antibodies at 4°C overnight 
with gentle agitation. Anti-mouse F4/80 (1:100) and anti-SV40-Tag (1:250) 
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immunohistochemistry (IHC) staining was conducted as previously described23,163. 
Immunohistochemistry analysis was performed following the protocol previously described in 
Sundaram et al.242 Following staining, slides were scanned into the Aperio Scanscope CS system 
(Aperio Technologies, Vista, CA, USA) at a magnification of 40× and staining was quantified 
using the Aperio Imagescope software. The scanned slides were analyzed using the appropriate 
algorithms as described previously163. The Aperio Imagescope software positive pixel counts for 
diaminobenzidine (DAB) staining in the color deconvolution algorithm was completed for F4-80 
and SV40-Tag 23,242. Aperio digital analysis of DAB prevents subjective bias in quantification. 
Random areas from sections (n = 6) were quantified and averaged per animal. N = 8-11 mice per 
diet exposure group for IHC of F4-80, SV40-Tag and H&E of unaffected mammary glands, as 
indicated in legends. Representative 40× images are presented. 
Microenvironment pathological analysis. Histopathologic analysis was completed by a certified 
veterinary pathologist (S.M.). Sections from unaffected mammary isolated at 15 weeks of age in 
study 2 were analyzed for the presence of normal ducts, atypical ductal hyperplasia, ductal 
carcinoma in situ, and invasive ductal carcinoma. Histological composition in n=6 random areas 
from each section were quantified and averaged. Representative 40× images are presented. 
Kinome Analysis. Multiplexed Inhibitor Bead (MIB) Affinity Chromatography: Isolation of 
activated kinases from tissue lysates was performed as described previously. Briefly, unaffected 
mammary glands from study 2 were collected at 15 weeks of age. Tissues were pulverized in 
liquid nitrogen and lysed on ice in MIB lysis buffer [50 mM HEPES (pH 7.5), 0.5% Triton X-
100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM sodium fluoride, 2.5 mM sodium 
orthovanadate, 1X protease inhibitor cocktail (Roche), and 1% of phosphatase inhibitor cocktail 
3 (Sigma-Aldrich)]. Two to four samples were pooled together for a total protein content of 
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2.5mg. Details of the MIB kinase analysis have been published previously. Briefly, tissue lysates 
were passed through a column of layered inhibitor-conjugated beads consisting of Sepharose-
conjugated Shokat, AGCbead (UNC-21474), Purvalanol B, PP58, VI-16832 and CTx-0294885 
(Figure 4.5A). Kinase-bound inhibitor beads were washed several times before elution in 1 mL 
of 0.5% SDS (100°C, 5 min). Eluted kinases were reduced, alkylated, and concentrated before 
chloroform/methanol extraction. Protein pellets were resuspended in 50 mM HEPES (pH 8.0) 
and were digested for 24 hours with sequencing grade modified trypsin (Promega). Digested 
peptides were labeled with iTRAQ reagent (AB SCIEX, Framingham, MA) for 2 hours at room 
temperature in the dark, according to the manufacturer’s instructions. Labeled peptides were 
cleaned with PepClean C18 spin columns (Thermo Scientific) before fractionation on a Tempo™ 
LC MALDI Spotting System (AB SCIEX) using a Chromolith® CapRod® RP-18e HR 
analytical column (Merck KGaA, Darmstadt, Germany). 
Mass spectrometry (MS) Analysis: As described previously, MS data were acquired with a 
MALDI TOF/TOF 5800 (AB SCIEX) and analyzed by ProteinPilot Software Version 3.0 (AB 
SCIEX) with a UniProtKB/Swiss-Prot database. Proteins were accepted when ≥1 unique peptide 
was identified at 99% confidence. Peptide quantitation by ProteinPilot was performed using the 
Pro Group Algorithm and quant ratios are bias and background-corrected.  
Statistical analysis: Data are expressed as mean and standard error of the mean (SEM).  
Percentage of tumor-free mice amongst the 3 diet exposure groups was compared with Kaplan-
Meier analyses. Log rank and chi-square test were used to investigate differences among groups 
for tumor latency. Continuous variables for two groups were compared using t-tests. Continuous 
variables for more than two groups were compared using one way Analysis of Variance 
(ANOVA) with Tukey's post hoc test.  The correlation of latency with body weight, adiposity or 
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leptin level at different time points was computed via Spearman Rank correlation. Analyses were 
performed using SAS Version 9.3 (SAS Institute, Cary NC USA) or GraphPad Prism 5 software 
(GraphPad Software, Inc. La Jolla, CA, USA). P-values <0.05 were considered statistically 
significant. 
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Figures and Tables 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Weight loss protected against HFD-mediated early BBC onset. A. 
Model of study design 1. At 8 weeks of age, C3(1)-Tag mice were randomly assigned 
to 10% (N=28) and 60% (N=59) diet groups. After 3 weeks on diet, at 11 weeks of age, 
N=28 mice on 60% were switched to 10% diet. Mice were monitored for tumor onset 
by palpation 3 times a week. Three weeks after tumor onset, mice were sacrificed. B. 
Body weight was measured weekly. 10% vs. 60-10% (^P<0.05); 10% vs. 60% (*P 
<0.01); and 60% vs. 60-10% (#P <0.0001). C. Mice were tumor free until first tumor 
palpated (P<0.01, 10% vs. 60%; 60-10% vs. 60%).  
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Figure 4.2. Body composition predicts latency.  A. MRI was used to evaluate body 
composition. 10% vs. 60% (#P <0.0001); 60% vs. 60-10% (^P <0.0001); and 10% vs. 
60-10% (*P<0.0001). N=28 10%, N=31 60%; N=28 60-10%). B. Plasma leptin was 
detected by Multiplex Assay. 10% vs. 60% (#P <0.0001); 60% vs. 60-10% (^P 
<0.0001); 10% vs. 60-10%(*P<0.0001). N=12 10%, N=12 60%; N=13 60-10%. C-E. 
Spearman correlations of plasma leptin with latency at 11 and 13 weeks of age and 
sacrifice (P=0.017, 0.043, and 0.0029, respectively).  
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Figure 4.3.  Diet did not affect tumor initiation. A. Model of study 2. A second set of 
mice were started on 10% (N=8) and 60% (N=20) at 8 weeks of age. At 11 weeks of age, 
N=11 of 60%-fed were switched to 10% as in study design 1. Mice were sacrificed at 15 
weeks of age prior to average tumor latency and unaffected mammary glands were 
isolated. B. T antigen (Tag) expression was measured in unaffected mammary glands by 
immunohistochemistry staining. C-E. Representative 40X images are shown of Tag IHC 
staining from (C) 10% diet group, (D) 60% diet group, and (E) 60-10% diet group. 
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Figure 4.4. Pathological changes in the unaffected mammary gland induced by high 
fat diet were reversed by weight loss. Unaffected mammary glands were collected from 
15-week old C3(1)-Tag mice in study 2. (A-D) Representative 40X images are shown of 
(A) normal duct, (B) atypical ductal hyperplasia, (C) ductal carcinoma in situ, and (D) 
invasive ductal carcinoma. E. Areas of atypical ductal hyperplasia were quantified in N=6 
40X regions per section per mouse. *P<0.05, 10% vs. 60%; 60-10% vs. 60%. F. Areas of 
ductal carcinoma in situ were quantified as in E. *P<0.05, 60-10% vs. 60%. G. Areas of 
invasive ductal carcinoma were quantified as in E. N = 8 10%; N = 9 60%; N =11 60-
10%. Representative 40× images are presented.  
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Figure 4.5. Kinome profiling of unaffected mammary glands revealed dramatic 
regulation of PKD1-PKC-α-PKA-MEK3 by diet exposure. To profile kinome, 
unaffected mammary glands from mice at 15 weeks of age were collected for 
Multiplexed Inhibitor Bead (MIB) Affinity Chromatography and Mass spectrometry 
analysis. A. MIBs consist of mixtures of sepharose beads with covalently immobilized, 
linker-adapted, broad pan-kinase inhibitors (listed on left of column) are designed to 
capture kinases in the active state in a reproducible and reliable assay. Two to 4 samples 
were pooled into a total of 3 runs per diet group. All kinase activity is normalized to 10%-
fed controls B. HFD (60%-fed) mammary gland kinase activity of greater than 1.5 or less 
than 0.5 fold compared to 10%-fed is presented. C. Weight loss (60-10%-fed) mammary 
gland kinase activity of greater than 1.25 or less than 0.5 fold compared to 10%-fed is 
presented. D. Mean kinase activity is presented to compare kinases in the unaffected 
mammary glands that were significantly different between mice in the 60% group and 60-
10% group. *P<0.005, ^P<0.05, 60% vs. 60-10% ) In C and D, no error bar is present in 
pooled samples when kinases were down-regulated below level of detection and only 1 
run detected activity.  
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Figure 4.6. Protein-Protein interactions of significantly altered kinases in unaffected 
mammary gland of mice on 60-10% diet compared to mice on 60% diet. A. Search 
Tool for the Retrieval of Interacting Genes/Proteins (STRING version 10) was used to 
visualize known protein-protein interactions between significantly regulated kinases. 
Confidence view was shown. Stronger associations are represented by thicker lines. B. 
Cartoon of a subset of kinases regulated by HFD and reserved by weight loss and the 
contribution of obesity-induced leptin signaling. 
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Figure 4.7. Tumor burden and size are not affected by diets. A. Tumor burden was 
quantified at sacrifice. B&C. Tumor volume was measured by calipers at detection and 
sacrifice.  B. Volume of the primary tumor was detected over 3 weeks. (N=28 10%; N=31 
60%; N=29 60-10%). 
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Figure 4.8. Measures of glucose intolerance were not altered by diet. A. Plasma 
insulin and glucose (B.) levels were measured in 6 h fasted mice at time points indicated. 
C. Homeostasis model assessment of insulin resistance (HOMAIR) was calculated. (N=12 
10%, N=12 60%; N=13 60-10%).  
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Figure 4.9. Kinome profiling reveals significant regulation of pathways by HFD 
that are reversed with weight loss. A&B. Quantitative comparison of kinases in 
unaffected mammary tissues from mice using MIB/MS was conducted. Legend indicates 
three iTRAQ runs with 2-4 samples pooled per group per run. The graphs indicates 
quantitative changes in kinase activity as a ratio of mice fed 60% (A) or 60-10% (B) diet 
relative to mice fed 10% diet group. Ratio <1 denotes decreased kinase activity and >1 
increased kinase activity. Kinase families are indicated (AGC: Containing PKA, PKG, 
PKC families; CAMK: Calcium/calmodulin-dependent protein kinase; CK1: Casein 
kinase 1; CMGC: Containing CDK, MAPK, GSK3, CLK families; STE: Homologs of 
yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK: Tyrosine kinase; TKL: Tyrosine 
kinase-like). C. Mean kinase activity is reported for mice fed 60% diet (dark grey) or 60-
10% diet (light grey) compared to mice on 10% diet group. Error bars are not indicated 
for clarity. Statistically significant comparisons are reported in Figure 4.5D. 
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Table 4.1. Adiposity of all the mice from 3 groups were stratified by quartiles. 
Quartile 1 includes the 25% mice with the lowest adiposity, while Quartile 4 has the 25% 
mice with the highest adiposity. Before diet started (8 weeks of age) no difference was 
found in latency between Quartile 1 and 4. At 11, 13 and 15 weeks of age (i.e. 3, 5, and 7 
weeks on diet) and at sacrifice, Quartile 4 had significantly shorter latency compared to 
Quartile 1 (P=0.028, 0.046,0.035, 0.012 respectively).  
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Table 4.2. Body weight of all the mice from 3 groups was stratified by quartiles. 
Quartile 1 includes the 25% mice with the lowest bodyweight, while Quartile 4 has the 
25% mice with the highest body weight. Before diet started (8 weeks of age) no difference 
was found in latency between Quartile 1 and 4. At 13 and 15 weeks of age (i.e. 5, and 7 
weeks on diet), Quartile 4 had significantly shorter latency compared to Quartile 1 
(P=0.033, 0.0074 respectively).  
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Table 4.3. Activated kinases regulated by high fat diet exposure and weight loss induced by 
diet switch. Proteomic analysis of activated kinases was conducted using MIB and MS/MS in 
unaffected mammary glands isolated at 15 weeks of age. Mean fold regulation of N=3 runs with 
2-4 samples pooled per run.  * Less than 3 measures were detectable. 
  
Kinase 
Family Gene Uniprot Name 
Avg. 
fold  
High fat diet-
regulated AGC Prkca KPCA Protein kinase C alpha type 2.09 
(> 1.5 and < 
0.5) Other Bmp2k BMP2K BMP-2-inducible protein kinase 1.61 
  Metabolic Pik3c3 PK3C3 
Phosphatidylinositol 3-kinase 
catalytic subunit type 3 1.60 
  CAMK Prkd1 KPCD1 Serine/threonine-protein kinase D1 1.56 
  CAMK Mark1 MARK1 
Serine/threonine-protein kinase 
MARK1 1.52 
  TK Kit KIT 
Mast/stem cell growth factor 
receptor Kit 1.50 
  CAMK Prkaa2 AAPK2 
5'-AMP-activated protein kinase 
catalytic subunit alpha-2 0.48 
  TKL Irak1 IRAK1 
Interleukin-1 receptor-associated 
kinase 1 0.48 
  Metabolic Fn3k FN3K Fructosamine-3-kinase 0.46 
  TK Ddr1 DDR1 
Epithelial discoidin domain-
containing receptor 1 0.36* 
Weight loss-
regulated Metabolic Adk ADK Adenosine kinase 1.50 
(> 1.25 and < 
0.5) TKL Tgfbr1 TGFR1 TGF-beta receptor type-1 1.46 
  Other Tbk1 TBK1 
Serine/threonine-protein kinase 
TBK1 1.39 
  CMGC Cdk1 CDK1 Cyclin-dependent kinase 1 1.39 
  CK1 Csnk1a1 KC1A Casein kinase I isoform alpha 1.38 
  CAMK Mark1 MARK1 
Serine/threonine-protein kinase 
MARK1 1.30 
  CAMK Sik2 SIK2 
Serine/threonine-protein kinase 
SIK2 1.26 
  CK1 Csnk1e KC1E Casein kinase I isoform epsilon 1.26 
  TK Pdgfra PGFRA 
Platelet-derived growth factor 
receptor alpha 1.26 
  Metabolic Chkb CHKB Choline/ethanolamine kinase 1.26 
  TK Jak1 JAK1 Tyrosine-protein kinase JAK1 1.25 
  AGC Cdc42bpb MRCKB 
Serine/threonine-protein kinase 
MRCK beta 1.25 
  Metabolic Pik3c3 PK3C3 Serine/threonine-protein kinase 1.25 
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MRCK beta 
  AGC Rps6ka3 KS6A3 
Ribosomal protein S6 kinase alpha-
3  1.25 
  AGC Prkca KPCA Protein kinase C alpha type 0.49* 
  CMGC Srpk2 SRPK2 SRSF protein kinase 2 0.49* 
  TKL Irak1 IRAK1 
Interleukin-1 receptor-associated 
kinase 1 0.38* 
  CAMK Prkd1 KPCD1 Serine/threonine-protein kinase D1 0.31* 
  STE Tnik TNIK 
Traf2 and NCK-interacting protein 
kinase 0.27* 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3. Activated kinases regulated by high fat diet exposure and weight loss 
induced by diet switch. High fat diet (HFD) increased 6 kinases in the unaffected 
mammary glands to more than a 1.5 fold change when normalized to those of mice on 10% 
diet. Four kinases were decreased by HFD to less than a 0.5-fold change when normalized 
to those of mice on 10% diet. Fourteen kinases had a more than 1.25-fold increase in the 
unaffected mammary glands after weight loss. Five kinases were decreased to less than a 
0.5-fold change by weight loss when normalized to those of mice on 10% diet (No error bar 
here because these kinases were only detected in one run). 
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Table 4. Activated kinases regulated by weight loss induced by diet switch compared to 
high fat diet exposure. Proteomic analysis of activated kinases was conducted using MIB and 
MS/MS in unaffected mammary glands isolated at 15 weeks of age. Mean fold regulation of N=3 
runs with 2-4 samples pooled per run. n.d.: Not determined because less than 3 measures were 
detectable in downregulated kinases. 
Kinase 
Family Gene Uniprot Name HFD 
HFD-
LFD P 
AGC Prkca KPCA Protein kinase C alpha type 2.09 0.49 n.d. 
CAMK Prkd1 KPCD1 Serine/threonine-protein kinase D1 1.56 0.31 n.d. 
STE Map2k3 MP2K3 
Dual specificity mitogen-activated 
protein kinase kinase 3 1.32 0.53 0.00 
AGC Prkacb KAPCB 
cAMP-dependent protein kinase 
catalytic subunit beta 1.27 0.82 0.00 
Other Ulk3 ULK3 
Serine/threonine-protein kinase 
ULK3 1.13 0.66 0.03 
TK Pdgfra PGFRA 
Platelet-derived growth factor 
receptor alpha 1.12 1.26 0.01 
Metabolic Adk ADK Adenosine kinase 1.00 1.50 0.05 
CAMK Prkaa2 AAPK2 
5'-AMP-activated protein kinase 
catalytic subunit alpha-2 0.48 1.08 0.04 
 
 
 
 
 
Table 4.4. Activated kinases regulated by weight loss induced by diet switch compared 
to high fat diet exposure. Kinases in the unaffected mammary glands that were 
significantly different between mice in the 60% group and 60%-10% group (N=2 or 4 
samples were pulled together per group for a total protein content of 2.5mg for one run of 
MIB. N=3 runs). 
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CHAPTER V: SYNTHESIS 
Overview of research findings 
We examined the effect of high fat diet and alcohol consumption in the onset and 
progression of varied disease states to determine how certain exposures altered the 
microenvironment. We reported for the first time that there is an augmented inflammatory 
response in adipose tissue after the combined challenge of ethanol and burn injury. Binge 
drinking not only leads to many forms of injuries, such as increased susceptibility to infection, it 
also leads to adipose tissue inflammation. Adipose tissue inflammation with macrophage 
infiltration contributes to insulin resistance in obese individuals. Therefore, the role of adipose 
tissue inflammation and insulin resistance after alcohol exposure, and especially associated with 
burn injury, warrants further investigation.  
 We also focused our research on controlling adipose inflammation through the novel 
approach of restricting macrophage metabolism with the goal of further understanding effects on 
inflammation. Data presented herein supports findings that demonstrated that manipulating 
substrate metabolism by deleting FATP1 in macrophages affected their metabolic and 
inflammatory phenotype.  We reported that macrophage-specific FATP1 plays an important role 
in controlling overall white adipose mass, as well as macrophage infiltration and inflammation, 
lipid peroxidation, and NLRP3 inflammasome activation in white adipose. Alteration of the 
adipose tissue was associated with systematic changes in body weight and glucose tolerance. 
Therefore, we demonstrated that manipulating macrophage metabolism is a unique approach to
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 controlling local composition of the adipose microenvironment, which has important effects 
systemically in diet-induced obesity.  
 In our third study, data supports the contribution of HFD exposure to the 
microenvironment and systemic biology associated with the onset of BBC. We demonstrated in a 
unique mouse model of BBC that HFD-induced changes to body composition and leptin levels, 
akin to obesity, led to increased tumor aggressivness, premalignant hyperplasia, and DCIS, as 
well as elevation of kinasesknown to be regulated by obesity and novel findings. The 
reversibility of these obesity-associated effects was demonstrated by a diet switch-induced 
weight loss that delayed tumor onset, reduced hyperplasia and DCIS, as well as reduced leptin 
levels in plasma and certain kinases in the mammary gland. Thus, high fat diet-induced changes 
to the pre-neoplastic microenvironment are not immutable, and demonstrate that weight loss 
prior to tumor onset could reduce BBC tumor burden. 
Through varied disease models exposed to alcohol or high fat diet, we have proved that 
lifestyle factors contribute to disease onset and progression through alterations to the 
microenvironment. In other words, the sequence of our genes is like the keys on the piano; it is 
the context that makes the music. 
 
Direction for Future research 
Obesity and alcohol abuse often co-exist, but few studies have investigated their 
combined deleterious effects on human health. Obesity and alcohol exposures can individually 
alter immune responses and induce immunosuppression, but their combined effects on systemic 
inflammation and immune defenses are largely unknown. It has been reported that obese 
individuals were at a greater risk for mortality/morbidity compared with healthy weight 
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individuals due to defects in immune regulation during the influenza 2009-2010 pandemic248. 
Considering the prevalence of obesity in the US and high rate of emergency events after alcohol 
consumption 7, future studies should focus on whether alcohol and obesity-mediated disease 
processes are synergistic and if they can be controlled by manipulating underlying inflammation. 
We can test future studies by putting the mice on high fat diet to induce obesity before alcohol 
consumption and burn as described in our study. 
The role of lipid metabolism, especially fatty acids released from adipoctyes in obesity249, 
is poorly understood and necessitates further study. One disadvantage of our study on FATP1 is 
the effect of radiation associated with BMT on weight gain and adiposity. Mice didn’t gain as 
much weight as those without radiation. The relative reduced amount of adiose tissue caused by 
radiation may affect the adipokines, blood glucose concentrations, and the inflammatory 
response.  In future studies, macrophage specific FATP1 knockout mice will be created using 
LysM-cre to further explore the mechanisms of how macrophages contribute to increased white 
adipose mass and glucose interolerance.  
Finally, future work should also focus on the mechanism of how obesity affects activated 
kinase expression in the microenvironment of mammary glands. The exact signaling pathways of 
kinases in tumor growth need to be further explored in specific kinase or their receptor knockout 
murine models or what type of cells. The activation of these kinases in high fat diet exposure 
may be due to growth factors, inflammatory mediators, or metabolites secreted from cells 
uniquely regulated in obesity. Since BBC has been characterized by unique epithelial- storma 
interations, the role of cells in the microenvieronment of mammary glands, like cancer-
associated adipocytes, cancer-associated fibroblasts, and macrophages, on kinase activation 
associated with carcinogenesis remains to be determined.  
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Public Health significance 
With dramatic increases in obesity worldwide, widespread alcohol consumption, the 
additive effect of these exposures is an especially significant and urgent global health challenge. 
About 4% and 7% of new cases of cancer in man and women, respectively, were due to obesity 
in the US in 2007250. Excess body weight contributes to as many as 1 out of 5 of all cancer-
related deaths251. A meta-analysis indicated that women who drank about 3 dirnks per day had 
1.5 times the risk of developing breast cancer as nondrinkers252. The data generated from our 
study will provide important information about underlying biochemical mechanisms that will 
inform strategies to provide the most effective treatment strategies for alcohol and obesity-
mediated pathology. Furthermore, understanding the metabolism associated with immune cells 
that contribute to obesity associated dysfunction is central to developing novel therapeutic targets 
for obesity and related diseases like diabetes.  
Considering obesity is a contributing factor in at least half of basal-like breast cancers, 
this aggressive subtype of breast cancer may be preventable through lifestyle interventions. 
Given that basal-like breast cancer is most prevalent in young African American women, 
targeted prevention may help reduce mortality disparities. Our study tested the reversibility of 
obesity-associated risk using dietary interventions, leading to identification of mechanistically-
based strategies for prevention of obesity-associated BBC. 
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